Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke by Bath, Philip M.W. et al.
Cochrane Database of Systematic Reviews
Nitric oxide donors (nitrates), L-arginine, or nitric oxide
synthase inhibitors for acute stroke (Review)
Bath PMW, Krishnan K, Appleton JP
Bath PMW, Krishnan K, Appleton JP.
Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke.
Cochrane Database of Systematic Reviews 2017, Issue 4. Art. No.: CD000398.
DOI: 10.1002/14651858.CD000398.pub2.
www.cochranelibrary.com
Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
5BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
16DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
33DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 1 Death or
dependency (mRS>2), end of trial. . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Analysis 1.2. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 2 Death or
dependency (mRS>2), end of trial, by stroke type. . . . . . . . . . . . . . . . . . . . . . 43
Analysis 1.3. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 3 Death or
dependency (mRS>2), end of trial, by time to randomisation. . . . . . . . . . . . . . . . . . 44
Analysis 1.4. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 4 Death or
dependency (mRS>2), end of trial, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . 46
Analysis 1.5. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 5 Death or
dependency (mean mRS), end of trial. . . . . . . . . . . . . . . . . . . . . . . . . . 48
Analysis 1.6. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 6 Death or
dependency (mean mRS), end of trial, by stroke type. . . . . . . . . . . . . . . . . . . . . 49
Analysis 1.7. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 7 Death or
dependency (mean mRS), end of trial, by time to randomisation. . . . . . . . . . . . . . . . . 50
Analysis 1.8. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 8 Death or
dependency (mean mRS), end of trial, by baseline SBP. . . . . . . . . . . . . . . . . . . . 51
Analysis 1.9. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 9 Death, end of
treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Analysis 1.10. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 10 Death, end
of treatment, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Analysis 1.11. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 11 Death, end
of treatment, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . . . . 55
Analysis 1.12. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 12 Death, end
of treatment, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Analysis 1.13. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 13 Death, end
of trial. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Analysis 1.14. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 14 Death, end
of trial, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
Analysis 1.15. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 15 Death, end
of trial, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Analysis 1.16. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 16 Death, end
of trial, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
iNitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.17. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 17 Neurological
deterioration, end of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Analysis 1.18. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 18 Neurological
deterioration, end of treatment, by stroke type. . . . . . . . . . . . . . . . . . . . . . . 66
Analysis 1.19. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 19 Neurological
deterioration, end of treatment, by time to randomisation. . . . . . . . . . . . . . . . . . . 67
Analysis 1.20. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 20 Neurological
deterioration, end of treatment, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . 69
Analysis 1.21. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 21 NIH Stroke
Scale, end of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
Analysis 1.22. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 22 NIH Stroke
Scale, end of treatment, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . 71
Analysis 1.23. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 23 NIH Stroke
Scale, end of treatment, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . 72
Analysis 1.24. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 24 NIH Stroke
Scale, end of treatment, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . 73
Analysis 1.25. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 25 Barthel
Index, end of trial. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
Analysis 1.26. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 26 Barthel
Index, end of trial, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Analysis 1.27. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 27 Barthel
Index, end of trial, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . . 77
Analysis 1.28. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 28 Barthel
Index, end of trial, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . 78
Analysis 1.29. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 29 Mood
(Zung), end of trial. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
Analysis 1.30. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 30 Mood
(Zung), end of trial, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Analysis 1.31. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 31 Mood
(Zung), end of trial, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . 82
Analysis 1.32. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 32 Mood
(Zung), end of trial, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Analysis 1.33. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 33 EQ5D-3L,
end of trial. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Analysis 1.34. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 34 EQ5D-3L,
end of trial, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
Analysis 1.35. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 35 EQ5D-3L,
end of trial, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . . . . 86
Analysis 1.36. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 36 EQ5D-3L,
end of trial, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Analysis 1.37. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 37 EQ VAS,
end of trial. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
Analysis 1.38. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 38 EQ VAS,
end of trial, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
Analysis 1.39. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 39 EQ VAS,
end of trial, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . . . . 91
Analysis 1.40. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 40 EQ VAS,
end of trial, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
Analysis 1.41. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 41 t-MMSE,
end of trial. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
Analysis 1.42. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 42 t-MMSE,
end of trial, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
iiNitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.43. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 43 t-MMSE,
end of trial, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . . . . 96
Analysis 1.44. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 44 t-MMSE,
end of trial, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Analysis 1.45. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 45 TICS, end
of trial. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
Analysis 1.46. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 46 TICS, end
of trial, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Analysis 1.47. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 47 TICS, end
of trial, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
Analysis 1.48. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 48 TICS, end
of trial, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Analysis 1.49. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 49 Animal
naming, end of trial. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Analysis 1.50. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 50 Animal
naming, end of trial, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Analysis 1.51. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 51 Animal
naming, end of trial, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . 104
Analysis 1.52. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 52 Animal
naming, end of trial, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Analysis 1.53. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 53
Physiotherapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Analysis 1.54. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 54
Physiotherapy, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Analysis 1.55. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 55
Physiotherapy, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . . . 108
Analysis 1.56. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 56
Physiotherapy, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Analysis 1.57. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 57
Occupational therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Analysis 1.58. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 58
Occupational therapy, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . 112
Analysis 1.59. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 59
Occupational therapy, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . 113
Analysis 1.60. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 60
Occupational therapy, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . 114
Analysis 1.61. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 61 Speech and
language therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
Analysis 1.62. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 62 Speech and
language therapy, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
Analysis 1.63. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 63 Speech and
language therapy, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . . 118
Analysis 1.64. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 64 Speech and
language therapy, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Analysis 1.65. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 65 Feeding
route (non-oral feeding at day 7). . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
Analysis 1.66. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 66 Feeding
route (non-oral feeding at day 7), by stroke type. . . . . . . . . . . . . . . . . . . . . . . 122
Analysis 1.67. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 67 Feeding
route (non-oral feeding at day 7), by time to randomisation. . . . . . . . . . . . . . . . . . . 123
Analysis 1.68. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 68 Feeding
route (non-oral feeding at day 7), by baseline SBP. . . . . . . . . . . . . . . . . . . . . . 124
iiiNitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.69. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 69 Length of
stay. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
Analysis 1.70. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 70 Length of
stay, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
Analysis 1.71. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 71 Length of
stay by time, to randomisation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
Analysis 1.72. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 72 Length of
stay, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
Analysis 1.73. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 73 Headache,
on treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
Analysis 1.74. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 74 Headache,
on treatment, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
Analysis 1.75. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 75 Headache,
on treatment, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . . . 133
Analysis 1.76. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 76 Headache,
on treatment, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
Analysis 1.77. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 77 Treatment
stopped early. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Analysis 1.78. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 78 Treatment
stopped early, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
Analysis 1.79. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 79 Treatment
stopped early, by time to randomisation. . . . . . . . . . . . . . . . . . . . . . . . . 138
Analysis 1.80. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 80 Treatment
stopped early, by baseline SBP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
Analysis 1.81. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 81 Systolic BP,
first treatment measurement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
Analysis 1.82. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 82 Systolic BP,
first treatment measurement, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . 143
Analysis 1.83. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 83 Systolic BP,
first treatment measurement, by time to randomisation. . . . . . . . . . . . . . . . . . . . 144
Analysis 1.84. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 84 Diastolic
BP, first treatment measurement. . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
Analysis 1.85. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 85 Diastolic
BP, first treatment measurement, by stroke type. . . . . . . . . . . . . . . . . . . . . . . 146
Analysis 1.86. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 86 Diastolic
BP, first treatment measurement, by time to randomisation. . . . . . . . . . . . . . . . . . . 147
Analysis 1.87. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 87 Heart rate,
first treatment measurement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
Analysis 1.88. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 88 Heart rate,
first treatment measurement, by stroke type. . . . . . . . . . . . . . . . . . . . . . . . 149
Analysis 1.89. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 89 Heart rate,
first treatment measurement, by time to randomisation. . . . . . . . . . . . . . . . . . . . 150
151APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
153WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
153HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
154CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
154DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
154SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
155DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
155INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ivNitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Nitric oxide donors (nitrates), L-arginine, or nitric oxide
synthase inhibitors for acute stroke
Philip MW Bath1, Kailash Krishnan1, Jason P Appleton1
1Stroke, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
Contact address: Philip MW Bath, Stroke, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus,
Nottingham, NG5 1PB, UK. philip.bath@nottingham.ac.uk.
Editorial group: Cochrane Stroke Group.
Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 4, 2017.
Citation: Bath PMW, Krishnan K, Appleton JP. Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute
stroke. Cochrane Database of Systematic Reviews 2017, Issue 4. Art. No.: CD000398. DOI: 10.1002/14651858.CD000398.pub2.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Nitric oxide (NO) has multiple effects that may be beneficial in acute stroke, including lowering blood pressure, and promoting reperfu-
sion and cytoprotection. Some forms of nitric oxide synthase inhibition (NOS-I) may also be beneficial. However, high concentrations
of NO are likely to be toxic to brain tissue. This is an update of a Cochrane review first published in 1998, and last updated in 2002.
Objectives
To assess the safety and efficacy of NO donors, L-arginine, and NOS-I in people with acute stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (last searched 6 February 2017), MEDLINE (1966 to June 2016), Embase
(1980 to June 2016), ISI Science Citation Indexes (1981 to June 2016), Stroke Trials Registry (searched June 2016), International
Standard Randomised Controlled Trial Number (ISRCTN) (searched June 2016), Clinical Trials registry (searched June 2016), and
International Clinical Trials Registry Platform (ICTRP) (searched June 2016). Previously, we had contacted drug companies and
researchers in the field.
Selection criteria
Randomised controlled trials comparing nitric oxide donors, L-arginine, or NOS-I versus placebo or open control in people within
one week of onset of confirmed stroke.
Data collection and analysis
Two review authors independently applied the inclusion criteria, assessed trial quality and risk of bias, and extracted data. The review
authors cross-checked data and resolved issues through discussion. We obtained published and unpublished data, as available. Data
were reported as mean difference (MD) or odds ratio (OR) with 95% confidence intervals (CI).
Main results
We included five completed trials, involving 4197 participants; all tested transdermal glyceryl trinitrate (GTN), an NO donor. The
assessed risk of bias was low across the included studies; one study was double-blind, one open-label and three were single-blind. All
included studies had blinded outcome assessment. Overall, GTN did not improve the primary outcome of death or dependency at the
end of trial (modified Rankin Scale (mRS) > 2, OR 0.97, 95% CI 0.86 to 1.10, 4195 participants, high-quality evidence). GTN did
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not improve secondary outcomes, including death (OR 0.78, 95% CI 0.40 to 1.50) and quality of life (MD -0.01, 95% CI -0.17 to
0.15) at the end of trial overall (high-quality evidence). Systolic/diastolic blood pressure (BP) was lower in people treated with GTN
(MD -7.2 mmHg (95% CI -8.6 to -5.9) and MD -3.3 (95% CI -4.2 to -2.5) respectively) and heart rate was higher (MD 2.0 beats
per minute (95% CI 1.1 to 2.9)). Headache was more common in those randomised to GTN (OR 2.37, 95% CI 1.55 to 3.62). We
did not find any trials assessing other nitrates, L-arginine, or NOS-I.
Authors’ conclusions
There is currently insufficient evidence to recommend the use of NO donors, L-arginine or NOS-I in acute stroke, and only one drug
(GTN) has been assessed. In people with acute stroke, GTN reduces blood pressure, increases heart rate and headache, but does not
alter clinical outcome (all based on high-quality evidence).
P L A I N L A N G U A G E S U M M A R Y
Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Question: Are nitric oxide donors, L-arginine, or nitric oxide synthase inhibitors safe and effective drugs for use in people soon after
they have suffered a stroke?
Background: Nitric oxide is a key molecule involved in the control of blood pressure, blood flow, and brain activity, both before and
during a brain attack (stroke, either due to a blockage or rupture of an artery in the brain). Drugs that produce nitric oxide or control
its production may be beneficial in acute stroke. This review looked at trials that tested such drugs in people with a stroke that came
on within the last few days.
Study characteristics: This review is up-to-date as of September 2016. We included five trials involving 4197 people; all trials assessed
glyceryl trinitrate, a drug that is given as a skin patch and which releases nitric oxide. One study was international, whilst the remainder
were studies performed at single centres. Not all trials contributed data to all outcomes. We used both unpublished and published
information, where available. We did not find any trials assessing other nitrate drugs, L-arginine, or nitric oxide synthase inhibitors.
Key results: Overall, glyceryl trinitrate did not improve the rate of death or dependency compared with those who did not receive
glyceryl trinitrate after acute stroke. Glyceryl trinitrate did not improve other outcomes including death and quality of life. Glyceryl
trinitrate lowers blood pressure, and increases heart rate and headache in people with acute stroke.
Quality of the evidence: The key results are based on high-quality evidence.
Conclusions: There is currently insufficient evidence to recommend the use of drugs affecting nitric oxide production in acute stroke.
Overall, glyceryl trinitrate is inexpensive, lowers blood pressure, increases heart rate and headache, but does not change clinical outcomes
in people who have suffered a stroke.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Patient or population: people with acute stroke
Settings: pre-hospital / hospital
Intervention: GTN
Comparison: no GTN
Outcomes Anticipated absolute effects (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no GTN /
placebo
Risk with GTN com-
pared with no GTN for
acute stroke
Death or dependency
(mRS>2), end of trial
(90 days)
609 per 1,000 601 per 1,000
(573 to 631)
OR 0.97
(0.86 to 1.10)
4195
(5 studies)
⊕⊕⊕⊕
high
Death, end of trial (90
days)
131 per 1,000 115 per 1,000
(90 to 184)
OR 0.78
(0.40 to 1.50)
4197
(5 studies)
⊕⊕⊕⊕
high
Quality of life, end of
trial (90 days)
The mean quality of lif e
(EQ-5D3L), end of trial
ranged across control
groups f rom 0.25 to 0.9
The mean quality of
lif e (EQ-5D3L), end of
trial in the intervent ion
group was 0.01 lower
(0.17 lower to 0.15
higher)
- 4088
(4 studies)
⊕⊕⊕⊕
high
Health ut ility status de-
rived f rom European
Quality of lif e-5 di-
mensions-3 levels (EQ-
5D3L). Signif icant het-
erogeneity between tri-
als (I2 = 78%).
Systolic BP, first
treatment measure-
ment (<24 hours after
randomisation)
The mean systolic
BP, f irst treatment
measurement ranged
across control groups
f rom 151.13 to 185.17
mmHg
The mean systolic BP,
f irst treatment mea-
surement in the inter-
vent ion group was 7.
21 mmHg lower (8.58
lower to 5.85 lower)
- 4197
(5 studies)
⊕⊕⊕⊕
high
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Diastolic BP, first
treatment measure-
ment (<24 hours after
randomisation)
The mean diastolic
BP, f irst treatment
measurement ranged
across control groups
f rom 82.34 to 91.0
mmHg
The mean diastolic BP,
f irst treatment mea-
surement in the inter-
vent ion group was 3.
31 mmHg lower (4.18
lower to 2.45 lower)
- 4197
(5 studies)
⊕⊕⊕⊕
high
Heart rate, first treat-
ment measure-
ment (<24 hours after
randomisation)
The mean heart rate,
f irst treatment mea-
surement
ranged across control
groups f rom 65.5 to 77.
27 beats per minute
The mean heart rate,
f irst treatment mea-
surement in the inter-
vent ion group was 2.
02 beats per minute
higher (1.13 higher to
2.91 higher)
- 4197
(5 studies)
⊕⊕⊕⊕
high
Signif icant heterogene-
ity between trials (I2 =
61%).
Adverse
event: Headache, on
treatment (7-12 days)
84 per 1,000 180 per 1,000
(125 to 250)
OR 2.37
(1.55 to 3.62)
4186
(5 studies)
⊕⊕⊕⊕
high
BP: blood pressure; CI: conf idence interval; GTN: glyceryl trinit rate; MD: mean dif ference; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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B A C K G R O U N D
Description of the condition
Stroke is the third most common cause of death and the most
common cause of disability in the western world (Mackay 2004).
Blood pressure (BP) is elevated in 75%, or more, of people with
acute stroke (whether due to blockage (ischaemic stroke) or rup-
ture (intracerebral haemorrhage (ICH)) of an artery), and half of
those have an existing diagnosis of hypertension (Britton 1986;
Oppenheimer 1992). In two-thirds of people with stroke, BP
spontaneously falls in the first week after stroke, whilst the re-
mainder have high BP, which is associated with a poor outcome
(Willmot 2004). Systolic BP is related to outcome in a ’U-shaped’
relationship with both high and low systolic BP associated with
increased death, and death or dependency (Leonardi-Bee 2002).
Elevated systolic BP is also associated with early stroke recurrence
(Sprigg 2006).
Cerebral autoregulation maintains cerebral blood flow (CBF) de-
spite changes in cerebral perfusion pressure (CPP: blood pressure
supplying the brain). In acute stroke, autoregulation is lost so that
cerebral perfusion becomes related to CPP, and therefore systemic
BP (Tikhonoff 2009). Thus, large and precipitous reductions in
BP reduce CBF, leading to further cerebral infarction (brain cell
death from lack of blood flow;Owens 2011) or perihaematomal is-
chaemia (reduced blood flow to brain tissue surrounding the ICH;
Qureshi 2008). Similarly, high BP increases the risk of haematoma
(bleed) growth in ICH, haemorrhagic transformation in ischaemic
stroke, and cerebral oedema (brain swelling) in both stroke types
(Fagan 1998; Willmot 2004).
Description of the intervention
Nitric oxide (NO) (endothelium-derived relaxing factor) is an en-
dogenous (present within humans) inorganic soluble gas formed
from the guanidino nitrogen of L-arginine and molecular oxy-
gen by the enzyme (catalyst) nitric oxide synthase (NOS) (Palmer
1987; Palmer 1988). This enzyme is present within endothelial
cells (endothelial NOS, eNOS, type III NOS) and some neurones
(brain cells; neuronal NOS, nNOS, type I NOS) in a calcium-de-
pendent constitutive form (Knowles 1989), and in macrophages
(white blood cells), astrocytes, microglia (brain cells), and vascular
smooth muscle cells (inducible NOS, iNOS, type II NOS) in a
calcium-independent inducible form (Fleming 1991; Cho 1992).
NO is one of the most versatile molecules in animal and human
biology with diverse roles in both physiology and pathophysiol-
ogy: it is a vasodilator (dilates blood vessels) with anti-smooth
muscle cell activity (Murad 1987); protects endothelium; inhibits
platelet (circulating cell fragments involved in clotting) adhesion
and aggregation (Radomski 1987a; Radomski 1987b) and leuco-
cyte (white blood cells) adhesion and chemotaxis (movement of
cells to an attractant) (Bath 1991), and has other anti-inflamma-
tory properties. Further, it is a neurotransmitter and neuromod-
ulator (chemical messenger) (Garthwaite 1988; Manzoni 1992;
Dawson 1994), and is involved in cerebral blood flow auto- and
chemo-regulation (control of brain blood flow) (Tanaka 1996;
White 2000; Lavi 2003).
In experimental pre-clinical studies of ischaemic stroke, significant
changes relating to NO occur in a time-dependent fashion. In
models of focal ischaemic stroke, there is increased NO produc-
tion for up to 30 minutes following middle cerebral artery occlu-
sion or blockage (Kader 1993; Malinski 1993), likely due to in-
creased calcium availability and nNOS activation (Huang 1994).
eNOS and nNOS activity increases in line with NO within the
first minutes following middle cerebral artery occlusion and sig-
nificantly reduces thereafter (Kader 1993), whilst iNOS is upreg-
ulated (increased activity) from 12 hours after the event, this last-
ing for up to seven days (Niwa 2001). Within brain tissue, NO
is undetectable for up to seven days following ictus (stroke onset)
(Malinski 1993).
Intravenous (injected into a vein) L-arginine given after middle
cerebral artery occlusion improved cerebral blood flow within the
ischaemic penumbra (area of brain tissue surrounding the infarct
that is at risk of infarction) and reduced infarct size and volume
(Morikawa 1992a; Morikawa 1994). However, this observation
was not seen in eNOS-deficient mice, who also have lower post-
ischaemic cerebral blood flow, larger infarcts, smaller penumbral
areas (Huang 1996; Lo 1996), and absent angiogenesis (develop-
ment of new blood vessels), potentially leading to increased post-
ischaemic damage (Cui 2009). The advantageous effects of eNOS
activity are supported by evidence that eNOSphosphorylation-de-
ficient mice (mice with inactive eNOS) (Atochin 2007) and mice
deficient in the alpha-1 subunit of soluble guanylate cyclase have
increased infarct size (Atochin 2010). Whilst eNOS and eNOS-
derivedNOare neuroprotective (protecting brain cells against fur-
ther damage) following cerebral infarction, nNOS-derived NO
(Huang 1994; Hara 1996; Zaharchuk 1997) and iNOS-derived
NO (Iadecola 1995; Zhang 1996; Iadecola 1997; Zhao 2003)
are detrimental to tissue survival resulting in poorer neurological
outcome. Despite being neurotoxic in the acute phase following
stroke, iNOS and nNOS seem to be important in neurogenesis
(formation of new brain cells) post-stroke, with iNOS promoting
(Sehara 2006; Corsani 2008) and nNOS attenuating this process
(Sun 2005).
With the weight of evidence for NO-mediated neuroprotection
post-stroke, several therapeutic strategies have been proposed: re-
placement or supplementation of NO deficiency through ad-
ministration of NO, NO donors or precursors; enhancement of
eNOS activity to modulate or increase endogenous NO produc-
tion (Endres 2004); and direct or indirect inhibition of NOS.
How the intervention might work
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Vascular NO levels are low in acute stroke and so replacement
might be beneficial (Ferlito 1998; Rashid 2003). NO, however
delivered, may have multiple effects that could improve outcome
after stroke.
• BP lowering: NO donors (intravenous sodium
nitroprusside (SNP) and transdermal glyceryl trinitrate (GTN))
lower BP, pulse pressure, and peak systolic BP; improve arterial
compliance; and maintain CBF in acute stroke (Butterworth
1998; Bath 2001; Rashid 2002; Willmot 2006). Whilst SNP
inhibits platelet function, thereby negating its use in ICH
(Butterworth 1998), GTN has no effect on platelets and can
therefore be used in people with stroke, regardless of stroke type
(Bath 2001).
• Reperfusion (improving blood supply): NO dilates cerebral
arteries and could then increase perilesional perfusion (blood
flow around the stroke lesion via the ’front door’) without
inducing cerebral steal (Willmot 2006). Pial artery (brain surface
artery) blood flow and, therefore, collateral flow may provide
’back-door’ reperfusion to the ischaemic penumbra in ischaemic
stroke (Morikawa 1992b) and the perihaematomal region in
ICH.
• Cytoprotection (cell protection): NO exhibits
neuroprotective effects, as found in experimental studies (see
above). Whether these effects involve cellular protection per se or
just reflect reperfusion remains unclear.
NO donors could also have adjunctive effects, enhancing the ef-
fects of existing reperfusion therapies by:
• Lowering BP: NO donors may prepare people with hyper-
acute (within a few hours) ischaemic stroke for thrombolysis
(clot-dissolving therapy; non-significant tendencies to more and
earlier intravenous thrombolysis were seen in the pilot RIGHT
trial (Ankolekar 2013);
• Dilating cerebral arteries around occluding clot, NO
donors may enhance access to the clot by both endogenous and
exogenous fibrinolysis (clot-dissolving compounds found within
the body and administered as treatment).
Why it is important to do this review
Evidence-based treatments for acute stroke are limited. In hy-
per-acute ischaemic stroke, there are interventions with high ef-
ficacy but limited utility (intravenous thrombolysis (Emberson
2014); thrombectomy (removal of clot causing large vessel occlu-
sion) (Goyal 2016); and decompressive hemicraniectomy (surgery
to remove one side of the skull to relieve intracranial pressure)
(Vahedi 2007)), and those with low efficacy but high utility (as-
pirin (Sandercock 2014)). In comparison, there are no defini-
tive treatments for ICH other than early BP lowering (Anderson
2013). All patients with stroke should have access to stroke unit
care (Stroke Unit Trialists’ Collaboration 2013).
NO donors are inexpensive (e.g. GTN costs approximately £1 per
patch) and, if efficacious, could be used in low, middle, and high
income economies.
O B J E C T I V E S
To assess the safety and efficacy of NO donors, L-arginine, or
NOS-I in people with acute stroke.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published and unpublished randomised controlled trials (RCTs)
of NO donors, L-arginine, or NOS-I in people with stroke ran-
domised within one week of ictus with either acute ischaemic
stroke or ICH. We excluded studies of people with subarachnoid
haemorrhage, uncontrolled studies, and confounded controlled
studies (i.e. where two or more active interventions were com-
pared).
Types of participants
Men and women of any age with recent ischaemic stroke or intrac-
erebral haemorrhage (ICH) eligible for randomisation to active
treatment or control.
Types of interventions
NO donors, L-arginine, and/or NOS-I given by any route of ad-
ministration versus placebo or open control.
Types of outcome measures
We assessed haemodynamic measures after first treatment, and
clinical measures at end of treatment and end of follow-up.
Primary outcomes
End-of-trial death or dependency, defined as modified Rankin
Scale (mRS) > 2. The mRS is a 7-level ordinal hierarchical scale
ascribing a score to grades of disability from 0: no symptoms;
1: symptoms but independent; 2: mostly independent but needs
some help; 3: moderate dependency but can walk; 4: dependency
needing help for walking and bodily needs; 5: severe dependency
and bedridden; and 6: death.
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Secondary outcomes
• First blood pressure and heart rate measurements after
randomisation
• Early case fatality (end of treatment)
• Late case fatality (end of trial)
• Early neurological deterioration by end of treatment defined
as a decrease in the Scandinavian Stroke Scale (SSS) by > 5 points
or a decrease in the consciousness part of the SSS by > 2 points
• Headache on treatment
• Treatment stopped early
• National Institutes of Health Stroke Scale (NIHSS) at end
of treatment derived from SSS (Gray 2009)
• Late dependency or disability defined as end-of-trial Barthel
Index (BI)
• Mood at end-of-trial using the short-form Zung Depression
Scale (Zung 1965)
• Quality of life at end-of-trial using health utility status
derived from European Quality of life-5 dimensions-3 levels
(EQ-5D3L) and EQ-visual analogue scale (EQ-VAS)
• Cognition at end-of-trial using telephone Mini-Mental
State Examination (t-MMSE, subscore derived from MMSE),
telephone interview cognition scale (TICS) and verbal fluency
(animal naming)
• Physiotherapy during hospital stay
• Occupational therapy during hospital stay
• Speech and language therapy during hospital stay
• Feeding route (non-oral feeding at day seven)
• Length of hospital stay (days)
Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module. We did not apply any language restrictions and sought
translations of articles where required.
Electronic searches
We searched the Cochrane Stroke Group Trials Register (last
searched 6 February 2017), MEDLINE (Ovid) (1966 to June
2016, Appendix 1), Embase (Ovid) (1980 to June 2016,
Appendix 2), Science Citation Index (ISI, Web of Science,
1900 to June 2016, Appendix 3), Stroke Trials Registry (
www.strokecenter.org/trials, searched June 2016), International
Standard Randomised Controlled Trial Number (ISRCTN) reg-
istry (www.controlled-trials.com, searched June 2016), Clinical
Trials registry (www.clinicaltrials.gov, searched June 2016), and
the International Clinical Trials Registry Platform (ICTRP) (
www.apps.who.int/trialsearch/, searched June 2016).
Searching other resources
For the 2002 version of this review we contacted pharmaceuti-
cal companies who made nitric oxide donors (Schwarz Pharma,
Schering-Plough) or nitric oxide synthase inhibitors (GlaxoWell-
come) and researchers in the field to help identify relevant trials
(Bath 2002). For this update, we also searched references lists of
included studies and systematic reviews.
Data collection and analysis
We extracted data using a standard proforma, which one review
author (JA) entered into Review Manager 5 (RevMan 2014) and
another review author (KK) checked.
Selection of studies
One author (JA) screened the outputs from the electronic searches,
and excluded irrelevant studies. We obtained full paper copies
of the remaining studies and both review authors (JA and PB)
selected studies based on the aforementioned inclusion criteria.
We resolved any disagreements through discussion.
Data extraction and management
We extracted data from published and unpublished material. We
recorded information on the following parameters: randomisation
method; allocation concealment; blinding of treatment; analysis
method; stroke type; treatment type, dose, route of administration
and timing; blood pressure and heart rate during treatment; case
fatality; functional status; quality of life; mood; cognition; length
of hospital stay; rates of physiotherapy, occupational therapy and
speech and language therapy; and feeding status. Individual pa-
tient data were available for all included trials and this allowed
subgroup analyses and calculation of means and standard devia-
tions to facilitate parametric analyses of ordinal outcomes such as
mRS. The search criteria did not require that individual patient
data were present in the included studies.
Assessment of risk of bias in included studies
We assessed risk of bias in the included studies using Cochrane’s
’Risk of bias’ tool, which is based on the following domains:
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective reporting.
• Other sources of bias.
Each domain includes one ormore specific entries in a ’Risk of bias’
table. Within each entry, the first part of the tool describes what
was reported to have happened in the study in sufficient detail to
support a judgement on the risk of bias. The second part assigns
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a judgement relating to the risk of bias: ’Low risk’ of bias, ’High
risk’ of bias, or ’Unclear risk’ of bias, according to the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Measures of treatment effect
We calculated the weighted estimate of the typical treatment ef-
fect across trials using RevMan 5.3 (RevMan 2014). We calcu-
lated odds ratios (OR) using the Mantel-Haenszel random-effects
model for binary data, and mean difference (MD) using the in-
verse variance method for continuous data, all with 95% confi-
dence intervals (CIs).
Unit of analysis issues
Where stroke severity was measured by the Scaninavian Stroke
Scale (SSS), the National Institutes of Health Stroke Scale
(NIHSS) score was calculated using a published conversion algo-
rithm (Gray 2009). Since many scales include a value for people
who have died (e.g. modified Rankin Scale = 6, Health Utility
Status = 0, Barthel Index = -5), extreme worst values were assigned
for death for other outcomes including mood (short-form Zung
Depression Scale (Zung 1965) = 102.5; EQ-VAS = -1; t-MMSE
= -1; TICS = -1; and animal naming = -1). Where secondary out-
comes were not assessed, trials were excluded from analysis of that
particular outcome.
Dealing with missing data
We made extensive attempts to find missing data, including util-
ising unpublished data from study authors.
Assessment of heterogeneity
We calculated heterogeneity between RCT results using the
I2 statistic based upon the DerSimonian-Laird formula (
DerSimonian 1986).
Assessment of reporting biases
We demonstrated reporting bias using funnel plots.
Data synthesis
We performed statistical analysis using RevMan 5.3 (RevMan
2014). We reported outcomes for dichotomous data as OR with
95% CIs, and continuous data as MD with 95% CIs. We used
random-effects models to analyse individual results, a conservative
approach appropriate for the heterogenous designs and popula-
tions of the trials involved. We used fixed-effect models to analyse
haemodynamic variables, given the size and precision of ENOS
2015 in relation to the other included studies.
Summary of findings table
We presented the primary outcome and important secondary out-
comes (including quality of life) of the review in Summary of
findings for themain comparison.We used the GRADE approach
to assess the quality of the supporting evidence for each analysis.
We downgraded quality depending upon: limitations in study de-
sign and implementation suggesting a high potential of bias; un-
explained heterogeneity or inconsistency of results; imprecision of
results (wide CIs); indirectness of evidence; or publication bias.
Subgroup analysis and investigation of heterogeneity
We reviewed the primary and secondary outcomes in the following
prespecified subgroups.
• Intervention type
• Type of stroke: ischaemic stroke or ICH
• Time from stroke onset to randomisation: ≤ 6 hours; 6.1 to
12 hours; 12.1 to 24 hours; 24.1 to 36 hours; and > 36 hours
• Baseline systolic blood pressure (systolic BP): ≤ 160
mmHg; 160.1 to 180 mmHg; 180.1 to 200 mmHg; > 200
mmHg
We considered heterogeneity to be significant if I2 was greater
than 50%; if present, we sought the potential reasons, e.g. differ-
ent trial designs, trial populations, time to treatment. If individual
subgroups had zero participants in either the intervention or no
intervention arms, then we excluded the trial concerned from that
particular individual subgroup analysis. As a result, the denomi-
nators for subgroups analyses vary.
Sensitivity analysis
Since ordinal or continuous analyses are more sensitive to treat-
ment effects than dichotomous measures (OAST 2007), we as-
sessed the comparison of the primary outcome, mRS, as MD in
addition to OR.
R E S U L T S
Description of studies
We includedfive randomised trials of participantswith ultra-acute,
hyper-acute, acute and sub-acute stroke.
Results of the search
Figure 1 shows the PRISMA study flow diagram. Of the 4772
records identified and screened, we excluded 4750. After full-text
review of the remaining 22 studies, we excluded 16 studies includ-
ing four ongoing studies that did not meet eligibility criteria. One
study met inclusion criteria but is currently ongoing. Therefore,
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we included five trials, which are completed and summarised in
Characteristics of included studies.
Figure 1. Results of Database Search
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Included studies
We identified five trials that fulfilled the inclusion criteria (
Ankolekar 2013; Bath 2001; ENOS 2015; Rashid 2002; Willmot
2006). All five trials involved administration of transdermal glyc-
eryl trinitrate (GTN) 5 to 10 mg daily via a patch. Individual
patient data were provided for all five studies, totaling 4197 par-
ticipants. All studies recruited participants with mixed stroke (is-
chaemic stroke and ICH). One of the trials was multicentre and
international (ENOS 2015), whilst the remainder wereUK-based,
single-centre studies.
Trial recruitment occurred at different time intervals following
stroke:
• within four hours of onset (Ankolekar 2013);
• within 48 hours of onset (ENOS 2015);
• within 72 hours of onset (Rashid 2002);
• within 168 hours of onset (Bath 2001; Willmot 2006).
The duration of the intervention period varied:
• seven days (Ankolekar 2013; ENOS 2015; Willmot 2006);
• 10 days (Rashid 2002);
• 12 days (Bath 2001).
Four studies used transdermal GTN patch 5 mg once daily
(Ankolekar 2013; Bath 2001; ENOS2015;Willmot 2006), whilst
Rashid 2002 adopted a different strategy with three treatment
groups: transdermal GTN patch 5 mg once daily for 10 days; 5
mg for four days then 10 mg for six days; and 10 mg for 10 days.
For this review, as with a previous version (2002), we combined
the three treatment arms into one group. All studies detailed the
equipment used and patient posture when blood pressure record-
ings were performed.
Multiple outcomes were reported:
• mRS end-of-trial in all studies (Ankolekar 2013; Bath
2001; ENOS 2015; Rashid 2002; Willmot 2006);
• BI end-of-trial in all studies (Ankolekar 2013; Bath 2001;
ENOS 2015; Rashid 2002; Willmot 2006);
• case fatality at end-of-treatment and end-of-trial in all
studies (Ankolekar 2013; Bath 2001; ENOS 2015; Rashid 2002;
Willmot 2006);
• early neurological deterioration by end-of-treatment in four
studies (Ankolekar 2013; ENOS 2015; Rashid 2002; Willmot
2006);
• mood (Zung Depression Scale) end-of-trial in three studies
(Ankolekar 2013; ENOS 2015; Willmot 2006);
• quality of life (EQ-5D and EQ-VAS) end-of-trial in four
studies (Ankolekar 2013; ENOS 2015; Rashid 2002; Willmot
2006);
• cognition at end-of-trial in three studies: MMSE
(Ankolekar 2013; Willmot 2006), t-MMSE (ENOS 2015),
TICS (ENOS 2015), animal naming (ENOS 2015);
• physiotherapy, occupational therapy and speech and
language therapy rates in three studies (Ankolekar 2013; ENOS
2015; Willmot 2006);
• feeding route (non-oral feeding at day seven) in three
studies (Ankolekar 2013; ENOS 2015; Willmot 2006);
• length of stay in four studies (Ankolekar 2013; Bath 2001;
ENOS 2015; Willmot 2006).
Excluded studies
We excluded 16 studies that either lacked randomisation, were
uncontrolled, were confounded, or were not relevant to this review
(Characteristics of excluded studies); four of these are ongoing
studies. One other study met the inclusion criteria and is currently
ongoing (Characteristics of ongoing studies).
Risk of bias in included studies
For full details see the corresponding ’Risk of bias’ tables in
Characteristics of included studies, and Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Randomisation can be summarised as follows (Characteristics of
included studies).
• Simple randomisation 1:1 (Ankolekar 2013) was deemed at
low risk of selection bias and ensured allocation concealment.
• Computer minimisation 1:1 (Bath 2001; ENOS 2015;
Rashid 2002) were deemed at low risk of selection bias and
ensured allocation concealment.
• Computer minimisation 2:1 (Willmot 2006) was deemed
at low risk of selection bias and ensured allocation concealment.
Blinding
Participants and investigators were blinded to treatment as follows.
• Double-blind (participant and investigator): one trial (Bath
2001).
• Single-blind (participant): three trials (Ankolekar 2013;
ENOS 2015; Willmot 2006).
• Open-label: one trial (Rashid 2002).
Blinding of participants and personnel (performance bias) were
deemed unclear risk for the three single-blind trials (Ankolekar
2013; ENOS 2015; Willmot 2006) and the open-label trial
(Rashid 2002). Blinding of outcome assessment (detection bias)
was deemed low risk for all included trials as outcomes were as-
sessed centrally blinded to treatment group.
Incomplete outcome data
All five included trials were analysed by intention-to-treat with no
differences in follow-up rates between treatment groups.
Selective reporting
The likelihood of reporting bias was demonstrated using funnel
plots (Figure 4; Figure 5) andwas not evident in any of the included
trials. Figure 4 assessed the primary outcome (mRS end-of-trial)
across the included studies, whilst Figure 5 assessed the first BP
measurement after treatment; this was included because it was the
primary outcome in the four phase II trials.
Figure 4. Funnel plot of comparison: Glyceryl trinitrate (GTN) compared with no GTN for acute stroke,
Outcome: 1.1 Death or dependency (mRS>2), end of trial.
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Figure 5. Funnel plot of comparison: Glyceryl trinitrate (GTN) compared with no GTN for acute stroke,
outcome: 1.81 Systolic BP, first treatment measurement.
Other potential sources of bias
We did not identify any other potential sources of bias that might
have impacted upon the validity of the included studies.
Effects of interventions
See: Summary of findings for the main comparison Glyceryl
trinitrate (GTN) compared with no GTN for acute stroke
Death or dependency, end of trial
Death or dependency was assessed as mRS > 2 at day 90 in all five
included trials totaling 4195 participants (Summary of findings
for the main comparison; Analysis 1.1). There was no significant
difference between GTN and control (OR 0.97, 95% CI 0.86 to
1.10), and no evidence of heterogeneity (I2 = 0%). When assessed
as continuous data to comparemeanmRS, there was no significant
difference between GTN and control (MD -0.08, 95% CI -0.52
to 0.36, I2 = 47%, Analysis 1.5).
Stroke type
There was no differential effect by stroke type (Analysis 1.2;
Analysis 1.6).
Time to randomisation
Those participants randomised to GTNwithin six hours of stroke
onset (two trials, 312 participants) had a tendency toward less
death and dependency (OR 0.65, 95% CI 0.41 to 1.02; P = 0.06;
I2 = 0%). Randomisation at more than six hours after ictus did not
influence the primary outcome and overall subgroup differences
were nonsignificant (P = 0.28, Analysis 1.3). In the sensitivity
analysis,meanmRSwas lower in those randomised toGTNwithin
six hours of onset as compared with control participants (MD -
0.79, 95% CI -1.35 to -0.23; P = 0.005); an effect not seen in any
other time period from randomisation although the interaction
between time and mRS was significant (P = 0.05, Analysis 1.7).
Baseline systolic BP
There was no differential effect by baseline systolic BP (Analysis
1.4; Analysis 1.8).
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Death, end of treatment and end of trial
There was no significant treatment effect of GTN compared with
control on death, whether measured early (Analysis 1.9) or end of
trial (Analysis 1.13; 4197 participants; Summary of findings for
themain comparison).No significant differenceswere noted in any
subgroups for death at end of treatment (Analysis 1.10; Analysis
1.11; Analysis 1.12), whilst death at end of trial was reduced in
those randomised to GTN within six hours of stroke onset (OR
0.30, 95% CI 0.15 to 0.60; P = 0.0006; I2 = 0%; Analysis 1.15),
with significant interaction between time and death (P = 0.01).
Neurological deterioration, end of treatment
No significant difference was noted in early neurological deterio-
ration between treatment and control (Analysis 1.17) in the four
studies with data (4158 participants). Stroke type did not change
the neutral effect seen overall (Analysis 1.18). Those randomised
between 24 and 36 hours toGTN in one study (1218 participants;
two studies were not estimable due to no events) had a higher like-
lihood of neurological deterioration than control participants (OR
2.00, 95% CI 1.19 to 3.35; P = 0.009). The other time groups
revealed no difference between GTN and control (Analysis 1.19).
Participants randomised to GTN with a baseline systolic BP of
< 160 mmHg (1688 participants) or 180 to 200 mmHg in two
studies (743 participants; two studies were not estimable due to
no events) were more likely to have neurological deterioration at
end of treatment than controls (OR 1.62, 95% CI 1.05 to 2.50, P
= 0.03 and OR 1.81, 95% CI 1.05 to 3.12, P = 0.03, respectively;
Analysis 1.20).
NIHSS, end of treatment
NIHSS was calculated using the SSS available from four trials
(4137 participants). There was no significant difference between
treatment and control (Analysis 1.21). Stroke type and baseline
systolic BP had no influence on the neutral effect seen overall
(Analysis 1.22; Analysis 1.24). Participants randomised to GTN
within six hours of stroke onset had lower NIHSS scores at end
of treatment compared with control (MD -2.07, 95% CI -3.81
to -0.34, P = 0.02), with no heterogeneity seen between the two
trials, and significant interaction between time and NIHSS (P =
0.03, Analysis 1.23).
Disability (Barthel Index), end of trial
Disability data in the form of BI was available for all five stud-
ies (4153 participants) with no significant difference detected be-
tween GTN and control (Analysis 1.25). Those randomised to
GTN within six hours of stroke ictus (2 trials, 312 participants)
had improved disability scores compared with control participants
(MD 14.57, 95% CI 5.95 to 23.19, P = 0.0009), with no het-
erogeneity seen between the studies, and significant interaction
between time and BI (P = 0.03, Analysis 1.27). Baseline systolic
BP and stroke type subgroups had no associations of note for this
outcome (Analysis 1.26; Analysis 1.28).
Mood (Zung), end of trial
Mood was assessed in three studies (3312 participants) using the
Zung depression scale (ZDS). No significant difference was seen
betweenGTN and control (Analysis 1.29). Improvedmood scores
were seen in those randomised to GTN within six hours of the in-
dex event compared with control participants (MD -11.12, 95%
CI -17.35 to -4.90, P = 0.0005) with no heterogeneity seen be-
tween the two studies (268 participants), and significant interac-
tion between time and ZDS (P = 0.007, Analysis 1.31). Stroke
type and baseline systolic BP had no associations of note for this
outcome (Analysis 1.30; Analysis 1.32).
Quality of life, end of trial
Two measures of quality of life were assessed: the EQ-5D was
transformed into a health utility status from data available in four
studies (4088 participants); and the EQ-VAS from four studies
(3575 participants). There was no significant difference between
treatment and control for either measure (Analysis 1.33; Analysis
1.37). Whilst the subgroups stroke type and baseline systolic BP
had no impact on the neutral effect seen overall, early treatment
with GTNwithin six hours of onset was associated with improved
quality of life at day 90 comparedwith those randomised to control
(EQ-5D (2 trials, 312 participants) MD 0.11, 95% CI 0.02 to
0.20, P = 0.02, with minimal heterogeneity (I2 = 3%; Analysis
1.35); and EQ-VAS (2 trials, 295 participants) MD 9.96, 95% CI
2.49 to 17.43, P = 0.009 with no heterogeneity (Analysis 1.39)).
Across time to randomisation, there was a significant interaction
with EQ-VAS (P = 0.04), but not EQ-5D (P = 0.10).
Cognition, end of trial
Three measures of cognition were assessed: three studies had t-
MMSE data (2078 participants, in two studies t-MMSE was de-
rived from MMSE); one study also used TICS and animal nam-
ing (ENOS 2015). Overall, there was no significant difference be-
tween GTN and control (Analysis 1.41; Analysis 1.45; Analysis
1.49). Stroke type and baseline systolic BP did not influence this
finding (Analysis 1.42; Analysis 1.44; Analysis 1.46; Analysis 1.48;
Analysis 1.50; Analysis 1.52). Improved cognitive scores were seen
across all three measures in those randomised to GTN within six
hours of onset (t-MMSE: MD 3.61, 95% CI 1.68 to 5.55, P =
0.0002 (2 trials, 219 participants, interaction P = 0.003; Analysis
1.43); TICS: MD 5.59, 95% CI 2.63 to 8.55, P = 0.0002 (1 trial,
182 participants, interaction P = 0.002; Analysis 1.47); and ani-
mal naming: MD 2.94, 95% CI 0.88 to 5.00, P = 0.005 (1 trial,
192 participants, interaction P = 0.04; Analysis 1.51)).
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Physiotherapy, occupational therapy, and speech and
language therapy
Data on whether individuals received physiotherapy, occupational
therapy or speech and language therapy during their admission
were available from three studies (4042 participants). There was
no difference between treatment groups in the rates of therapy
required (Analysis 1.53; Analysis 1.57; Analysis 1.61). Rates of
occupational therapy were lower, with borderline significance, in
those randomised to GTNwith baseline systolic BP level of 180.1
to 200mmHg comparedwith control participants (OR0.74, 95%
CI 0.54 to 1.00, P = 0.05), with no heterogeneity seen between the
three studies (730 participants), and higher in those randomised
to GTN with baseline systolic BP > 200 mmHg compared with
controls (OR 2.11, 95% CI 1.25 to 3.54, P = 0.005), with no
heterogeneity between the two studies (255 participants; Analysis
1.60). No other associations regarding baseline systolic BP were
noted for rates of either physiotherapy (Analysis 1.56) or speech
and language therapy (Analysis 1.64). Neither time to randomi-
sation nor stroke type had any effect on therapy rates between
treatment and control.
Feeding route (non-oral feeding at day 7)
Feeding route was recorded in three trials (4009 participants) and
assessed as non-oral feeding at day seven. Overall, there was no
difference between GTN versus no GTN regarding rates of non-
oral feeding at day seven (Analysis 1.65). Early treatment with
GTNwithin six hours of onsetwas associatedwith a nonsignificant
tendency towards less non-oral feeding (OR 0.59, 95%CI 0.32 to
1.08, P =0.09), with noheterogeneity seenbetween the two studies
(301 participants; Analysis 1.67). No associations of note were
seen regarding other factors (time groups from randomisation,
stroke type or baseline systolic BP (Analysis 1.66; Analysis 1.68)).
Length of stay
The length of hospital stay relating to the index randomising event
was assessed in four studies (4078 participants), with no significant
treatment effect noted (Analysis 1.69). No subgroup effects were
noted (Analysis 1.70; Analysis 1.71; Analysis 1.72).
Headache on treatment
Headache on treatment was more common in people randomised
toGTNthan to control (OR2.37, 95%CI 1.55 to 3.62; 4186 par-
ticipants), with no significant heterogeneity seen (Analysis 1.73;
Summary of findings for the main comparison). GTN led to in-
creased reporting of headache on treatment in both ischaemic
stroke (OR 2.39, 95% CI 1.59 to 3.61, P < 0.0001; 3409 partic-
ipants; I2 = 4%) and ICH (OR 1.91, 95% CI 1.24 to 2.93, P =
0.003; 639 participants; I2 = 0%) compared with control (Analysis
1.74). Headache was more common in participants randomised to
GTN than controls for all time periods of randomisation (Analysis
1.75) and all baseline systolic BP subgroups except > 200 mmHg,
which was neutral (Analysis 1.76).
Treatment stopped early
There was no significant difference in the rate of treatment be-
ing stopped early between those randomised to GTN or control
(4193 participants), although there was significant heterogeneity
between trials (I2 = 88%; Analysis 1.77). Treatment was more
likely to be stopped in those randomised to GTN after six, and
before 36, hours but these groups were dominated by ENOS2015
(Analysis 1.79). Stroke type and baseline systolic BP did not alter
the overall neutral effect seen.
Haemodynamics
Haemodynamics are the first measurements on treatment (4197
participants; Summary of findings for the main comparison; high-
quality evidence). BP (mmHg) was significantly lowered in those
randomised to GTN compared with control (systolic BP: MD -
7.21, 95% CI -8.58 to -5.85, Analysis 1.81; diastolic BP: MD
-3.31, 95% CI -4.18 to -2.45, Analysis 1.84), whilst heart rate
(beats per minute) was significantly increased (MD 2.02, 95%
CI 1.13 to 2.91, Analysis 1.87). Of note, for heart rate there was
significant heterogeneity (I2 = 61%) between trials. Regardless
of stroke type, BP was significantly lowered by GTN compared
with control, and heart rate was increased (Analysis 1.82; Analysis
1.85; Analysis 1.88). BP was significantly lowered in those ran-
domised to GTN compared with control in all time to randomi-
sation groups (Analysis 1.83; Analysis 1.86), whilst heart rate was
significantly increased in those randomised to GTN after 24, and
before 36, hours (MD 3.44, 95% CI 1.79 to 5.09; 1218 partic-
ipants; I2 = 32%), with nonsignificant results seen in other time
groups (Analysis 1.89).
D I S C U S S I O N
Summary of main results
Five trials involving 4197 participants assessed transdermal GTN
in acute stroke. Overall, GTN did not significantly influence clin-
ical outcomes including death or disability, death, neurological
deterioration, severity, mood, quality of life, cognition, length of
hospital stay, therapy requirements, or feeding route.
Subgroup analyses showed that participants randomised to GTN
with baseline systolic BP <160 or 180 to 200mmHg had increased
rates of neurological deterioration compared with controls. Con-
versely, receiving GTN with a baseline systolic BP 180 to 200
mmHgwas associatedwith lower rates of occupational therapy but
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higher rates were seen with a baseline systolic BP > 200 mmHg.
There were no consistent effects across outcomes regarding base-
line systolic BP. Participants randomised to GTNwithin six hours
of symptom onset had nonsignificant reductions in the rates of
death or dependency (mRS > 2) and non-oral feeding, and signif-
icant improvements in NIHSS at end of treatment, and death or
dependency (mean mRS), death, disability, mood, quality of life,
and cognition at end of trial. Although participants randomised to
GTN between 24 and 36 hours after stroke onset had an increased
chance of neurological deterioration, no significant findings were
noted in any other clinical outcomes for this time period. Some of
the heterogeneity seen between the trials for several outcomes may
relate to the differing times from stroke onset to randomisation,
which ranged from within four hours of onset up to 168 hours
from onset.
In respect of haemodynamics, BP was significantly lowered by
GTN as compared with control regardless of stroke type and time
to randomisation,whilst heart ratewas significantly increased over-
all, regardless of stroke type, and in those randomised between 24
and 36 hours after stroke onset. Headache, a recognised side effect
of GTN, was more commonly seen in those randomised to GTN
overall, in both stroke types, at all times of randomisation and in
all but those with baseline systolic BP > 200 mmHg.
Of note, there was no significant difference in the rate of treat-
ment being stopped early betweenGTN and control but there was
significant heterogeneity between the trials. Those who received
GTN between six and 36 hours of stroke onset were more likely
to stop treatment early; a finding driven by ENOS (ENOS 2015).
Overall completeness and applicability of
evidence
This review includes all identified trials of NO donors in people
with recent stroke. All five trials studied transdermal GTN and
no RCTs assessing other NO donors, L-arginine or nitric oxide
synthase inhibitors have been completed. The results from trials
assessing GTN should not be extrapolated to other NO donors,
L-arginine or nitric oxide synthase inhibitors. With 4197 partici-
pants across five trials, this review has substantial external validity
and is able to comment on the safety and efficacy of GTN in acute
stroke. Overall, GTN was safe, lowered BP and increased heart
rate, but had no beneficial effect on primary and secondary clinical
outcomes.
The potential benefit of GTN seen in participants randomised
within six hours of onsetmay represent chance, but there are several
explanations to suggest that the association could be real.
1. The beneficial effects seen were across multiple outcomes
including death, dependency (mRS), disability (BI), mood
(ZDS), NIHSS, quality of life (EQ-5D health utility status and
EQ-VAS) and cognition (t-MMSE, TICS, animal naming).
2. The effects were seen in two separate trials (Ankolekar
2013; ENOS 2015).
3. The effects were seen in a population of over 300
participants. This group is equivalent in size to each of the parts
of the positive NINDS trials of intravenous alteplase (NINDS
1995) and recent trials of mechanical thrombectomy (Goyal
2016).
4. The time-dependent effect of NO donors has been
demonstrated in a meta-analysis of pre-clinical studies in which
early treatment within 60 minutes of ischaemia was associated
with positive outcomes as compared with neutral outcomes in
those studies assessing treatment up to 48 hours following
induction of ischaemic stroke (Willmot 2005).
Hyperacute administration of NO donors, such as GTN, has sev-
eral potential mechanisms of action alluded to in the background
of this review.
1. NO levels are low in acute stroke and replacing this
deficiency may be beneficial.
2. NO donors lower BP, pulse pressure and peak systolic BP,
and improve arterial compliance. Lowering BP acutely may
reduce early recurrence following ischaemic stroke, and
haematoma expansion in ICH (Anderson 2013).
3. NO dilates cerebral arteries thereby increasing perilesional
perfusion through the ’front door’ without resultant cerebral
steal (Willmot 2006).
4. NO is a potent vasodilator of pial arteries leading to ’back-
door’ collateral reperfusion (Morikawa 1992b).
5. NO donors are neuroprotective when administered early
after preclinical ischaemic stroke (Willmot 2005).
6. NO donors might augment the effects of established
interventions such as intravenous alteplase, both through
preparing patients for treatment by lowering BP, and potentially
by increasing access of lytics to occluding clot.
Quality of the evidence
This review has several strengths.
1. The study cohort was large, involving more than 4000
participants.
2. Individual patient data were used from all identified
controlled trials of NO donors, facilitating subgroup analyses.
3. Differing participant characteristics between trials
broadened external validity.
4. The trials examined different time-windows after stroke
onset including ultra-acute/pre-hospital (Ankolekar 2013),
hyper-acute (< 6 hours) (ENOS 2015), acute (< 48 hours)
(ENOS 2015), and sub-acute (< 168 hours) (Bath 2001; Rashid
2002; Willmot 2006).
5. Safety and efficacy were assessed across a multitude of
outcomes encompassing multiple clinical domains; similar
results across outcome domains and trials suggest intra- and
inter-trial consistency.
There are also several limitations of this review.
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1. GTN was the only NO donor assessed in the included
RCTs and therefore the results cannot be extrapolated to other
NO donors, for which there is no RCT-based evidence.
2. ENOS 2015 accounted for 95.6% of all participants
included in this review, and therefore dominated the data and
subsequent analyses.
3. All these data were reported by the same research group and
therefore the results need to be validated and extended by other
research groups.
4. Only one of the included studies was double-blind (Bath
2001), with the remainder being single-blind (Ankolekar 2013;
ENOS 2015; Willmot 2006) or open-label (Rashid 2002).
Further, headache, a common side effect of GTN, may have
unblinded some participants. In addition, despite all end-of-trial
outcome measures being performed by assessors blinded to
treatment in the included studies, observer bias cannot be
excluded.
5. The results relating to ultra-acute and hyper-acute
treatment involved a relatively small number of participants
(Ankolekar 2013; ENOS 2015); these findings should be
considered provisional and require formal testing.
6. This review contains analyses involving a variety of
outcomes assessed in several subgroups. Such multiple testing
can lead to spurious results and it is possible that some findings
may simply reflect chance, e.g. increased neurological
deterioration in certain BP subgroups (in the absence of a trend
across BP, or a negative effect on the NIHSS), or variation in
occupational therapy utilisation in BP subgroups.
In summary, the overall quality of the evidence as assessed by
GRADE criteria was high, due to the aforementioned strengths of
the included studies.
Potential biases in the review process
This review was compiled following an extensive literature search,
without language restrictions, by both the review authors and
Cochrane Stroke Group. The resultant risk for publication bias
is therefore low. However, all the included trials were from the
same research group - of which the authors are members - which
may have potentially introduced bias in the review process, e.g.
in choice of outcomes and subgroups. Nevertheless, all outcomes
reported in the included trials were summarised here (including
mRS, BI, EQ-5D, EQ-VAS, t-MMSE, TICS-M, animal naming,
ZDS, NIHSS, death), and subgroups (time, stroke type, blood
pressure) were used as prespecified in the ENOS trial (ENOS
2015).
Agreements and disagreements with other
studies or reviews
A recently published systematic review and individual patient data
meta-analysis assessed the same five trials of transdermal GTN
under the auspices of the Blood pressure in Acute Stroke Collabo-
ration (BASC 2016). Both unadjusted and adjusted analyses were
performed including a predefined subgroup analysis by time to
randomisation. In this regard, the results and conclusions of both
reviews were similar showing that GTN is safe though ineffective
overall, but may improve outcome in a time-dependent manner if
given within six hours of stroke onset.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently insufficient evidence to determine the efficacy
of NO donors, L-arginine, or nitric oxide synthase inhibitors in
acute stroke, with only RCT evidence available for the NO donor,
GTN. In people with acute stroke, transdermal GTN reduces
blood pressure, increases heart rate and headache, but does not
alter outcome. When administered within six hours, GTN may
improve clinical outcomes, a finding that requires confirmation in
an independent trial (e.g. RIGHT-2 2015).
Implications for research
Large phase III randomised trials are required to assess the admin-
istration of NO donors in ultra-acute and hyper-acute strokes.
• The safety and efficacy of NO donors other than GTN.
• The safety and efficacy of GTN administered in the ultra-
acute phase/prehospital environment (e.g. RIGHT-2 2015).
• The effect of GTN on long-term functional outcome and
death, i.e. beyond 90 days (e.g. RIGHT-2 2015).
• Mechanisms by which GTN might work, e.g. potentially
through reducing haematoma expansion in ICH, and improving
collateral supply in ischaemic stroke (e.g. RIGHT-2 2015).
• The health economics of GTN (although the low cost of
treatment, i.e. < £5 per patient, means that GTN will dominate
if efficacy is seen for mRS).
• Whether there are particular subgroups who benefit, or do
not benefit, from GTN.
• Whether GTN acts as adjunctive therapy to intravenous
thrombolysis in ischaemic stroke.
• Whether GTN acts as adjunctive therapy to mechanical
thrombectomy in ischaemic stroke.
• Whether GTN reduces the need for hospital-based
therapies such as mechanical thrombectomy, hemicraniectomy,
need for rehabilitation therapy.
18Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Whether low and middle income countries can utilise GTN
in the hyperacute period.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ankolekar 2013
Methods Single-blind, blinded endpoint
Randomisation (1:1)
Participants UK, single centre
41 participants: treatment 25; control 16
Mean age: treatment 79 years; control 81 years
Male: treatment 15 (65%); control 7 (43.8%)
Inclusion: FAST positive test; systolic BP ≥ 140 mmHg; age > 40 years for men and >
55 years for women
Time to randomisation: within 4 hours of onset
Interventions Treatment: transdermal GTN patch 5 mg once daily
Control: no patch
(Blinding with gauze dressing over patch/equivalent area of skin)
Duration: 7 days
Outcomes Primary: systolic BP at 2 hours
Secondary:
• 15 minutes: systolic BP, diastolic BP, HR
• Day 7: SSS; recurrent stroke; death; hypotension; neurological deterioration (5-
point decrease in SSS)
• Day 90: mRS; BI; EQ-5D, EQ-VAS; MMSE; Zung Depression Scale
Notes Exclusion: requirement for or contraindication to nitrate therapy; GCS ≤ 8; blood
glucose < 2.5 mmol/L; non-ambulatory prior to symptom onset
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple randomisation. Equal distribution
between trial groups
Allocation concealment (selection bias) Low risk Opaque envelope containing a gauze dress-
ing +/- GTN patch was only opened after
consent was obtained
Blinding (performance bias and detection
bias)
All outcomes
Low risk GTN was given single-blinded (partic-
ipant), whilst outcomes were assessed
blinded to treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk GTN was given single-blinded as no
placebo patches were available. A gauze
dressing was placed over the GTN patch
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Ankolekar 2013 (Continued)
or equivalent area of skin out of sight. As a
result, participants were blinded whilst the
treating clinician was unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed blinded to treatment
group
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for. No differ-
ence between trial groups
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk None found
Bath 2001
Methods Double-blind, placebo-controlled
Randomisation by computer (minimisation by age, mean arterial BP, baseline SSS, hours
from onset, presence of stroke lesion on CT)
Participants UK, single centre
37 participants: treatment 16; control 21
Age: treatment 76 years; control 72 years
Male: treatment 6 (38%); control; 12 (57%)
Inclusion: IS or ICH
Time to randomisation: within five days of onset
Interventions Treatment: transdermal GTN patch 5 mg once daily
Control: matching placebo
Duration: 12 days
Outcomes Primary: BP on day 1 (24 hour ambulatory BP measured 3 times per hour during the
day and hourly at night at days 0, 1, 8)
Secondary: death at end of treatment; death or dependency (mRS > 2), death, and BI at
3 months
Notes Exclusion: taking part in another trial
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation with minimisa-
tion
Allocation concealment (selection bias) Low risk Computer randomisation with minimisa-
tion
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Bath 2001 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Matching treatment and placebo patches
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Matching treatment and placebo patches
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed blinded to treatment
group
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differences between trial groups
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk None found
ENOS 2015
Methods Single-blind, parallel-group, partial factorial study
Randomisation via password-protected, data-encrypted website (minimisation by age,
sex, stroke severity, time to treatment and total anterior circulation syndrome)
Participants International (23 countries), multicentre (173 sites)
4011 participants: treatment 2000; control 2011
Age: treatment 70 years; control 70 years
Male: treatment 1147 (57%); control 1150 (57%)
Inclusion: IS or ICH; motor deficit in arm or leg, or both; systolic BP 140 to 220 mmHg
Time to randomisation: within 48 hours of onset
Interventions • Treatment: transdermal GTN patch 5 mg once daily
• Control: no GTN (blinding with gauze dressing over patch/equivalent area of
skin)
In appropriate participants:
• Treatment: continue pre-stroke antihypertensive medication
• Control: stop pre-stroke antihypertensive medication
Duration: 7 days
Outcomes Primary: mRS at day 90
Secondary:
• days 1 to 7: BP and HR
• day 7: recurrent stroke
• discharge: length of hospital stay; disposition
• day 90: death or dependency (mRS > 2); BI; EQ-5D, EQ-VAS; MMSE, TICS-
M; animal naming; Zung Depression Scale
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ENOS 2015 (Continued)
Notes Exclusions: GCS < 8; pure sensory stroke; preceding dependency (mRS 3 to 5); con-
founding neurological or psychiatric illness; stroke mimic; severe liver or renal dysfunc-
tion; severe comorbidity; pregnant or breastfeeding; planned surgical intervention; pre-
vious participation in ENOS 2015; contraindication to or definite need for nitrates and/
or prestroke antihypertensive medication
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer randomisation with
minimisation
Allocation concealment (selection bias) Low risk Central website-based
Blinding (performance bias and detection
bias)
All outcomes
Low risk GTN was given single-blinded (partici-
pant), whilst outcomes were assessed cen-
trally and blinded to treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk GTN was given single-blinded as no
placebo patches were available. A gauze
dressing was placed over the GTN patch
or equivalent area of skin out of sight. As a
result, participants were blinded whilst the
treating clinician was unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed centrally, blinded to
treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk No difference between trial groups
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk None found
Rashid 2002
Methods Open-label, blinded endpoint dose comparison controlled trial
Randomisation by computer (minimisation by age, gender, SSS, mean arterial pressure)
Participants UK, single centre
90 participants: treatment 60; control 30
Mean age: treatment 70.8 years; control 73.9 years
Male: treatment 28 (46.7%); control 13 (43.3%)
Inclusion: IS or ICH
Time to randomisation: within 72 hours of onset
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Rashid 2002 (Continued)
Interventions Treatment: transdermal GTN patch 5 mg for 10 days; 5 mg for 4 days, then 10 mg for
6 days; 10 mg for 10 days
Control: no patch
Duration: 10 days
Outcomes Primary: BP on day 1 (24 hour ambulatory BP measured 3 times per hour during the
day and hourly at night at days 0, 1, 4, 5, 10)
Secondary: death at end of treatment; death or dependency (mRS > 2), death, BI and
QoL at 3 months
Notes Exclusion: systolic BP > 230 or < 100 mmHg; diastolic BP > 130 or < 60 mmHg; HR >
130 or < 50 bpm; mild stroke; coma; premorbid dependence (mRS ≥ 3); requirement
for or contraindication to nitrate therapy; presence of illness that could confound neu-
rological or functional evaluation
Any antihypertensive medication was stopped on admission and recommenced after 10
days
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation with minimisa-
tion
Allocation concealment (selection bias) Low risk Computer randomisation with minimisa-
tion
Blinding (performance bias and detection
bias)
All outcomes
Low risk GTN was given single-blinded (partic-
ipant), whilst outcomes were assessed
blinded to treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label as no matching treatment and
placebo patches were available
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed blinded to treatment
group
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differences between trial groups
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk None found
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Willmot 2006
Methods Participant- and measurement-blinded RCT
Randomisation by computer (2:1, minimisation by age, sex, baseline systolic BP, baseline
SSS, time from onset, presence of stroke lesion on CT)
Participants UK, single centre
18 participants: treatment 12; control 6
Age: treatment 69 years; control 70 years
Male: treatment 2 (16.7%); control 3 (50%)
Inclusion: IS or ICH; previously independent; clinical stroke syndrome and limb weak-
ness
Time to randomisation: within 5 days of onset
Interventions Treatment: transdermal GTN patch 5 mg once daily
Control: no patch
(Blinding with gauze dressing over patch/equivalent area of skin)
Duration: 7 days
Outcomes Primary: BP (immediately before the baseline Xenon-CT and immediately after the post-
treatment scan), cerebral blood flow (Xenon-CT and transcranial doppler) and cerebral
perfusion pressure (transcranial doppler)
Secondary:
• days 1 to 7: BP and HR
• day 7: SSS, recurrent stroke, death, neurological deterioration
• day 90: mRS, BI, EQ-5D, EQ-VAS, MMSE, Zung Depression Scale
Notes Exclusion: requirement for or contraindication to nitrate therapy; definite need for pre-
vious antihypertensive or vasoactive drugs; unable to cooperate with scanning
Prior antihypertensive medication was stopped on admission
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation with minimisa-
tion
Allocation concealment (selection bias) Low risk Computer randomisation with minimisa-
tion
Blinding (performance bias and detection
bias)
All outcomes
Low risk GTN was given single-blinded (partic-
ipant), whilst outcomes were assessed
blinded to treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk GTN was given single-blinded as no
placebo patches were available. A gauze
dressing was placed over the GTN patch
or equivalent area of skin out of sight. As a
result, participants were blinded whilst the
treating clinician was unblinded
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Willmot 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed blinded to treatment
group
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk None found
BI: Barthel Index
bpm: beats per minute
BP: blood pressure
CT: computed tomography
DBP: diastolic blood pressure
EQ-5D: European Quality of life - 5 Dimensions
EQ-VAS: European Quality of life - Visual Analogue Scale
GCS: Glasgow Coma Scale
GTN: glyceryl trinitrate
HR: heart rate
ICH: intracerebral haemorrhage
IS: ischaemic stroke
MMSE: Mini Mental State Examination
mRS: modified Rankin Scale
QoL: quality of life
SBP: systolic blood pressure
SSS: Scandinavian Stroke Scale
TICS-M: Modified Telephone Interview Cognition Scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Butterworth 1998 Nonrandomised study assessing sodium nitroprusside in acute IS
El Mously 2014 Case-control study
El-Zammer 2012 Not randomised or controlled
FAST-BP 2013 Not randomised or controlled (ongoing)
Flinders 2014 Nonrandomised study as part of Field Administration of Stroke Therapy-Magnesium (FAST-MAG) clinical
trial
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(Continued)
Kate 2015 Nonrandomised, controlled study assessing treatment with sublingual nitroglycerin +/- intravenous labetalol
depending on baseline systolic BP on CBF
Kerr 2000 Unable to obtain published or unpublished data
MAPAS 2009 Non-controlled, target-based study (ongoing)
Nakamura 2010 Head-to-head comparison study comparing perindopril vs candesartan vs conventional therapy (including ni-
trates)
PATICH 2014 Target-based study (ongoing)
PATIS 2009 Non-randomised, target-based study (ongoing)
Roitberg 2008 Confounded randomised controlled trial of nicardipine versus sodium nitroprusside in ICH and subarachnoid
haemorrhage
Sakamoto 2015 Not randomised or controlled
Sanossian 2012 Nonrandomised study as part of FAST-MAG clinical trial
Suri 2009 Retrospective study on the use of nicardipine or sodium nitroprusside in ICH
Xu 2007 Assessing vertebrobasilar insufficiency, not acute stroke
CBF: cerebral blood flow
ICH: intracerebral haemorrhage
IS: ischaemic stroke
SBP: systolic blood pressure
vs: versus
Characteristics of ongoing studies [ordered by study ID]
RIGHT-2 2015
Trial name or title Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2)
Methods Prospective multicentre single-blind randomised controlled trial
Participants 850 participants
Inclusion: FAST positive test, BP ≥ 120 mmHg, presenting to ambulance service following a 999 emergency
call
Time to randomisation: within 4 hours of onset
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RIGHT-2 2015 (Continued)
Interventions Treatment: transdermal GTN patch 5 mg once daily
Control: sham patch
(Blinding with gauze dressing over patch)
Duration: 4 days
Outcomes Primary: mRS at 90 days
Secondary:
• Hospital admission: NIHSS; systolic BP, DBP, HR; stroke lesion size on CT
• Day 2-4: systolic BP, diastolic BP, HR; NIHSS; recurrent stroke; death; hypotension; neurological
deterioration (NIHSS ≥ 4 points or ≥ 2 point increase in any domain)
• Discharge/death: length of stay; patient disposition
• Day 90 and 365: mRS; BI; EQ-5D, EQ-VAS; MMSE; TICS-M; animal naming; Zung Depression
Scale; stroke recurrence
Starting date October 2015
Contact information Philip Bath, Stroke Association Professor of StrokeMedicine, Stroke, Division of Clinical Neuroscience, B52,
Clinical Sciences Building, University of Nottingham, City Hospital Campus, Hucknall Road, Nottingham,
NG5 1PB (philip.bath@nottingham.ac.uk)
Notes
BI: Barthel index
BP: Blood pressure
CT: Computed tomography
DBP: Diastolic blood pressure
EQ-5D: European quality of life-5 dimensions
EQ-VAS: European quality of life-visual analogue scale
GTN: Glyceryl trinitrate
HR: Heart rate
ICH: Intracerebral haemorrhage
IS: Ischaemic stroke
MMSE: Mini-mental state examination
MRI: Magnetic resonance imaging
mRS: Modified Rankin scale
NIHSS: National Institutes of Health Stroke Scale
QoL: Quality of life
SBP: Systolic blood pressure
SSS: Scandanavian stroke scale
TICS-M: modified Telephone Interview for Cognitive Status
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D A T A A N D A N A L Y S E S
Comparison 1. Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or dependency (mRS>2),
end of trial
5 4195 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.86, 1.10]
1.1 Overall 5 4195 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.86, 1.10]
2 Death or dependency (mRS>2),
end of trial, by stroke type
5 4143 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.81, 1.23]
2.1 Ischaemic 5 3502 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.62, 1.53]
2.2 Intracerebral haemorrhage 4 641 Odds Ratio (M-H, Random, 95% CI) 1.20 [0.45, 3.21]
3 Death or dependency (mRS>2),
end of trial, by time to
randomisation
5 4194 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.86, 1.10]
3.1 < 6 hours 2 312 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.41, 1.02]
3.2 6.1 to 12 hours 2 440 Odds Ratio (M-H, Random, 95% CI) 1.21 [0.83, 1.77]
3.3 12.1 to 24 hours 2 1070 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.76, 1.24]
3.4 24.1 to 36 hours 3 1218 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.83, 1.33]
3.5 > 36 hours 4 1154 Odds Ratio (M-H, Random, 95% CI) 0.91 [0.72, 1.16]
4 Death or dependency (mRS>2),
end of trial, by baseline SBP
5 4193 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.85, 1.10]
4.1 < 160 mmHg 5 1706 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.21]
4.2 160.1 to 180 mmHg 5 1480 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.23, 2.60]
4.3 180.1 to 200 mmHg 5 747 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.70, 1.28]
4.4 > 200 mmHg 3 260 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.53, 1.48]
5 Death or dependency (mean
mRS), end of trial
5 4195 Mean Difference (IV, Random, 95% CI) -0.08 [-0.52, 0.36]
5.1 Overall 5 4195 Mean Difference (IV, Random, 95% CI) -0.08 [-0.52, 0.36]
6 Death or dependency (mean
mRS), end of trial, by stroke
type
5 4143 Mean Difference (IV, Random, 95% CI) -0.05 [-0.31, 0.21]
6.1 Ischaemic 5 3502 Mean Difference (IV, Random, 95% CI) -0.13 [-0.62, 0.35]
6.2 ICH 4 641 Mean Difference (IV, Random, 95% CI) 0.02 [-0.24, 0.28]
7 Death or dependency (mean
mRS), end of trial, by time to
randomisation
5 4194 Mean Difference (IV, Random, 95% CI) -0.08 [-0.27, 0.11]
7.1 < 6 hours 2 312 Mean Difference (IV, Random, 95% CI) -0.79 [-1.35, -0.23]
7.2 6.1 to 12 hours 2 440 Mean Difference (IV, Random, 95% CI) 0.19 [-0.15, 0.53]
7.3 12.1 to 24 hours 2 1070 Mean Difference (IV, Random, 95% CI) -0.03 [-0.24, 0.18]
7.4 24.1 to 36 hours 3 1218 Mean Difference (IV, Random, 95% CI) 0.06 [-0.13, 0.25]
7.5 > 36 hours 4 1154 Mean Difference (IV, Random, 95% CI) -0.04 [-0.35, 0.28]
8 Death or dependency (mean
mRS), end of trial, by baseline
SBP
5 4193 Mean Difference (IV, Random, 95% CI) -0.04 [-0.26, 0.17]
8.1 <160 mmHg 5 1706 Mean Difference (IV, Random, 95% CI) 0.01 [-0.16, 0.17]
8.2 160.1-180 mmHg 5 1480 Mean Difference (IV, Random, 95% CI) -0.38 [-1.42, 0.66]
8.3 180.1-200 mmHg 5 747 Mean Difference (IV, Random, 95% CI) 0.04 [-0.20, 0.28]
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8.4 >200 mmHg 3 260 Mean Difference (IV, Random, 95% CI) -0.26 [-0.70, 0.17]
9 Death, end of treatment 5 4197 Odds Ratio (M-H, Random, 95% CI) 1.09 [0.76, 1.56]
9.1 Overall 5 4197 Odds Ratio (M-H, Random, 95% CI) 1.09 [0.76, 1.56]
10 Death, end of treatment, by
stroke type
5 4143 Odds Ratio (M-H, Random, 95% CI) 1.04 [0.73, 1.49]
10.1 Ischaemic 5 3502 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.69, 1.51]
10.2 ICH 4 641 Odds Ratio (M-H, Random, 95% CI) 1.16 [0.50, 2.69]
11 Death, end of treatment, by
time to randomisation
5 4195 Odds Ratio (M-H, Random, 95% CI) 1.07 [0.74, 1.54]
11.1 < 6 hours 2 312 Odds Ratio (M-H, Random, 95% CI) 0.82 [0.28, 2.43]
11.2 6.1 to 12 hours 2 440 Odds Ratio (M-H, Random, 95% CI) 1.69 [0.49, 5.87]
11.3 12.1 to 24 hours 2 1070 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.46, 1.54]
11.4 24.1 to 36 hours 3 1218 Odds Ratio (M-H, Random, 95% CI) 1.90 [0.90, 4.00]
11.5 > 36 hours 4 1155 Odds Ratio (M-H, Random, 95% CI) 0.80 [0.35, 1.80]
12 Death, end of treatment, by
baseline SBP
5 4196 Odds Ratio (M-H, Random, 95% CI) 1.09 [0.76, 1.56]
12.1 < 160 mmHg 5 1706 Odds Ratio (M-H, Random, 95% CI) 1.46 [0.83, 2.56]
12.2 160.1-180 mmHg 5 1480 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.47, 1.54]
12.3 180.1 to 200 mmHg 5 748 Odds Ratio (M-H, Random, 95% CI) 0.67 [0.28, 1.65]
12.4 > 200 mmHg 4 262 Odds Ratio (M-H, Random, 95% CI) 2.13 [0.60, 7.61]
13 Death, end of trial 5 4197 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.40, 1.50]
13.1 Overall 5 4197 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.40, 1.50]
14 Death, end of trial, by stroke
type
5 4143 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.72, 1.04]
14.1 Ischaemic 5 3502 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.69, 1.05]
14.2 ICH 4 641 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.22, 5.21]
15 Death, end of trial, by time to
randomisation
5 4195 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.58, 1.14]
15.1 < 6 hours 2 312 Odds Ratio (M-H, Random, 95% CI) 0.30 [0.15, 0.60]
15.2 6.1 to 12 hours 2 440 Odds Ratio (M-H, Random, 95% CI) 1.34 [0.79, 2.25]
15.3 12.1 to 24 hours 2 1070 Odds Ratio (M-H, Random, 95% CI) 1.52 [0.20, 11.53]
15.4 24.1 to 36 hours 3 1218 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.69, 1.37]
15.5 > 36 hours 4 1155 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.27, 2.44]
16 Death, end of trial, by baseline
SBP
5 4196 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.05]
16.1 < 160 mmHg 5 1706 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.71, 1.27]
16.2 160.1 to 180 mmHg 5 1480 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.44, 1.41]
16.3 180.1 to 200 mmHg 5 748 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.54, 1.33]
16.4 > 200 mmHg 4 262 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.40, 1.50]
17 Neurological deterioration, end
of treatment
4 4158 Odds Ratio (M-H, Random, 95% CI) 1.24 [0.97, 1.60]
17.1 Overall 4 4158 Odds Ratio (M-H, Random, 95% CI) 1.24 [0.97, 1.60]
18 Neurological deterioration, end
of treatment, by stroke type
4 4106 Odds Ratio (M-H, Random, 95% CI) 1.17 [0.74, 1.86]
18.1 Ischaemic 4 3469 Odds Ratio (M-H, Random, 95% CI) 0.58 [0.09, 3.75]
18.2 ICH 3 637 Odds Ratio (M-H, Random, 95% CI) 1.46 [0.83, 2.57]
19 Neurological deterioration,
end of treatment, by time to
randomisation
4 4159 Odds Ratio (M-H, Random, 95% CI) 1.18 [0.81, 1.72]
19.1 < 6 hours 2 312 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.28, 1.16]
19.2 6.1 to 12 hours 2 440 Odds Ratio (M-H, Random, 95% CI) 2.11 [0.93, 4.78]
19.3 12.1 to 24 hours 2 1070 Odds Ratio (M-H, Random, 95% CI) 1.18 [0.74, 1.88]
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19.4 24.1 to 36 hours 3 1218 Odds Ratio (M-H, Random, 95% CI) 2.00 [1.19, 3.35]
19.5 > 36 hours 3 1119 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.55, 1.59]
20 Neurological deterioration, end
of treatment, by baseline SBP
4 4159 Odds Ratio (M-H, Random, 95% CI) 1.22 [0.88, 1.68]
20.1 Baseline SBP < 160 4 1688 Odds Ratio (M-H, Random, 95% CI) 1.62 [1.05, 2.50]
20.2 Baseline SBP 160.1 to
180
4 1468 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.58, 1.35]
20.3 Baseline SBP 180.1 to
200
4 743 Odds Ratio (M-H, Random, 95% CI) 1.81 [1.05, 3.12]
20.4 Baseline SBP > 200 3 260 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.25, 1.57]
21 NIH Stroke Scale, end of
treatment
4 4137 Mean Difference (IV, Random, 95% CI) -0.28 [-0.70, 0.14]
21.1 Overall 4 4137 Mean Difference (IV, Random, 95% CI) -0.28 [-0.70, 0.14]
22 NIH Stroke Scale, end of
treatment, by stroke type
4 4085 Mean Difference (IV, Random, 95% CI) -0.19 [-1.19, 0.81]
22.1 Ischaemic 4 3452 Mean Difference (IV, Random, 95% CI) -0.47 [-2.39, 1.45]
22.2 ICH 3 633 Mean Difference (IV, Random, 95% CI) 0.12 [-0.94, 1.18]
23 NIH Stroke Scale, end
of treatment, by time to
randomisation
4 4136 Mean Difference (IV, Random, 95% CI) -0.32 [-0.88, 0.25]
23.1 < 6 hours 2 309 Mean Difference (IV, Random, 95% CI) -2.07 [-3.81, -0.34]
23.2 6.1 to 12 hours 2 440 Mean Difference (IV, Random, 95% CI) 1.17 [-0.14, 2.48]
23.3 12.1-24 hours 2 1062 Mean Difference (IV, Random, 95% CI) -0.26 [-1.13, 0.61]
23.4 24.1 to 36 hours 3 1213 Mean Difference (IV, Random, 95% CI) -0.07 [-0.81, 0.68]
23.5 > 36 hours 3 1112 Mean Difference (IV, Random, 95% CI) -0.72 [-1.50, 0.05]
24 NIH Stroke Scale, end of
treatment, by baseline SBP
4 4135 Mean Difference (IV, Random, 95% CI) -0.16 [-0.65, 0.33]
24.1 < 160 mmHg 4 1681 Mean Difference (IV, Random, 95% CI) -0.15 [-1.04, 0.75]
24.2 160.1 to 180 mmHg 4 1454 Mean Difference (IV, Random, 95% CI) -0.47 [-2.32, 1.38]
24.3 180.1 to 200 mmHg 4 741 Mean Difference (IV, Random, 95% CI) -0.11 [-1.05, 0.83]
24.4 > 200 mmHg 3 259 Mean Difference (IV, Random, 95% CI) 0.29 [-1.46, 2.04]
25 Barthel Index, end of trial 5 4153 Mean Difference (IV, Random, 95% CI) -0.09 [-5.39, 5.20]
25.1 Overall 5 4153 Mean Difference (IV, Random, 95% CI) -0.09 [-5.39, 5.20]
26 Barthel Index, end of trial, by
stroke type
5 4100 Mean Difference (IV, Random, 95% CI) 0.57 [-3.72, 4.87]
26.1 Ischaemic 5 3466 Mean Difference (IV, Random, 95% CI) 0.60 [-5.27, 6.47]
26.2 ICH 4 634 Mean Difference (IV, Random, 95% CI) 0.92 [-5.19, 7.03]
27 Barthel Index, end of trial, by
time to randomisation
5 4152 Mean Difference (IV, Random, 95% CI) 1.81 [-1.62, 5.25]
27.1 < 6 hours 2 312 Mean Difference (IV, Random, 95% CI) 14.57 [5.95, 23.19]
27.2 6.1 to 12 hours 2 434 Mean Difference (IV, Random, 95% CI) -3.47 [-11.00, 4.06]
27.3 12.1 to 24 hours 2 1057 Mean Difference (IV, Random, 95% CI) 1.49 [-3.21, 6.19]
27.4 24.1 to 36 hours 3 1205 Mean Difference (IV, Random, 95% CI) 0.59 [-3.81, 4.98]
27.5 > 36 hours 4 1144 Mean Difference (IV, Random, 95% CI) 0.50 [-4.88, 5.89]
28 Barthel Index, end of trial, by
baseline SBP
5 4150 Mean Difference (IV, Random, 95% CI) 0.66 [-3.00, 4.32]
28.1 < 160 mmHg 5 1687 Mean Difference (IV, Random, 95% CI) 0.47 [-2.89, 3.83]
28.2 160.1 to 180 mmHg 5 1464 Mean Difference (IV, Random, 95% CI) 4.30 [-8.25, 16.85]
28.3 180.1 to 200 mmHg 5 741 Mean Difference (IV, Random, 95% CI) 0.28 [-5.36, 5.91]
28.4 > 200 mmHg 3 258 Mean Difference (IV, Random, 95% CI) 7.74 [-2.49, 17.97]
29 Mood (Zung), end of trial 3 3312 Mean Difference (IV, Random, 95% CI) -0.83 [-4.44, 2.79]
29.1 Overall 3 3312 Mean Difference (IV, Random, 95% CI) -0.83 [-4.44, 2.79]
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30 Mood (Zung), end of trial, by
stroke type
3 3269 Mean Difference (IV, Random, 95% CI) -0.54 [-2.20, 1.12]
30.1 Ischaemic 3 2745 Mean Difference (IV, Random, 95% CI) -1.04 [-7.81, 5.72]
30.2 ICH 3 524 Mean Difference (IV, Random, 95% CI) 0.51 [-3.67, 4.69]
31 Mood (Zung), end of trial, by
time to randomisation
3 3311 Mean Difference (IV, Random, 95% CI) -1.24 [-4.38, 1.91]
31.1 < 6 hours 2 268 Mean Difference (IV, Random, 95% CI) -11.12 [-17.35, -4.
90]
31.2 6.1 to 12 hours 2 372 Mean Difference (IV, Random, 95% CI) 2.55 [-2.58, 7.68]
31.3 12.1 to 24 hours 1 834 Mean Difference (IV, Random, 95% CI) 0.98 [-2.34, 4.30]
31.4 24.1 to 36 hours 2 989 Mean Difference (IV, Random, 95% CI) 0.42 [-2.58, 3.42]
31.5 > 36 hours 2 848 Mean Difference (IV, Random, 95% CI) -1.54 [-4.66, 1.57]
32 Mood (Zung), end of trial, by
baseline SBP
3 3312 Mean Difference (IV, Random, 95% CI) -0.41 [-2.06, 1.24]
32.1 < 160 mmHg 3 1344 Mean Difference (IV, Random, 95% CI) 1.19 [-9.36, 11.75]
32.2 160.1 to 180 mmHg 3 1179 Mean Difference (IV, Random, 95% CI) -0.33 [-3.09, 2.43]
32.3 180.1 to 200 mmHg 3 582 Mean Difference (IV, Random, 95% CI) -0.19 [-4.07, 3.69]
32.4 > 200 mmHg 2 207 Mean Difference (IV, Random, 95% CI) -4.32 [-11.37, 2.74]
33 EQ5D-3L, end of trial 4 4088 Mean Difference (IV, Random, 95% CI) -0.01 [-0.17, 0.15]
33.1 Overall 4 4088 Mean Difference (IV, Random, 95% CI) -0.01 [-0.17, 0.15]
34 EQ5D-3L, end of trial, by
stroke type
4 4084 Mean Difference (IV, Random, 95% CI) 0.01 [-0.08, 0.09]
34.1 Ischaemic 4 3457 Mean Difference (IV, Random, 95% CI) 0.01 [-0.17, 0.18]
34.2 ICH 2 627 Mean Difference (IV, Random, 95% CI) -0.02 [-0.08, 0.04]
35 EQ5D-3L, end of trial, by time
to randomisation
4 4087 Mean Difference (IV, Random, 95% CI) 0.01 [-0.04, 0.06]
35.1 < 6 hours 2 312 Mean Difference (IV, Random, 95% CI) 0.11 [0.02, 0.20]
35.2 6.1 to 12 hours 2 435 Mean Difference (IV, Random, 95% CI) -0.04 [-0.12, 0.04]
35.3 12.1 to 24 hours 2 1052 Mean Difference (IV, Random, 95% CI) -0.01 [-0.06, 0.04]
35.4 24.1 to 36 hours 2 1196 Mean Difference (IV, Random, 95% CI) 0.01 [-0.04, 0.06]
35.5 > 36 hours 3 1092 Mean Difference (IV, Random, 95% CI) -0.10 [-0.33, 0.13]
36 EQ5D-3L, end of trial, by
baseline SBP
4 4086 Mean Difference (IV, Random, 95% CI) 0.02 [-0.05, 0.08]
36.1 < 160 mmHg 4 1664 Mean Difference (IV, Random, 95% CI) -0.12 [-0.34, 0.10]
36.2 160.1 to 180 mmHg 4 1438 Mean Difference (IV, Random, 95% CI) 0.22 [-0.08, 0.51]
36.3 180.1 to 200 mmHg 3 726 Mean Difference (IV, Random, 95% CI) -0.01 [-0.07, 0.05]
36.4 > 200 mmHg 3 258 Mean Difference (IV, Random, 95% CI) 0.08 [-0.01, 0.18]
37 EQ VAS, end of trial 4 3575 Mean Difference (IV, Random, 95% CI) 1.12 [-0.91, 3.15]
37.1 Overall 4 3575 Mean Difference (IV, Random, 95% CI) 1.12 [-0.91, 3.15]
38 EQ VAS, end of trial, by stroke
type
4 3523 Mean Difference (IV, Random, 95% CI) 0.92 [-1.13, 2.96]
38.1 Ischaemic 4 2974 Mean Difference (IV, Random, 95% CI) 1.15 [-1.06, 3.37]
38.2 ICH 2 549 Mean Difference (IV, Random, 95% CI) -0.43 [-5.72, 4.86]
39 EQ VAS, end of trial, by time
to randomisation
4 3574 Mean Difference (IV, Random, 95% CI) 1.91 [-1.21, 5.04]
39.1 < 6 hours 2 295 Mean Difference (IV, Random, 95% CI) 9.96 [2.49, 17.43]
39.2 6.1 to 12 hours 2 392 Mean Difference (IV, Random, 95% CI) -2.92 [-9.45, 3.61]
39.3 12.1 to 24 hours 2 906 Mean Difference (IV, Random, 95% CI) 0.67 [-3.42, 4.76]
39.4 24.1 to 36 hours 3 1045 Mean Difference (IV, Random, 95% CI) -1.56 [-5.31, 2.18]
39.5 > 36 hours 3 936 Mean Difference (IV, Random, 95% CI) 4.63 [-1.21, 10.48]
40 EQ VAS, end of trial, by
baseline SBP
4 3574 Mean Difference (IV, Random, 95% CI) 0.88 [-1.16, 2.92]
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40.1 < 160 mmHg 4 1480 Mean Difference (IV, Random, 95% CI) 0.41 [-2.74, 3.57]
40.2 160.1 to 180 mmHg 4 1258 Mean Difference (IV, Random, 95% CI) 2.02 [-6.59, 10.64]
40.3 180.1 to 200 mmHg 4 617 Mean Difference (IV, Random, 95% CI) 0.77 [-4.21, 5.75]
40.4 > 200 mmHg 3 219 Mean Difference (IV, Random, 95% CI) 5.22 [-3.55, 14.00]
41 t-MMSE, end of trial 3 2078 Mean Difference (IV, Random, 95% CI) 1.13 [-1.77, 4.03]
41.1 Overall 3 2078 Mean Difference (IV, Random, 95% CI) 1.13 [-1.77, 4.03]
42 t-MMSE, end of trial, by stroke
type
3 2041 Mean Difference (IV, Random, 95% CI) 0.78 [-0.90, 2.45]
42.1 Ischaemic 3 1729 Mean Difference (IV, Random, 95% CI) 3.15 [-3.44, 9.74]
42.2 ICH 2 312 Mean Difference (IV, Random, 95% CI) 0.15 [-1.61, 1.91]
43 t-MMSE, end of trial, by time
to randomisation
3 2078 Mean Difference (IV, Random, 95% CI) 0.69 [-0.59, 1.97]
43.1 < 6 hours 2 219 Mean Difference (IV, Random, 95% CI) 3.61 [1.68, 5.55]
43.2 6.1 to 12 hours 2 254 Mean Difference (IV, Random, 95% CI) -1.75 [-3.68, 0.18]
43.3 12.1 to -24 hours 1 556 Mean Difference (IV, Random, 95% CI) 0.0 [-1.24, 1.24]
43.4 24.1 to 36 hours 1 587 Mean Difference (IV, Random, 95% CI) 0.33 [-0.90, 1.56]
43.5 > 36 hours 2 462 Mean Difference (IV, Random, 95% CI) 0.82 [-0.58, 2.22]
44 t-MMSE, end of trial, by
baseline SBP
3 2073 Mean Difference (IV, Random, 95% CI) 0.52 [-0.46, 1.50]
44.1 < 160 mmHg 2 860 Mean Difference (IV, Random, 95% CI) -0.20 [-1.21, 0.82]
44.2 160.1 to 180 mmHg 3 744 Mean Difference (IV, Random, 95% CI) 4.78 [-4.78, 14.33]
44.3 180.1 to 200 mmHg 2 346 Mean Difference (IV, Random, 95% CI) 0.04 [-1.56, 1.64]
44.4 > 200 mmHg 2 123 Mean Difference (IV, Random, 95% CI) 1.44 [-1.49, 4.36]
45 TICS, end of trial 1 2013 Mean Difference (IV, Random, 95% CI) 0.30 [-0.63, 1.23]
45.1 Overall 1 2013 Mean Difference (IV, Random, 95% CI) 0.30 [-0.63, 1.23]
46 TICS, end of trial, by stroke
type
1 1985 Mean Difference (IV, Random, 95% CI) 0.35 [-0.59, 1.28]
46.1 Ischaemic 1 1683 Mean Difference (IV, Random, 95% CI) 0.42 [-0.59, 1.43]
46.2 ICH 1 302 Mean Difference (IV, Random, 95% CI) -0.12 [-2.65, 2.41]
47 TICS, end of trial, by time to
randomisation
1 2013 Mean Difference (IV, Random, 95% CI) 0.62 [-1.33, 2.56]
47.1 < 6 hours 1 182 Mean Difference (IV, Random, 95% CI) 5.59 [2.63, 8.55]
47.2 6.1 to 12 hours 1 248 Mean Difference (IV, Random, 95% CI) -2.19 [-4.94, 0.56]
47.3 12.1 to 24 hours 1 549 Mean Difference (IV, Random, 95% CI) -0.56 [-2.32, 1.20]
47.4 24.1 to 36 hours 1 583 Mean Difference (IV, Random, 95% CI) 0.25 [-1.46, 1.96]
47.5 > 36 hours 1 451 Mean Difference (IV, Random, 95% CI) 0.66 [-1.32, 2.64]
48 TICS, end of trial, by baseline
SBP
1 2013 Mean Difference (IV, Random, 95% CI) 0.30 [-0.76, 1.37]
48.1 < 160 mmHg 1 838 Mean Difference (IV, Random, 95% CI) -0.66 [-2.11, 0.79]
48.2 160.1 to 180 mmHg 1 728 Mean Difference (IV, Random, 95% CI) 1.31 [-0.21, 2.83]
48.3 180.1 to 200 mmHg 1 332 Mean Difference (IV, Random, 95% CI) 0.05 [-2.20, 2.30]
48.4 > 200 mmHg 1 115 Mean Difference (IV, Random, 95% CI) 1.32 [-1.00, 5.64]
49 Animal naming, end of trial 1 2366 Mean Difference (IV, Random, 95% CI) 0.10 [-0.53, 0.73]
49.1 Overall 1 2366 Mean Difference (IV, Random, 95% CI) 0.10 [-0.53, 0.73]
50 Animal naming, end of trial, by
stroke type
1 2336 Mean Difference (IV, Random, 95% CI) 0.12 [-0.51, 0.75]
50.1 Ischaemic 1 1960 Mean Difference (IV, Random, 95% CI) 0.09 [-0.60, 0.78]
50.2 ICH 1 376 Mean Difference (IV, Random, 95% CI) 0.28 [-1.25, 1.81]
51 Animal naming, end of trial, by
time to randomisation
1 2366 Mean Difference (IV, Random, 95% CI) 0.25 [-0.80, 1.30]
51.1 < 6 hours 1 192 Mean Difference (IV, Random, 95% CI) 2.94 [0.88, 5.00]
51.2 6.1 to 12 hours 1 286 Mean Difference (IV, Random, 95% CI) -1.33 [-3.26, 0.60]
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51.3 12.1 to 24 hours 1 625 Mean Difference (IV, Random, 95% CI) 0.02 [-1.21, 1.25]
51.4 24.1 to 36 hours 1 695 Mean Difference (IV, Random, 95% CI) -0.34 [-1.48, 0.80]
51.5 > 36 hours 1 568 Mean Difference (IV, Random, 95% CI) 0.48 [-0.82, 1.78]
52 Animal naming, end of trial, by
baseline SBP
1 2366 Mean Difference (IV, Random, 95% CI) 0.10 [-0.53, 0.73]
52.1 < 160 mmHg 1 966 Mean Difference (IV, Random, 95% CI) -0.36 [-1.36, 0.64]
52.2 160.1 to 180 mmHg 1 850 Mean Difference (IV, Random, 95% CI) 0.40 [-0.64, 1.44]
52.3 180.1 to 200 mmHg 1 410 Mean Difference (IV, Random, 95% CI) 0.26 [-1.25, 1.77]
52.4 > 200 mmHg 1 140 Mean Difference (IV, Random, 95% CI) 0.92 [-1.69, 3.53]
53 Physiotherapy 3 4042 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.79, 1.12]
53.1 Overall 3 4042 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.79, 1.12]
54 Physiotherapy, by stroke type 3 3994 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.80, 1.15]
54.1 Ischaemic 3 3363 Odds Ratio (M-H, Random, 95% CI) 0.91 [0.74, 1.11]
54.2 ICH 3 631 Odds Ratio (M-H, Random, 95% CI) 1.16 [0.79, 1.70]
55 Physiotherapy, by time to
randomisation
3 4041 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.80, 1.15]
55.1 < 6 hours 2 307 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.40, 2.05]
55.2 6.1 to 12 hours 2 439 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.56, 1.36]
55.3 12.1 to 24 hours 1 1064 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.77, 1.51]
55.4 24.1 to 36 hours 2 1198 Odds Ratio (M-H, Random, 95% CI) 1.07 [0.76, 1.49]
55.5 > 36 hours 2 1033 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.54, 1.27]
56 Physiotherapy, by baseline SBP 3 4042 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.78, 1.13]
56.1 < 160 mmHg 3 1624 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.75, 1.32]
56.2 160.1 to 180 mmHg 3 1433 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.46, 1.72]
56.3 180.1 to 200 mmHg 3 730 Odds Ratio (M-H, Random, 95% CI) 0.68 [0.44, 1.04]
56.4 > 200 mmHg 2 255 Odds Ratio (M-H, Random, 95% CI) 1.80 [0.54, 5.98]
57 Occupational therapy 3 4042 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.72, 1.41]
57.1 Overall 3 4042 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.72, 1.41]
58 Occupational therapy, by stroke
type
3 3994 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.24]
58.1 Ischaemic 3 3363 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.81, 1.08]
58.2 ICH 3 631 Odds Ratio (M-H, Random, 95% CI) 1.26 [0.92, 1.73]
59 Occupational therapy, by time
to randomisation
3 4041 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.86, 1.13]
59.1 < 6 hours 2 307 Odds Ratio (M-H, Random, 95% CI) 1.15 [0.36, 3.68]
59.2 6.1 to 12 hours 2 439 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.65, 1.37]
59.3 12.1 to 24 hours 1 1064 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.82, 1.36]
59.4 24.1 to 36 hours 2 1198 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.79, 1.28]
59.5 > 36 hours 2 1033 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.72, 1.28]
60 Occupational therapy, by
baseline SBP
3 4042 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.81, 1.30]
60.1 < 160 mmHg 3 1624 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.81, 1.23]
60.2 160.1 to 180 mmHg 3 1433 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.76, 1.17]
60.3 180.1 to 200 mmHg 3 730 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.54, 1.00]
60.4 > 200 mmHg 2 255 Odds Ratio (M-H, Random, 95% CI) 2.11 [1.25, 3.54]
61 Speech and language therapy 3 4042 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.84, 1.08]
61.1 Overall 3 4042 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.84, 1.08]
62 Speech and language therapy,
by stroke type
3 3994 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.85, 1.09]
62.1 Ischaemic 3 3363 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.82, 1.08]
62.2 ICH 3 631 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.14, 4.19]
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63 Speech and language therapy,
by time to randomisation
3 4041 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.85, 1.09]
63.1 < 6 hours 2 307 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.44, 2.29]
63.2 6.1 to 12 hours 2 439 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.64, 1.40]
63.3 12.1 to 24 hours 1 1064 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.75, 1.21]
63.4 24.1 to 36 hours 2 1198 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.76, 1.20]
63.5 > 36 hours 2 1033 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.79, 1.29]
64 Speech and language therapy,
by baseline SBP
3 4042 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.84, 1.08]
64.1 < 160 mmHg 3 1624 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.58, 1.66]
64.2 160.1 to 180 mmHg 3 1433 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.76, 1.16]
64.3 180.1 to 200 mmHg 3 730 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.75, 1.34]
64.4 > 200 mmHg 2 255 Odds Ratio (M-H, Random, 95% CI) 1.38 [0.84, 2.26]
65 Feeding route (non-oral feeding
at day 7)
3 4009 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.82, 1.15]
65.1 Overall 3 4009 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.82, 1.15]
66 Feeding route (non-oral feeding
at day 7), by stroke type
3 3962 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.80, 1.22]
66.1 Ischaemic 3 3339 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.75, 1.09]
66.2 ICH 2 623 Odds Ratio (M-H, Random, 95% CI) 1.28 [0.88, 1.87]
67 Feeding route (non-oral
feeding at day 7), by time to
randomisation
3 4004 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.82, 1.16]
67.1 < 6 hours 2 301 Odds Ratio (M-H, Random, 95% CI) 0.59 [0.32, 1.08]
67.2 6.1 to 12 hours 1 435 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.61, 1.75]
67.3 12.1 to 24 hours 1 1043 Odds Ratio (M-H, Random, 95% CI) 1.16 [0.83, 1.64]
67.4 24.1 to 36 hours 1 1192 Odds Ratio (M-H, Random, 95% CI) 1.14 [0.84, 1.55]
67.5 > 36 hours 2 1033 Odds Ratio (M-H, Random, 95% CI) 0.80 [0.58, 1.10]
68 Feeding route (non-oral feeding
at day 7), by baseline SBP
3 4000 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.82, 1.15]
68.1 < 160 mmHg 3 1613 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.74, 1.29]
68.2 160.1 to 180 mmHg 2 1413 Odds Ratio (M-H, Random, 95% CI) 0.73 [0.27, 1.95]
68.3 180.1 to 200 mmHg 2 720 Odds Ratio (M-H, Random, 95% CI) 1.35 [0.92, 1.97]
68.4 > 200 mmHg 2 254 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.49, 1.62]
69 Length of stay 4 4078 Mean Difference (IV, Random, 95% CI) 1.29 [-6.21, 8.78]
69.1 Overall 4 4078 Mean Difference (IV, Random, 95% CI) 1.29 [-6.21, 8.78]
70 Length of stay, by stroke type 4 4055 Mean Difference (IV, Random, 95% CI) 1.33 [-3.28, 5.93]
70.1 Ischaemic 4 3414 Mean Difference (IV, Random, 95% CI) 2.99 [-9.65, 15.63]
70.2 ICH 4 641 Mean Difference (IV, Random, 95% CI) 2.55 [-1.51, 6.61]
71 Length of stay by time, to
randomisation
4 4077 Mean Difference (IV, Random, 95% CI) -0.34 [-1.76, 1.09]
71.1 < 6 hours 2 307 Mean Difference (IV, Random, 95% CI) -1.55 [-6.30, 3.21]
71.2 6.1 to 12 hours 2 439 Mean Difference (IV, Random, 95% CI) -1.64 [-5.13, 1.85]
71.3 12.1 to 24 hours 1 1064 Mean Difference (IV, Random, 95% CI) -0.76 [-3.56, 2.04]
71.4 24.1 to 36 hours 2 1197 Mean Difference (IV, Random, 95% CI) 0.04 [-2.68, 2.76]
71.5 > 36 hours 3 1070 Mean Difference (IV, Random, 95% CI) 1.52 [-9.40, 12.44]
72 Length of stay, by baseline SBP 4 4077 Mean Difference (IV, Random, 95% CI) 0.13 [-2.82, 3.07]
72.1 < 160 mmHg 4 1644 Mean Difference (IV, Random, 95% CI) 8.63 [-8.44, 25.71]
72.2 160.1 to 180 mmHg 4 1443 Mean Difference (IV, Random, 95% CI) -3.77 [-18.94, 11.
40]
72.3 180.1 to 200 mmHg 4 733 Mean Difference (IV, Random, 95% CI) -1.17 [-4.86, 2.51]
72.4 > 200 mmHg 3 257 Mean Difference (IV, Random, 95% CI) 4.50 [-2.45, 11.45]
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73 Headache, on treatment 5 4186 Odds Ratio (M-H, Random, 95% CI) 2.37 [1.55, 3.62]
73.1 Overall 5 4186 Odds Ratio (M-H, Random, 95% CI) 2.37 [1.55, 3.62]
74 Headache, on treatment, by
stroke type
4 4048 Odds Ratio (M-H, Random, 95% CI) 2.34 [1.93, 2.84]
74.1 Ischaemic 4 3409 Odds Ratio (M-H, Random, 95% CI) 2.39 [1.59, 3.61]
74.2 ICH 4 639 Odds Ratio (M-H, Random, 95% CI) 1.91 [1.24, 2.93]
75 Headache, on treatment, by
time to randomisation
4 4094 Odds Ratio (M-H, Random, 95% CI) 2.36 [1.95, 2.86]
75.1 < 6 hours 2 309 Odds Ratio (M-H, Random, 95% CI) 2.22 [1.10, 4.45]
75.2 6.1 to 12 hours 2 440 Odds Ratio (M-H, Random, 95% CI) 2.08 [1.16, 3.73]
75.3 12.1 to 24 hours 1 1065 Odds Ratio (M-H, Random, 95% CI) 2.57 [1.78, 3.71]
75.4 24.1 to 36 hours 2 1202 Odds Ratio (M-H, Random, 95% CI) 2.27 [1.59, 3.22]
75.5 > 36 hours 3 1078 Odds Ratio (M-H, Random, 95% CI) 2.42 [1.64, 3.58]
76 Headache, on treatment, by
baseline SBP
4 4095 Odds Ratio (M-H, Random, 95% CI) 2.29 [1.83, 2.86]
76.1 < 160 mmHg 4 1649 Odds Ratio (M-H, Random, 95% CI) 2.37 [1.74, 3.21]
76.2 160.1 to 180 mmHg 4 1453 Odds Ratio (M-H, Random, 95% CI) 2.97 [2.14, 4.12]
76.3 180.1 to 200 mmHg 4 736 Odds Ratio (M-H, Random, 95% CI) 1.42 [0.92, 2.18]
76.4 > 200 mmHg 3 257 Odds Ratio (M-H, Random, 95% CI) 1.25 [0.08, 20.46]
77 Treatment stopped early 5 4193 Odds Ratio (M-H, Random, 95% CI) 1.84 [0.27, 12.42]
77.1 Overall 5 4193 Odds Ratio (M-H, Random, 95% CI) 1.84 [0.27, 12.42]
78 Treatment stopped early, by
stroke type
4 4102 Odds Ratio (M-H, Random, 95% CI) 2.49 [0.72, 8.59]
78.1 Ischaemic 4 3465 Odds Ratio (M-H, Random, 95% CI) 1.26 [0.07, 21.87]
78.2 ICH 3 637 Odds Ratio (M-H, Random, 95% CI) 6.81 [3.46, 13.43]
79 Treatment stopped early, by
time to randomisation
5 4192 Odds Ratio (M-H, Random, 95% CI) 4.56 [2.10, 9.87]
79.1 < 6 hours 2 312 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.05, 22.27]
79.2 6.1 to 12 hours 2 440 Odds Ratio (M-H, Random, 95% CI) 12.12 [4.26, 34.44]
79.3 12.1 to 24 hours 2 1070 Odds Ratio (M-H, Random, 95% CI) 6.42 [4.07, 10.12]
79.4 24.1 to 36 hours 3 1218 Odds Ratio (M-H, Random, 95% CI) 9.23 [1.63, 52.33]
79.5 > 36 hours 4 1152 Odds Ratio (M-H, Random, 95% CI) 3.86 [0.58, 25.79]
80 Treatment stopped early, by
baseline SBP
4 4159 Odds Ratio (M-H, Random, 95% CI) 2.84 [1.37, 5.88]
80.1 < 160 mmHg 4 1687 Odds Ratio (M-H, Random, 95% CI) 1.33 [0.09, 20.26]
80.2 160.1 to 180 mmHg 4 1467 Odds Ratio (M-H, Random, 95% CI) 2.17 [0.17, 27.08]
80.3 180.1 to 200 mmHg 4 742 Odds Ratio (M-H, Random, 95% CI) 1.38 [0.17, 11.13]
80.4 > 200 mmHg 3 263 Odds Ratio (M-H, Random, 95% CI) 2.16 [0.21, 22.44]
81 Systolic BP, first treatment
measurement
5 4197 Mean Difference (IV, Fixed, 95% CI) -7.21 [-8.58, -5.85]
81.1 Overall 5 4197 Mean Difference (IV, Fixed, 95% CI) -7.21 [-8.58, -5.85]
82 Systolic BP, first treatment
measurement, by stroke type
5 4143 Mean Difference (IV, Fixed, 95% CI) -7.01 [-8.37, -5.66]
82.1 Ischaemic 5 3502 Mean Difference (IV, Fixed, 95% CI) -7.05 [-8.51, -5.59]
82.2 ICH 4 641 Mean Difference (IV, Fixed, 95% CI) -6.77 [-10.45, -3.09]
83 Systolic BP, first treatment
measurement, by time to
randomisation
5 4195 Mean Difference (IV, Fixed, 95% CI) -7.21 [-8.57, -5.84]
83.1 < 6 hours 2 312 Mean Difference (IV, Fixed, 95% CI) -9.52 [-14.28, -4.75]
83.2 6.1 to 12 hours 2 440 Mean Difference (IV, Fixed, 95% CI) -7.92 [-12.18, -3.66]
83.3 12.1 to 24 hours 2 1070 Mean Difference (IV, Fixed, 95% CI) -5.33 [-8.07, -2.59]
83.4 24.1 to 36 hours 3 1218 Mean Difference (IV, Fixed, 95% CI) -7.17 [-9.66, -4.68]
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83.5 > 36 hours 4 1155 Mean Difference (IV, Fixed, 95% CI) -8.02 [-10.66, -5.37]
84 Diastolic BP, first treatment
measurement
5 4197 Mean Difference (IV, Fixed, 95% CI) -3.31 [-4.18, -2.45]
84.1 Overall 5 4197 Mean Difference (IV, Fixed, 95% CI) -3.31 [-4.18, -2.45]
85 Diastolic BP, first treatment
measurement, by stroke type
5 4143 Mean Difference (IV, Fixed, 95% CI) -3.24 [-4.10, -2.38]
85.1 Ischaemic 5 3502 Mean Difference (IV, Fixed, 95% CI) -3.13 [-4.05, -2.21]
85.2 ICH 4 641 Mean Difference (IV, Fixed, 95% CI) -3.96 [-6.36, -1.55]
86 Diastolic BP, first treatment
measurement, by time to
randomisation
5 4195 Mean Difference (IV, Fixed, 95% CI) -3.31 [-4.17, -2.45]
86.1 < 6 hours 2 312 Mean Difference (IV, Fixed, 95% CI) -2.31 [-5.53, 0.90]
86.2 6.1 to 12 hours 2 440 Mean Difference (IV, Fixed, 95% CI) -4.5 [-7.27, -1.73]
86.3 12.1 to 24 hours 2 1070 Mean Difference (IV, Fixed, 95% CI) -3.33 [-3.00, -1.66]
86.4 24.1 to 36 hours 3 1218 Mean Difference (IV, Fixed, 95% CI) -1.90 [-3.49, -0.30]
86.5 > 36 hours 4 1155 Mean Difference (IV, Fixed, 95% CI) -4.68 [-6.35, -3.01]
87 Heart rate, first treatment
measurement
5 4197 Mean Difference (IV, Fixed, 95% CI) 2.02 [1.13, 2.91]
87.1 Overall 5 4197 Mean Difference (IV, Fixed, 95% CI) 2.02 [1.13, 2.91]
88 Heart rate, first treatment
measurement, by stroke type
5 4143 Mean Difference (IV, Fixed, 95% CI) 2.18 [1.29, 3.08]
88.1 Ischaemic 5 3502 Mean Difference (IV, Fixed, 95% CI) 2.12 [1.14, 3.09]
88.2 ICH 4 641 Mean Difference (IV, Fixed, 95% CI) 2.56 [0.25, 4.88]
89 Heart rate, first treatment
measurement, by time to
randomisation
5 4195 Mean Difference (IV, Fixed, 95% CI) 1.91 [1.02, 2.80]
89.1 < 6 hours 2 312 Mean Difference (IV, Fixed, 95% CI) 1.89 [-1.62, 5.40]
89.2 6.1 to 12 hours 2 440 Mean Difference (IV, Fixed, 95% CI) -0.13 [-3.16, 2.90]
89.3 12.1 to 24 hours 2 1070 Mean Difference (IV, Fixed, 95% CI) 1.69 [-0.11, 3.49]
89.4 24.1 to 36 hours 3 1218 Mean Difference (IV, Fixed, 95% CI) 3.44 [1.79, 5.09]
89.5 > 36 hours 4 1155 Mean Difference (IV, Fixed, 95% CI) 1.23 [-0.36, 2.82]
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Analysis 1.1. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 1
Death or dependency (mRS>2), end of trial.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 1 Death or dependency (mRS>2), end of trial
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overall
Ankolekar 2013 13/25 12/16 0.8 % 0.36 [ 0.09, 1.43 ]
Bath 2001 10/16 8/19 0.8 % 2.29 [ 0.59, 8.94 ]
ENOS 2015 1205/2000 1227/2011 96.1 % 0.97 [ 0.85, 1.10 ]
Rashid 2002 37/60 19/30 1.9 % 0.93 [ 0.38, 2.31 ]
Willmot 2006 5/12 2/6 0.4 % 1.43 [ 0.18, 11.09 ]
Total (95% CI) 2113 2082 100.0 % 0.97 [ 0.86, 1.10 ]
Total events: 1270 (NO donor), 1268 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.65, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 2
Death or dependency (mRS>2), end of trial, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 2 Death or dependency (mRS>2), end of trial, by stroke type
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic
Ankolekar 2013 8/16 10/11 0.9 % 0.10 [ 0.01, 0.98 ]
Bath 2001 8/14 8/19 2.2 % 1.83 [ 0.45, 7.41 ]
ENOS 2015 985/1664 1015/1678 62.6 % 0.95 [ 0.83, 1.09 ]
Rashid 2002 35/54 19/30 4.9 % 1.07 [ 0.42, 2.70 ]
Willmot 2006 4/11 1/5 0.7 % 2.29 [ 0.19, 28.19 ]
Subtotal (95% CI) 1759 1743 71.3 % 0.97 [ 0.62, 1.53 ]
Total events: 1040 (NO donor), 1053 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 5.14, df = 4 (P = 0.27); I2 =22%
Test for overall effect: Z = 0.13 (P = 0.90)
2 Intracerebral haemorrhage
Ankolekar 2013 3/5 1/1 0.3 % 0.47 [ 0.01, 16.89 ]
Bath 2001 2/2 0/2 0.2 % 25.00 [ 0.34, 1831.59 ]
ENOS 2015 204/310 204/319 28.1 % 1.08 [ 0.78, 1.51 ]
Willmot 2006 1/1 1/1 Not estimable
Subtotal (95% CI) 318 323 28.7 % 1.20 [ 0.45, 3.21 ]
Total events: 210 (NO donor), 206 (Control)
Heterogeneity: Tau2 = 0.26; Chi2 = 2.26, df = 2 (P = 0.32); I2 =12%
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 2077 2066 100.0 % 1.00 [ 0.81, 1.23 ]
Total events: 1250 (NO donor), 1259 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.03, df = 7 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 1.3. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 3
Death or dependency (mRS>2), end of trial, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 3 Death or dependency (mRS>2), end of trial, by time to randomisation
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 6 hours
Ankolekar 2013 12/24 11/15 0.8 % 0.36 [ 0.09, 1.47 ]
ENOS 2015 74/144 78/129 6.7 % 0.69 [ 0.43, 1.12 ]
Subtotal (95% CI) 168 144 7.5 % 0.65 [ 0.41, 1.02 ]
Total events: 86 (NO donor), 89 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
2 6.1 to 12 hours
Ankolekar 2013 1/1 1/1 Not estimable
ENOS 2015 135/224 119/214 10.7 % 1.21 [ 0.83, 1.77 ]
Subtotal (95% CI) 225 215 10.7 % 1.21 [ 0.83, 1.77 ]
Total events: 136 (NO donor), 120 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
3 12.1 to 24 hours
ENOS 2015 320/541 315/526 25.9 % 0.97 [ 0.76, 1.24 ]
Rashid 2002 1/1 1/2 0.1 % 3.00 [ 0.06, 151.19 ]
Subtotal (95% CI) 542 528 26.0 % 0.97 [ 0.76, 1.24 ]
Total events: 321 (NO donor), 316 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
4 24.1 to 36 hours
ENOS 2015 380/593 385/610 28.1 % 1.04 [ 0.82, 1.32 ]
Rashid 2002 7/9 3/4 0.2 % 1.17 [ 0.07, 18.35 ]
Willmot 2006 1/1 0/1 0.1 % 9.00 [ 0.10, 831.78 ]
Subtotal (95% CI) 603 615 28.4 % 1.05 [ 0.83, 1.33 ]
Total events: 388 (NO donor), 388 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
5 > 36 hours
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bath 2001 10/16 8/19 0.8 % 2.29 [ 0.59, 8.94 ]
ENOS 2015 296/498 330/532 24.7 % 0.90 [ 0.70, 1.15 ]
Rashid 2002 29/50 15/24 1.6 % 0.83 [ 0.31, 2.25 ]
Willmot 2006 4/11 2/4 0.3 % 0.57 [ 0.06, 5.77 ]
Subtotal (95% CI) 575 579 27.4 % 0.91 [ 0.72, 1.16 ]
Total events: 339 (NO donor), 355 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.97, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 2113 2081 100.0 % 0.97 [ 0.86, 1.10 ]
Total events: 1270 (NO donor), 1268 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.95, df = 11 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 5.06, df = 4 (P = 0.28), I2 =21%
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Analysis 1.4. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 4
Death or dependency (mRS>2), end of trial, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 4 Death or dependency (mRS>2), end of trial, by baseline SBP
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 160 mmHg
Ankolekar 2013 8/11 5/7 0.3 % 1.07 [ 0.13, 8.79 ]
Bath 2001 2/5 6/13 0.4 % 0.78 [ 0.10, 6.32 ]
ENOS 2015 460/788 481/819 39.4 % 0.99 [ 0.81, 1.20 ]
Rashid 2002 24/33 13/21 1.1 % 1.64 [ 0.51, 5.27 ]
Willmot 2006 3/7 1/2 0.2 % 0.75 [ 0.03, 17.51 ]
Subtotal (95% CI) 844 862 41.4 % 1.00 [ 0.82, 1.21 ]
Total events: 497 (NO donor), 506 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
2 160.1 to 180 mmHg
Ankolekar 2013 0/4 3/3 0.1 % 0.02 [ 0.00, 1.02 ]
Bath 2001 5/7 2/5 0.3 % 3.75 [ 0.33, 42.47 ]
ENOS 2015 429/720 431/714 34.8 % 0.97 [ 0.78, 1.20 ]
Rashid 2002 5/15 4/6 0.4 % 0.25 [ 0.03, 1.86 ]
Willmot 2006 1/3 0/3 0.1 % 4.20 [ 0.12, 151.97 ]
Subtotal (95% CI) 749 731 35.6 % 0.78 [ 0.23, 2.60 ]
Total events: 440 (NO donor), 440 (Control)
Heterogeneity: Tau2 = 0.80; Chi2 = 7.33, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 0.41 (P = 0.68)
3 180.1 to 200 mmHg
Ankolekar 2013 3/7 1/1 0.1 % 0.26 [ 0.01, 8.52 ]
Bath 2001 2/3 0/1 0.1 % 5.00 [ 0.11, 220.62 ]
ENOS 2015 241/374 228/349 16.6 % 0.96 [ 0.71, 1.31 ]
Rashid 2002 4/7 2/2 0.1 % 0.26 [ 0.01, 7.27 ]
Willmot 2006 1/2 1/1 0.1 % 0.33 [ 0.01, 16.80 ]
Subtotal (95% CI) 393 354 17.1 % 0.95 [ 0.70, 1.28 ]
Total events: 251 (NO donor), 232 (Control)
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 2.14, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
4 > 200 mmHg
Ankolekar 2013 2/3 3/5 0.2 % 1.33 [ 0.07, 26.62 ]
ENOS 2015 75/118 87/129 5.6 % 0.84 [ 0.50, 1.42 ]
Rashid 2002 3/4 0/1 0.1 % 7.00 [ 0.17, 291.34 ]
Subtotal (95% CI) 125 135 5.9 % 0.89 [ 0.53, 1.48 ]
Total events: 80 (NO donor), 90 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.29, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 2111 2082 100.0 % 0.97 [ 0.85, 1.10 ]
Total events: 1268 (NO donor), 1268 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.78, df = 17 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.61)
Test for subgroup differences: Chi2 = 0.34, df = 3 (P = 0.95), I2 =0.0%
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Analysis 1.5. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 5
Death or dependency (mean mRS), end of trial.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 5 Death or dependency (mean mRS), end of trial
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Overall
Ankolekar 2013 25 2.96 (1.88) 16 4.25 (1.81) 10.9 % -1.29 [ -2.44, -0.14 ]
Bath 2001 16 3.5 (1.79) 19 2.53 (1.68) 10.9 % 0.97 [ -0.19, 2.13 ]
ENOS 2015 2000 3.07 (1.69) 2011 3.1 (1.77) 44.2 % -0.03 [ -0.14, 0.08 ]
Rashid 2002 60 2.77 (1.62) 30 2.93 (1.86) 18.5 % -0.16 [ -0.94, 0.62 ]
Willmot 2006 12 2.33 (0.65) 6 2.33 (1.03) 15.5 % 0.0 [ -0.90, 0.90 ]
Total (95% CI) 2113 2082 100.0 % -0.08 [ -0.52, 0.36 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 7.56, df = 4 (P = 0.11); I2 =47%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 6
Death or dependency (mean mRS), end of trial, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 6 Death or dependency (mean mRS), end of trial, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic
Ankolekar 2013 16 2.75 (1.88) 11 4.64 (1.43) 4.0 % -1.89 [ -3.14, -0.64 ]
Bath 2001 14 3.14 (1.61) 19 2.76 (1.6) 4.9 % 0.38 [ -0.73, 1.49 ]
ENOS 2015 1664 3.04 (1.7) 1678 3.08 (1.77) 41.5 % -0.04 [ -0.16, 0.08 ]
Rashid 2002 54 2.83 (1.66) 30 2.93 (1.86) 8.6 % -0.10 [ -0.90, 0.70 ]
Willmot 2006 11 2.27 (0.65) 5 2 (0.71) 9.9 % 0.27 [ -0.46, 1.00 ]
Subtotal (95% CI) 1759 1743 68.9 % -0.13 [ -0.62, 0.35 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 9.67, df = 4 (P = 0.05); I2 =59%
Test for overall effect: Z = 0.54 (P = 0.59)
2 ICH
Ankolekar 2013 5 4 (2) 1 6 (0) Not estimable
Bath 2001 2 6 (0) 2 0.5 (0.71) Not estimable
ENOS 2015 310 3.26 (1.64) 319 3.24 (1.71) 31.1 % 0.02 [ -0.24, 0.28 ]
Willmot 2006 1 3 (0) 1 4 (0) Not estimable
Subtotal (95% CI) 318 323 31.1 % 0.02 [ -0.24, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Total (95% CI) 2077 2066 100.0 % -0.05 [ -0.31, 0.21 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 9.87, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 0.30, df = 1 (P = 0.58), I2 =0.0%
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Analysis 1.7. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 7
Death or dependency (mean mRS), end of trial, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 7 Death or dependency (mean mRS), end of trial, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 6 hours
Ankolekar 2013 24 2.83 (1.81) 15 4.2 (1.86) 2.4 % -1.37 [ -2.56, -0.18 ]
ENOS 2015 144 2.58 (1.73) 129 3.23 (1.9) 11.4 % -0.65 [ -1.08, -0.22 ]
Subtotal (95% CI) 168 144 13.8 % -0.79 [ -1.35, -0.23 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 2.78 (P = 0.0055)
2 6.1 to 12 hours
Ankolekar 2013 1 6 (0) 1 5 (0) Not estimable
ENOS 2015 224 3.18 (1.79) 214 2.99 (1.8) 14.8 % 0.19 [ -0.15, 0.53 ]
Subtotal (95% CI) 225 215 14.8 % 0.19 [ -0.15, 0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
3 12.1 to 24 hours
ENOS 2015 541 3.04 (1.71) 526 3.07 (1.74) 20.4 % -0.03 [ -0.24, 0.18 ]
Rashid 2002 1 6 (0) 2 2.5 (2.12) Not estimable
Subtotal (95% CI) 542 528 20.4 % -0.03 [ -0.24, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
4 24.1 to 36 hours
ENOS 2015 593 3.19 (1.68) 610 3.13 (1.73) 21.1 % 0.06 [ -0.13, 0.25 ]
Rashid 2002 9 3.78 (1.56) 4 3.75 (2.06) 0.7 % 0.03 [ -2.23, 2.29 ]
Willmot 2006 1 3 (0) 1 2 (0) Not estimable
Subtotal (95% CI) 603 615 21.8 % 0.06 [ -0.13, 0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
5 > 36 hours
Bath 2001 16 3.5 (1.79) 19 2.53 (1.68) 2.5 % 0.97 [ -0.19, 2.13 ]
ENOS 2015 498 3.05 (1.61) 532 3.12 (1.79) 20.4 % -0.07 [ -0.28, 0.14 ]
Rashid 2002 50 2.52 (1.52) 24 2.83 (1.86) 4.3 % -0.31 [ -1.17, 0.55 ]
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Willmot 2006 11 2.27 (0.65) 4 2.5 (1.29) 2.0 % -0.23 [ -1.55, 1.09 ]
Subtotal (95% CI) 575 579 29.2 % -0.04 [ -0.35, 0.28 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.44, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.22 (P = 0.83)
Total (95% CI) 2113 2081 100.0 % -0.08 [ -0.27, 0.11 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 18.75, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 9.43, df = 4 (P = 0.05), I2 =58%
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Analysis 1.8. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 8
Death or dependency (mean mRS), end of trial, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 8 Death or dependency (mean mRS), end of trial, by baseline SBP
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 <160 mmHg
Ankolekar 2013 11 3.55 (1.81) 7 4.43 (1.81) 1.5 % -0.88 [ -2.60, 0.84 ]
Bath 2001 5 2.8 (2.05) 13 2.62 (1.94) 1.0 % 0.18 [ -1.90, 2.26 ]
ENOS 2015 788 3.02 (1.71) 819 3.02 (1.76) 23.6 % 0.0 [ -0.17, 0.17 ]
Rashid 2002 33 3.21 (1.56) 21 2.71 (1.9) 4.2 % 0.50 [ -0.47, 1.47 ]
Willmot 2006 7 2.43 (0.54) 2 2.5 (0.71) 3.6 % -0.07 [ -1.13, 0.99 ]
Subtotal (95% CI) 844 862 34.0 % 0.01 [ -0.16, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.07, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 160.1-180 mmHg
Ankolekar 2013 4 1.5 (0.58) 3 4.67 (1.53) 1.3 % -3.17 [ -4.99, -1.35 ]
Bath 2001 7 3.71 (1.7) 5 2.4 (1.14) 1.7 % 1.31 [ -0.30, 2.92 ]
ENOS 2015 720 3.02 (1.7) 714 3.07 (1.78) 23.2 % -0.05 [ -0.23, 0.13 ]
Rashid 2002 15 1.8 (1.47) 6 3.5 (2.07) 1.4 % -1.70 [ -3.52, 0.12 ]
Willmot 2006 3 2.33 (0.58) 3 1.67 (0.58) 4.6 % 0.66 [ -0.27, 1.59 ]
Subtotal (95% CI) 749 731 32.1 % -0.38 [ -1.42, 0.66 ]
Heterogeneity: Tau2 = 0.98; Chi2 = 19.43, df = 4 (P = 0.00065); I2 =79%
Test for overall effect: Z = 0.72 (P = 0.47)
3 180.1-200 mmHg
Ankolekar 2013 7 2.43 (2.07) 1 3 (0) Not estimable
Bath 2001 3 3.33 (1.53) 1 2 (0) Not estimable
ENOS 2015 374 3.24 (1.62) 349 3.2 (1.71) 20.5 % 0.04 [ -0.20, 0.28 ]
Rashid 2002 7 2.71 (1.6) 2 4 (0) Not estimable
Willmot 2006 2 2 (1.41) 1 4 (0) Not estimable
Subtotal (95% CI) 393 354 20.5 % 0.04 [ -0.20, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
4 >200 mmHg
Ankolekar 2013 3 4 (2) 5 4 (2.35) 0.5 % 0.0 [ -3.06, 3.06 ]
ENOS 2015 118 3.26 (1.7) 129 3.53 (1.82) 12.9 % -0.27 [ -0.71, 0.17 ]
Rashid 2002 4 2.5 (1.73) 1 2 (0) Not estimable
Subtotal (95% CI) 125 135 13.4 % -0.26 [ -0.70, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Total (95% CI) 2111 2082 100.0 % -0.04 [ -0.26, 0.17 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 23.20, df = 12 (P = 0.03); I2 =48%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 2.00, df = 3 (P = 0.57), I2 =0.0%
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Analysis 1.9. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome 9
Death, end of treatment.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 9 Death, end of treatment
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overall
Ankolekar 2013 2/25 1/16 2.0 % 1.30 [ 0.11, 15.69 ]
Bath 2001 2/16 1/21 2.0 % 2.86 [ 0.24, 34.66 ]
ENOS 2015 61/2000 58/2011 94.7 % 1.06 [ 0.74, 1.53 ]
Rashid 2002 1/60 0/30 1.2 % 1.54 [ 0.06, 38.88 ]
Willmot 2006 0/12 0/6 Not estimable
Total (95% CI) 2113 2084 100.0 % 1.09 [ 0.76, 1.56 ]
Total events: 66 (NO donor), 60 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours NO donor Favours control
53Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
10 Death, end of treatment, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 10 Death, end of treatment, by stroke type
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic
Ankolekar 2013 0/16 1/11 1.2 % 0.21 [ 0.01, 5.71 ]
Bath 2001 1/14 1/19 1.6 % 1.38 [ 0.08, 24.23 ]
ENOS 2015 49/1664 48/1678 78.1 % 1.03 [ 0.69, 1.54 ]
Rashid 2002 1/54 0/30 1.2 % 1.71 [ 0.07, 43.29 ]
Willmot 2006 0/11 0/5 Not estimable
Subtotal (95% CI) 1759 1743 82.1 % 1.02 [ 0.69, 1.51 ]
Total events: 51 (NO donor), 50 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
2 ICH
Ankolekar 2013 2/5 0/1 1.0 % 2.14 [ 0.06, 77.54 ]
Bath 2001 1/2 0/2 0.9 % 5.00 [ 0.11, 220.62 ]
ENOS 2015 10/310 10/319 16.1 % 1.03 [ 0.42, 2.51 ]
Willmot 2006 0/1 0/1 Not estimable
Subtotal (95% CI) 318 323 17.9 % 1.16 [ 0.50, 2.69 ]
Total events: 13 (NO donor), 10 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Total (95% CI) 2077 2066 100.0 % 1.04 [ 0.73, 1.49 ]
Total events: 64 (NO donor), 60 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.84, df = 6 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 1.11. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
11 Death, end of treatment, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 11 Death, end of treatment, by time to randomisation
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 6 hours
Ankolekar 2013 2/24 1/15 2.1 % 1.27 [ 0.11, 15.38 ]
ENOS 2015 5/144 6/129 9.0 % 0.74 [ 0.22, 2.48 ]
Subtotal (95% CI) 168 144 11.1 % 0.82 [ 0.28, 2.43 ]
Total events: 7 (NO donor), 7 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
2 6.1 to 12 hours
Ankolekar 2013 0/1 0/1 Not estimable
ENOS 2015 7/224 4/214 8.5 % 1.69 [ 0.49, 5.87 ]
Subtotal (95% CI) 225 215 8.5 % 1.69 [ 0.49, 5.87 ]
Total events: 7 (NO donor), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
3 12.1 to 24 hours
ENOS 2015 21/541 24/526 36.7 % 0.84 [ 0.46, 1.54 ]
Rashid 2002 0/1 0/2 Not estimable
Subtotal (95% CI) 542 528 36.7 % 0.84 [ 0.46, 1.54 ]
Total events: 21 (NO donor), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
4 24.1 to 36 hours
ENOS 2015 20/593 11/610 23.7 % 1.90 [ 0.90, 4.00 ]
Rashid 2002 0/9 0/4 Not estimable
Willmot 2006 0/1 0/1 Not estimable
Subtotal (95% CI) 603 615 23.7 % 1.90 [ 0.90, 4.00 ]
Total events: 20 (NO donor), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
5 > 36 hours
Bath 2001 2/16 1/20 2.1 % 2.71 [ 0.22, 32.99 ]
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ENOS 2015 8/498 13/532 16.6 % 0.65 [ 0.27, 1.59 ]
Rashid 2002 1/50 0/24 1.3 % 1.48 [ 0.06, 37.80 ]
Willmot 2006 0/11 0/4 Not estimable
Subtotal (95% CI) 575 580 20.0 % 0.80 [ 0.35, 1.80 ]
Total events: 11 (NO donor), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.26, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.59)
Total (95% CI) 2113 2082 100.0 % 1.07 [ 0.74, 1.54 ]
Total events: 66 (NO donor), 60 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.56, df = 7 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 4.15, df = 4 (P = 0.39), I2 =4%
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Analysis 1.12. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
12 Death, end of treatment, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 12 Death, end of treatment, by baseline SBP
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 160 mmHg
Ankolekar 2013 0/11 0/7 Not estimable
Bath 2001 0/5 1/13 1.1 % 0.76 [ 0.03, 21.68 ]
ENOS 2015 28/788 20/819 37.6 % 1.47 [ 0.82, 2.63 ]
Rashid 2002 1/33 0/21 1.2 % 1.98 [ 0.08, 51.01 ]
Willmot 2006 0/7 0/2 Not estimable
Subtotal (95% CI) 844 862 40.0 % 1.46 [ 0.83, 2.56 ]
Total events: 29 (NO donor), 21 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
2 160.1-180 mmHg
Ankolekar 2013 0/4 0/3 Not estimable
Bath 2001 1/7 0/5 1.1 % 2.54 [ 0.09, 75.76 ]
ENOS 2015 20/720 24/714 35.1 % 0.82 [ 0.45, 1.50 ]
Rashid 2002 0/15 0/6 Not estimable
Willmot 2006 0/3 0/3 Not estimable
Subtotal (95% CI) 749 731 36.2 % 0.85 [ 0.47, 1.54 ]
Total events: 21 (NO donor), 24 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
3 180.1 to 200 mmHg
Ankolekar 2013 1/7 0/1 1.0 % 0.69 [ 0.02, 26.90 ]
Bath 2001 0/3 0/2 Not estimable
ENOS 2015 8/374 11/349 15.0 % 0.67 [ 0.27, 1.69 ]
Rashid 2002 0/7 0/2 Not estimable
Willmot 2006 0/2 0/1 Not estimable
Subtotal (95% CI) 393 355 15.9 % 0.67 [ 0.28, 1.65 ]
Total events: 9 (NO donor), 11 (Control)
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
4 > 200 mmHg
Ankolekar 2013 1/3 1/5 1.2 % 2.00 [ 0.08, 51.59 ]
Bath 2001 1/1 0/1 0.6 % 9.00 [ 0.10, 831.78 ]
ENOS 2015 5/118 3/129 6.0 % 1.86 [ 0.43, 7.95 ]
Rashid 2002 0/4 0/1 Not estimable
Subtotal (95% CI) 126 136 7.9 % 2.13 [ 0.60, 7.61 ]
Total events: 7 (NO donor), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.24)
Total (95% CI) 2112 2084 100.0 % 1.09 [ 0.76, 1.56 ]
Total events: 66 (NO donor), 60 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.89, df = 9 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 3.87, df = 3 (P = 0.28), I2 =22%
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Analysis 1.13. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
13 Death, end of trial.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 13 Death, end of trial
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overall
Ankolekar 2013 4/25 6/16 15.4 % 0.32 [ 0.07, 1.38 ]
Bath 2001 3/16 1/21 6.9 % 4.62 [ 0.43, 49.30 ]
ENOS 2015 233/2000 263/2011 65.0 % 0.88 [ 0.73, 1.06 ]
Rashid 2002 3/60 3/30 12.7 % 0.47 [ 0.09, 2.50 ]
Willmot 2006 0/12 0/6 Not estimable
Total (95% CI) 2113 2084 100.0 % 0.78 [ 0.40, 1.50 ]
Total events: 243 (NO donor), 273 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 4.22, df = 3 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
14 Death, end of trial, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 14 Death, end of trial, by stroke type
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic
Ankolekar 2013 2/16 4/11 0.9 % 0.25 [ 0.04, 1.71 ]
Bath 2001 1/14 1/19 0.4 % 1.38 [ 0.08, 24.23 ]
ENOS 2015 186/1664 212/1678 79.6 % 0.87 [ 0.71, 1.07 ]
Rashid 2002 3/54 3/30 1.3 % 0.53 [ 0.10, 2.80 ]
Willmot 2006 0/11 0/5 Not estimable
Subtotal (95% CI) 1759 1743 82.2 % 0.85 [ 0.69, 1.05 ]
Total events: 192 (NO donor), 220 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.02, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
2 ICH
Ankolekar 2013 2/5 1/1 0.3 % 0.24 [ 0.01, 8.62 ]
Bath 2001 2/2 0/2 0.2 % 25.00 [ 0.34, 1831.59 ]
ENOS 2015 42/310 47/319 17.4 % 0.91 [ 0.58, 1.42 ]
Willmot 2006 0/1 0/1 Not estimable
Subtotal (95% CI) 318 323 17.8 % 1.08 [ 0.22, 5.21 ]
Total events: 46 (NO donor), 48 (Control)
Heterogeneity: Tau2 = 0.83; Chi2 = 2.82, df = 2 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.09 (P = 0.92)
Total (95% CI) 2077 2066 100.0 % 0.86 [ 0.72, 1.04 ]
Total events: 238 (NO donor), 268 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.94, df = 6 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.77), I2 =0.0%
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Analysis 1.15. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
15 Death, end of trial, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 15 Death, end of trial, by time to randomisation
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 6 hours
Ankolekar 2013 3/24 6/15 3.9 % 0.21 [ 0.04, 1.05 ]
ENOS 2015 11/144 26/129 11.7 % 0.33 [ 0.15, 0.69 ]
Subtotal (95% CI) 168 144 15.6 % 0.30 [ 0.15, 0.60 ]
Total events: 14 (NO donor), 32 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 3.45 (P = 0.00057)
2 6.1 to 12 hours
Ankolekar 2013 1/1 0/1 0.5 % 9.00 [ 0.10, 831.78 ]
ENOS 2015 38/224 29/214 16.5 % 1.30 [ 0.77, 2.20 ]
Subtotal (95% CI) 225 215 17.1 % 1.34 [ 0.79, 2.25 ]
Total events: 39 (NO donor), 29 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
3 12.1 to 24 hours
ENOS 2015 65/541 66/526 20.7 % 0.95 [ 0.66, 1.37 ]
Rashid 2002 1/1 0/2 0.6 % 15.00 [ 0.18, 1236.18 ]
Subtotal (95% CI) 542 528 21.3 % 1.52 [ 0.20, 11.53 ]
Total events: 66 (NO donor), 66 (Control)
Heterogeneity: Tau2 = 1.25; Chi2 = 1.49, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.40 (P = 0.69)
4 24.1 to 36 hours
ENOS 2015 74/593 77/610 21.4 % 0.99 [ 0.70, 1.39 ]
Rashid 2002 1/9 1/4 1.2 % 0.38 [ 0.02, 8.10 ]
Willmot 2006 0/1 0/1 Not estimable
Subtotal (95% CI) 603 615 22.6 % 0.98 [ 0.69, 1.37 ]
Total events: 75 (NO donor), 78 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
5 > 36 hours
Bath 2001 3/16 1/20 1.9 % 4.38 [ 0.41, 46.93 ]
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ENOS 2015 45/498 65/532 19.8 % 0.71 [ 0.48, 1.07 ]
Rashid 2002 1/50 2/24 1.8 % 0.22 [ 0.02, 2.61 ]
Willmot 2006 0/11 0/4 Not estimable
Subtotal (95% CI) 575 580 23.5 % 0.81 [ 0.27, 2.44 ]
Total events: 49 (NO donor), 68 (Control)
Heterogeneity: Tau2 = 0.43; Chi2 = 3.10, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI) 2113 2082 100.0 % 0.81 [ 0.58, 1.14 ]
Total events: 243 (NO donor), 273 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 19.33, df = 10 (P = 0.04); I2 =48%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi2 = 12.59, df = 4 (P = 0.01), I2 =68%
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Analysis 1.16. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
16 Death, end of trial, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 16 Death, end of trial, by baseline SBP
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 160 mmHg
Ankolekar 2013 2/11 3/7 0.7 % 0.30 [ 0.03, 2.52 ]
Bath 2001 0/5 1/13 0.3 % 0.76 [ 0.03, 21.68 ]
ENOS 2015 97/788 103/819 39.0 % 0.98 [ 0.73, 1.31 ]
Rashid 2002 3/33 2/21 1.0 % 0.95 [ 0.15, 6.22 ]
Willmot 2006 0/7 0/2 Not estimable
Subtotal (95% CI) 844 862 41.0 % 0.95 [ 0.71, 1.27 ]
Total events: 102 (NO donor), 109 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.19, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
2 160.1 to 180 mmHg
Ankolekar 2013 0/4 1/3 0.3 % 0.19 [ 0.01, 6.48 ]
Bath 2001 2/7 0/5 0.3 % 5.00 [ 0.19, 130.02 ]
ENOS 2015 78/720 92/714 33.2 % 0.82 [ 0.60, 1.13 ]
Rashid 2002 0/15 1/6 0.3 % 0.12 [ 0.00, 3.36 ]
Willmot 2006 0/3 0/3 Not estimable
Subtotal (95% CI) 749 731 34.1 % 0.79 [ 0.44, 1.41 ]
Total events: 80 (NO donor), 94 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.14, df = 3 (P = 0.37); I2 =4%
Test for overall effect: Z = 0.80 (P = 0.43)
3 180.1 to 200 mmHg
Ankolekar 2013 1/7 0/1 0.3 % 0.69 [ 0.02, 26.90 ]
Bath 2001 0/3 0/2 Not estimable
ENOS 2015 41/374 44/349 16.7 % 0.85 [ 0.54, 1.34 ]
Rashid 2002 0/7 0/2 Not estimable
Willmot 2006 0/2 0/1 Not estimable
Subtotal (95% CI) 393 355 16.9 % 0.85 [ 0.54, 1.33 ]
Total events: 42 (NO donor), 44 (Control)
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
4 > 200 mmHg
Ankolekar 2013 1/3 2/5 0.4 % 0.75 [ 0.04, 14.97 ]
Bath 2001 1/1 0/1 0.2 % 9.00 [ 0.10, 831.78 ]
ENOS 2015 17/118 24/129 7.4 % 0.74 [ 0.37, 1.45 ]
Rashid 2002 0/4 0/1 Not estimable
Subtotal (95% CI) 126 136 8.0 % 0.78 [ 0.40, 1.50 ]
Total events: 19 (NO donor), 26 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.15, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 2112 2084 100.0 % 0.87 [ 0.72, 1.05 ]
Total events: 243 (NO donor), 273 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.17, df = 12 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Chi2 = 0.58, df = 3 (P = 0.90), I2 =0.0%
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Analysis 1.17. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
17 Neurological deterioration, end of treatment.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 17 Neurological deterioration, end of treatment
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overall
Ankolekar 2013 5/25 5/16 3.0 % 0.55 [ 0.13, 2.32 ]
ENOS 2015 141/2000 113/2011 96.4 % 1.27 [ 0.99, 1.64 ]
Rashid 2002 1/58 0/30 0.6 % 1.59 [ 0.06, 40.25 ]
Willmot 2006 0/12 0/6 Not estimable
Total (95% CI) 2095 2063 100.0 % 1.24 [ 0.97, 1.60 ]
Total events: 147 (NO donor), 118 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.29, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
18 Neurological deterioration, end of treatment, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 18 Neurological deterioration, end of treatment, by stroke type
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic
Ankolekar 2013 2/16 5/11 5.5 % 0.17 [ 0.03, 1.14 ]
ENOS 2015 109/1664 91/1678 58.2 % 1.22 [ 0.92, 1.63 ]
Rashid 2002 0/54 0/30 Not estimable
Willmot 2006 0/11 0/5 Not estimable
Subtotal (95% CI) 1745 1724 63.7 % 0.58 [ 0.09, 3.75 ]
Total events: 111 (NO donor), 96 (Control)
Heterogeneity: Tau2 = 1.45; Chi2 = 4.02, df = 1 (P = 0.04); I2 =75%
Test for overall effect: Z = 0.57 (P = 0.57)
2 ICH
Ankolekar 2013 2/5 0/1 1.6 % 2.14 [ 0.06, 77.54 ]
ENOS 2015 30/310 22/319 34.7 % 1.45 [ 0.81, 2.57 ]
Willmot 2006 0/1 0/1 Not estimable
Subtotal (95% CI) 316 321 36.3 % 1.46 [ 0.83, 2.57 ]
Total events: 32 (NO donor), 22 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Total (95% CI) 2061 2045 100.0 % 1.17 [ 0.74, 1.86 ]
Total events: 143 (NO donor), 118 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.54, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Chi2 = 0.86, df = 1 (P = 0.35), I2 =0.0%
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Analysis 1.19. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
19 Neurological deterioration, end of treatment, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 19 Neurological deterioration, end of treatment, by time to randomisation
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 6 hours
Ankolekar 2013 5/24 5/15 5.7 % 0.53 [ 0.12, 2.26 ]
ENOS 2015 11/144 16/129 13.7 % 0.58 [ 0.26, 1.31 ]
Subtotal (95% CI) 168 144 19.4 % 0.57 [ 0.28, 1.16 ]
Total events: 16 (NO donor), 21 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
2 6.1 to 12 hours
Ankolekar 2013 0/1 0/1 Not estimable
ENOS 2015 19/224 9/214 13.5 % 2.11 [ 0.93, 4.78 ]
Subtotal (95% CI) 225 215 13.5 % 2.11 [ 0.93, 4.78 ]
Total events: 19 (NO donor), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
3 12.1 to 24 hours
ENOS 2015 42/541 35/526 23.4 % 1.18 [ 0.74, 1.88 ]
Rashid 2002 0/1 0/2 Not estimable
Subtotal (95% CI) 542 528 23.4 % 1.18 [ 0.74, 1.88 ]
Total events: 42 (NO donor), 35 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
4 24.1 to 36 hours
ENOS 2015 43/593 23/610 21.5 % 2.00 [ 1.19, 3.35 ]
Rashid 2002 0/9 0/4 Not estimable
Willmot 2006 0/1 0/1 Not estimable
Subtotal (95% CI) 603 615 21.5 % 2.00 [ 1.19, 3.35 ]
Total events: 43 (NO donor), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0092)
5 > 36 hours
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ENOS 2015 26/498 30/532 20.9 % 0.92 [ 0.54, 1.58 ]
Rashid 2002 1/50 0/24 1.3 % 1.48 [ 0.06, 37.80 ]
Willmot 2006 0/11 0/4 Not estimable
Subtotal (95% CI) 559 560 22.2 % 0.93 [ 0.55, 1.59 ]
Total events: 27 (NO donor), 30 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI) 2097 2062 100.0 % 1.18 [ 0.81, 1.72 ]
Total events: 147 (NO donor), 118 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 10.72, df = 6 (P = 0.10); I2 =44%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Chi2 = 10.62, df = 4 (P = 0.03), I2 =62%
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Analysis 1.20. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
20 Neurological deterioration, end of treatment, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 20 Neurological deterioration, end of treatment, by baseline SBP
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Baseline SBP < 160
Ankolekar 2013 2/11 2/7 2.0 % 0.56 [ 0.06, 5.24 ]
ENOS 2015 52/788 33/819 30.0 % 1.68 [ 1.08, 2.63 ]
Rashid 2002 1/33 0/21 1.0 % 1.98 [ 0.08, 51.01 ]
Willmot 2006 0/7 0/2 Not estimable
Subtotal (95% CI) 839 849 33.0 % 1.62 [ 1.05, 2.50 ]
Total events: 55 (NO donor), 35 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
2 Baseline SBP 160.1 to 180
Ankolekar 2013 0/4 1/3 0.8 % 0.19 [ 0.01, 6.48 ]
ENOS 2015 43/720 47/714 31.7 % 0.90 [ 0.59, 1.38 ]
Rashid 2002 0/15 0/6 Not estimable
Willmot 2006 0/3 0/3 Not estimable
Subtotal (95% CI) 742 726 32.5 % 0.88 [ 0.58, 1.35 ]
Total events: 43 (NO donor), 48 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
3 Baseline SBP 180.1 to 200
Ankolekar 2013 2/7 0/1 0.8 % 1.36 [ 0.04, 46.65 ]
ENOS 2015 39/374 21/349 23.0 % 1.82 [ 1.05, 3.16 ]
Rashid 2002 0/7 0/2 Not estimable
Willmot 2006 0/2 0/1 Not estimable
Subtotal (95% CI) 390 353 23.9 % 1.81 [ 1.05, 3.12 ]
Total events: 41 (NO donor), 21 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
4 Baseline SBP > 200
Ankolekar 2013 1/3 2/5 1.1 % 0.75 [ 0.04, 14.97 ]
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ENOS 2015 7/118 12/129 9.6 % 0.61 [ 0.23, 1.62 ]
Rashid 2002 0/4 0/1 Not estimable
Subtotal (95% CI) 125 135 10.7 % 0.63 [ 0.25, 1.57 ]
Total events: 8 (NO donor), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 2096 2063 100.0 % 1.22 [ 0.88, 1.68 ]
Total events: 147 (NO donor), 118 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 9.58, df = 8 (P = 0.30); I2 =16%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Chi2 = 7.87, df = 3 (P = 0.05), I2 =62%
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Analysis 1.21. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
21 NIH Stroke Scale, end of treatment.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 21 NIH Stroke Scale, end of treatment
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Overall
Ankolekar 2013 25 7.28 (7.85) 16 11.41 (10.44) 0.5 % -4.13 [ -10.10, 1.84 ]
ENOS 2015 1992 8.87 (6.84) 1999 9.13 (7) 95.6 % -0.26 [ -0.69, 0.17 ]
Rashid 2002 57 7.14 (5.52) 30 7.95 (5.4) 3.0 % -0.81 [ -3.22, 1.60 ]
Willmot 2006 12 5.22 (5.6) 6 3.89 (4.17) 0.8 % 1.33 [ -3.27, 5.93 ]
Total (95% CI) 2086 2051 100.0 % -0.28 [ -0.70, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.26, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
22 NIH Stroke Scale, end of treatment, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 22 NIH Stroke Scale, end of treatment, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic
Ankolekar 2013 16 6.12 (6.43) 11 14.07 (9.81) 2.2 % -7.95 [ -14.55, -1.35 ]
ENOS 2015 1657 8.54 (6.8) 1670 8.86 (6.99) 45.0 % -0.32 [ -0.79, 0.15 ]
Rashid 2002 51 7.27 (5.6) 30 7.95 (5.4) 12.3 % -0.68 [ -3.15, 1.79 ]
Willmot 2006 11 4.3 (4.82) 6 2.29 (1.54) 8.6 % 2.01 [ -1.09, 5.11 ]
Subtotal (95% CI) 1735 1717 68.0 % -0.47 [ -2.39, 1.45 ]
Heterogeneity: Tau2 = 2.05; Chi2 = 7.38, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 0.48 (P = 0.63)
2 ICH
Ankolekar 2013 5 11.71 (11.03) 1 23.96 (0) Not estimable
ENOS 2015 310 10.84 (6.63) 315 10.72 (6.88) 32.0 % 0.12 [ -0.94, 1.18 ]
Willmot 2006 1 15.36 (0) 1 11.92 (0) Not estimable
Subtotal (95% CI) 316 317 32.0 % 0.12 [ -0.94, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
Total (95% CI) 2051 2034 100.0 % -0.19 [ -1.19, 0.81 ]
Heterogeneity: Tau2 = 0.52; Chi2 = 7.94, df = 4 (P = 0.09); I2 =50%
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
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Analysis 1.23. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
23 NIH Stroke Scale, end of treatment, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 23 NIH Stroke Scale, end of treatment, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 6 hours
Ankolekar 2013 24 7.56 (7.9) 15 11.15 (10.75) 0.8 % -3.59 [ -9.88, 2.70 ]
ENOS 2015 144 8.13 (6.97) 126 10.08 (8.03) 8.1 % -1.95 [ -3.76, -0.14 ]
Subtotal (95% CI) 168 141 8.9 % -2.07 [ -3.81, -0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.34 (P = 0.019)
2 6.1 to 12 hours
Ankolekar 2013 1 0.74 (0) 1 15.36 (0) Not estimable
ENOS 2015 224 9.63 (7.26) 214 8.46 (6.77) 13.3 % 1.17 [ -0.14, 2.48 ]
Subtotal (95% CI) 225 215 13.3 % 1.17 [ -0.14, 2.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
3 12.1-24 hours
ENOS 2015 537 9.06 (7.08) 522 9.32 (7.29) 22.4 % -0.26 [ -1.13, 0.61 ]
Rashid 2002 1 11.49 (0) 2 6.76 (3.04) Not estimable
Subtotal (95% CI) 538 524 22.4 % -0.26 [ -1.13, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
4 24.1 to 36 hours
ENOS 2015 590 8.82 (6.69) 608 8.89 (6.6) 25.7 % -0.07 [ -0.82, 0.68 ]
Rashid 2002 9 11.63 (6.71) 4 11.49 (3.51) 1.0 % 0.14 [ -5.43, 5.71 ]
Willmot 2006 1 1.17 (0) 1 0.74 (0) Not estimable
Subtotal (95% CI) 600 613 26.7 % -0.07 [ -0.81, 0.68 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
5 > 36 hours
ENOS 2015 497 8.57 (6.47) 529 9.27 (6.96) 23.6 % -0.70 [ -1.52, 0.12 ]
Rashid 2002 47 6.19 (4.89) 24 7.46 (5.67) 4.1 % -1.27 [ -3.93, 1.39 ]
Willmot 2006 11 5.59 (5.71) 4 4.93 (4.88) 0.9 % 0.66 [ -5.19, 6.51 ]
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Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 555 557 28.7 % -0.72 [ -1.50, 0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.068)
Total (95% CI) 2086 2050 100.0 % -0.32 [ -0.88, 0.25 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 10.98, df = 8 (P = 0.20); I2 =27%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Chi2 = 10.35, df = 4 (P = 0.03), I2 =61%
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Analysis 1.24. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
24 NIH Stroke Scale, end of treatment, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 24 NIH Stroke Scale, end of treatment, by baseline SBP
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 160 mmHg
Ankolekar 2013 11 8.32 (6.74) 7 10.2 (10.74) 0.3 % -1.88 [ -10.78, 7.02 ]
ENOS 2015 786 8.44 (6.94) 816 8.77 (6.97) 30.1 % -0.33 [ -1.01, 0.35 ]
Rashid 2002 31 8.09 (5.93) 21 7.5 (5.34) 2.4 % 0.59 [ -2.50, 3.68 ]
Willmot 2006 7 7.56 (6.43) 2 3.32 (1.82) 0.8 % 4.24 [ -1.15, 9.63 ]
Subtotal (95% CI) 835 846 33.6 % -0.15 [ -1.04, 0.75 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 3.13, df = 3 (P = 0.37); I2 =4%
Test for overall effect: Z = 0.33 (P = 0.74)
2 160.1 to 180 mmHg
Ankolekar 2013 4 1.92 (1.13) 3 11.78 (12.16) 0.1 % -9.86 [ -23.66, 3.94 ]
ENOS 2015 714 8.77 (6.69) 707 9.25 (7.03) 28.4 % -0.48 [ -1.19, 0.23 ]
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Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rashid 2002 14 5.07 (5.1) 6 10.56 (6.53) 0.7 % -5.49 [ -11.36, 0.38 ]
Willmot 2006 3 2.6 (0.66) 3 1.6 (1.14) 9.3 % 1.00 [ -0.49, 2.49 ]
Subtotal (95% CI) 735 719 38.5 % -0.47 [ -2.32, 1.38 ]
Heterogeneity: Tau2 = 1.65; Chi2 = 8.01, df = 3 (P = 0.05); I2 =63%
Test for overall effect: Z = 0.50 (P = 0.62)
3 180.1 to 200 mmHg
Ankolekar 2013 7 7.25 (9.58) 1 8.48 (0) Not estimable
ENOS 2015 374 9.6 (6.75) 347 9.54 (6.97) 17.8 % 0.06 [ -0.94, 1.06 ]
Rashid 2002 7 5.41 (3.46) 2 6.76 (0.61) 3.1 % -1.35 [ -4.05, 1.35 ]
Willmot 2006 2 0.96 (0.3) 1 11.92 (0) Not estimable
Subtotal (95% CI) 390 351 20.9 % -0.11 [ -1.05, 0.83 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
4 > 200 mmHg
Ankolekar 2013 2 12.35 (15.2) 5 13.47 (12.3) 0.0 % -1.12 [ -24.78, 22.54 ]
ENOS 2015 118 9.94 (7.03) 129 9.64 (7.02) 7.0 % 0.30 [ -1.45, 2.05 ]
Rashid 2002 4 8.59 (5.29) 1 4.18 (0) Not estimable
Subtotal (95% CI) 124 135 7.0 % 0.29 [ -1.46, 2.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI) 2084 2051 100.0 % -0.16 [ -0.65, 0.33 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 12.49, df = 11 (P = 0.33); I2 =12%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Chi2 = 0.36, df = 3 (P = 0.95), I2 =0.0%
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Analysis 1.25. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
25 Barthel Index, end of trial.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 25 Barthel Index, end of trial
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Overall
Ankolekar 2013 25 62.5 (42.99) 16 38.44 (46.18) 3.3 % 24.06 [ -4.15, 52.27 ]
Bath 2001 16 9.5 (9.68) 18 14.28 (7.64) 30.3 % -4.78 [ -10.69, 1.13 ]
ENOS 2015 1983 65.47 (38.14) 1987 63.29 (39.43) 44.3 % 2.18 [ -0.23, 4.59 ]
Rashid 2002 60 68.73 (37.25) 30 66.33 (36.51) 8.8 % 2.40 [ -13.71, 18.51 ]
Willmot 2006 12 84.58 (15.14) 6 89.17 (11.14) 13.3 % -4.59 [ -16.95, 7.77 ]
Total (95% CI) 2096 2057 100.0 % -0.09 [ -5.39, 5.20 ]
Heterogeneity: Tau2 = 14.95; Chi2 = 7.95, df = 4 (P = 0.09); I2 =50%
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 1.26. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
26 Barthel Index, end of trial, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 26 Barthel Index, end of trial, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic
Ankolekar 2013 16 71.67 (40.12) 11 30.45 (41.56) 1.8 % 41.22 [ 9.76, 72.68 ]
Bath 2001 14 11.57 (8.44) 16 13.63 (7.88) 22.7 % -2.06 [ -7.93, 3.81 ]
ENOS 2015 1649 66.06 (38.11) 1660 63.69 (39.32) 34.3 % 2.37 [ -0.27, 5.01 ]
Rashid 2002 54 67.55 (37.46) 30 66.33 (36.51) 5.8 % 1.22 [ -15.23, 17.67 ]
Willmot 2006 11 87.27 (12.52) 5 93 (6.71) 13.5 % -5.73 [ -15.18, 3.72 ]
Subtotal (95% CI) 1744 1722 78.1 % 0.60 [ -5.27, 6.47 ]
Heterogeneity: Tau2 = 21.81; Chi2 = 10.20, df = 4 (P = 0.04); I2 =61%
Test for overall effect: Z = 0.20 (P = 0.84)
2 ICH
Ankolekar 2013 5 39 (46.29) 1 -5 (0) Not estimable
Bath 2001 2 -5 (0) 2 19.5 (0.71) Not estimable
ENOS 2015 309 62.33 (38.06) 313 61.41 (39.71) 21.9 % 0.92 [ -5.19, 7.03 ]
Willmot 2006 1 55 (0) 1 70 (0) Not estimable
Subtotal (95% CI) 317 317 21.9 % 0.92 [ -5.19, 7.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
Total (95% CI) 2061 2039 100.0 % 0.57 [ -3.72, 4.87 ]
Heterogeneity: Tau2 = 12.16; Chi2 = 10.22, df = 5 (P = 0.07); I2 =51%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
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Analysis 1.27. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
27 Barthel Index, end of trial, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 27 Barthel Index, end of trial, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 6 hours
Ankolekar 2013 24 65.43 (41.42) 15 40 (47.36) 1.3 % 25.43 [ -3.71, 54.57 ]
ENOS 2015 144 73.61 (34.35) 129 60.08 (40.96) 9.4 % 13.53 [ 4.51, 22.55 ]
Subtotal (95% CI) 168 144 10.7 % 14.57 [ 5.95, 23.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.31 (P = 0.00092)
2 6.1 to 12 hours
Ankolekar 2013 1 -5 (0) 1 15 (0) Not estimable
ENOS 2015 222 62.93 (40.4) 210 66.4 (39.49) 11.7 % -3.47 [ -11.00, 4.06 ]
Subtotal (95% CI) 223 211 11.7 % -3.47 [ -11.00, 4.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
3 12.1 to 24 hours
ENOS 2015 534 65.29 (38.61) 520 63.8 (39.26) 17.8 % 1.49 [ -3.21, 6.19 ]
Rashid 2002 1 -5 (0) 2 80 (28.28) Not estimable
Subtotal (95% CI) 535 522 17.8 % 1.49 [ -3.21, 6.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
4 24.1 to 36 hours
ENOS 2015 588 64.4 (38.75) 602 63.89 (38.92) 18.6 % 0.51 [ -3.90, 4.92 ]
Rashid 2002 9 43.33 (41.98) 4 33.75 (40.29) 0.5 % 9.58 [ -38.49, 57.65 ]
Willmot 2006 1 70 (0) 1 100 (0) Not estimable
Subtotal (95% CI) 598 607 19.1 % 0.59 [ -3.81, 4.98 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
5 > 36 hours
Bath 2001 16 9.5 (9.68) 18 13.94 (7.73) 14.9 % -4.44 [ -10.38, 1.50 ]
ENOS 2015 495 65.72 (36.72) 526 61.66 (39.81) 17.9 % 4.06 [ -0.63, 8.75 ]
Rashid 2002 50 74.9 (33.31) 24 70.63 (34.84) 3.6 % 4.27 [ -12.45, 20.99 ]
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Willmot 2006 11 85.91 (15.14) 4 86.25 (12.5) 4.3 % -0.34 [ -15.51, 14.83 ]
Subtotal (95% CI) 572 572 40.7 % 0.50 [ -4.88, 5.89 ]
Heterogeneity: Tau2 = 11.43; Chi2 = 5.03, df = 3 (P = 0.17); I2 =40%
Test for overall effect: Z = 0.18 (P = 0.85)
Total (95% CI) 2096 2056 100.0 % 1.81 [ -1.62, 5.25 ]
Heterogeneity: Tau2 = 11.45; Chi2 = 16.54, df = 9 (P = 0.06); I2 =46%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 10.80, df = 4 (P = 0.03), I2 =63%
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Analysis 1.28. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
28 Barthel Index, end of trial, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 28 Barthel Index, end of trial, by baseline SBP
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 160 mmHg
Ankolekar 2013 11 51.5 (43.85) 7 35 (49.16) 0.7 % 16.50 [ -28.20, 61.20 ]
Bath 2001 5 12.8 (9.88) 12 13.42 (8.78) 8.9 % -0.62 [ -10.60, 9.36 ]
ENOS 2015 780 66.63 (38.11) 809 65.19 (39.21) 20.3 % 1.44 [ -2.36, 5.24 ]
Rashid 2002 33 61.97 (41.1) 21 70.48 (34.06) 2.9 % -8.51 [ -28.73, 11.71 ]
Willmot 2006 7 81.43 (15.47) 2 87.5 (3.54) 6.5 % -6.07 [ -18.54, 6.40 ]
Subtotal (95% CI) 836 851 39.3 % 0.47 [ -2.89, 3.83 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.60, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
2 160.1 to 180 mmHg
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ankolekar 2013 4 97.5 (5) 3 28.33 (41.63) 0.6 % 69.17 [ 21.81, 116.53 ]
Bath 2001 7 7.86 (9.91) 5 16.2 (5.36) 10.5 % -8.34 [ -17.06, 0.38 ]
ENOS 2015 714 66.43 (37.71) 705 63.41 (39.23) 19.9 % 3.02 [ -0.98, 7.02 ]
Rashid 2002 14 82.14 (29.07) 6 46.67 (45.57) 0.8 % 35.47 [ -4.04, 74.98 ]
Willmot 2006 3 91.67 (14.43) 3 96.67 (5.77) 3.7 % -5.00 [ -22.59, 12.59 ]
Subtotal (95% CI) 742 722 35.5 % 4.30 [ -8.25, 16.85 ]
Heterogeneity: Tau2 = 114.27; Chi2 = 16.65, df = 4 (P = 0.002); I2 =76%
Test for overall effect: Z = 0.67 (P = 0.50)
3 180.1 to 200 mmHg
Ankolekar 2013 7 70.71 (41.17) 1 80 (0) Not estimable
Bath 2001 3 12.67 (7.51) 1 15 (0) Not estimable
ENOS 2015 372 62.35 (38.21) 345 62.12 (39.04) 16.1 % 0.23 [ -5.43, 5.89 ]
Rashid 2002 7 70 (38.08) 2 65 (35.36) 0.4 % 5.00 [ -51.54, 61.54 ]
Willmot 2006 2 85 (21.21) 1 70 (0) Not estimable
Subtotal (95% CI) 391 350 16.5 % 0.28 [ -5.36, 5.91 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
4 > 200 mmHg
Ankolekar 2013 3 33.33 (53.93) 5 41 (54.48) 0.2 % -7.67 [ -85.16, 69.82 ]
ENOS 2015 117 61.88 (40.43) 128 53.87 (41.95) 8.5 % 8.01 [ -2.31, 18.33 ]
Rashid 2002 4 82.5 (19.36) 1 100 (0) Not estimable
Subtotal (95% CI) 124 134 8.7 % 7.74 [ -2.49, 17.97 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
Total (95% CI) 2093 2057 100.0 % 0.66 [ -3.00, 4.32 ]
Heterogeneity: Tau2 = 13.40; Chi2 = 21.31, df = 13 (P = 0.07); I2 =39%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 2.08, df = 3 (P = 0.56), I2 =0.0%
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Analysis 1.29. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
29 Mood (Zung), end of trial.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 29 Mood (Zung), end of trial
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Overall
Ankolekar 2013 25 34.71 (31.39) 16 52.25 (40.47) 2.4 % -17.54 [ -40.88, 5.80 ]
ENOS 2015 1633 58.3 (23.71) 1620 58.8 (24.55) 94.5 % -0.50 [ -2.16, 1.16 ]
Willmot 2006 12 51.04 (16.77) 6 49.17 (22.29) 3.1 % 1.87 [ -18.33, 22.07 ]
Total (95% CI) 1670 1642 100.0 % -0.83 [ -4.44, 2.79 ]
Heterogeneity: Tau2 = 2.88; Chi2 = 2.09, df = 2 (P = 0.35); I2 =4%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 1.30. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
30 Mood (Zung), end of trial, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 30 Mood (Zung), end of trial, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic
Ankolekar 2013 16 31.73 (29.25) 11 51.54 (40.65) 0.4 % -19.81 [ -47.78, 8.16 ]
ENOS 2015 1361 57.81 (23.6) 1341 58.52 (24.6) 83.3 % -0.71 [ -2.53, 1.11 ]
Willmot 2006 11 52.5 (16.77) 5 45 (22.15) 0.6 % 7.50 [ -14.30, 29.30 ]
Subtotal (95% CI) 1388 1357 84.3 % -1.04 [ -7.81, 5.72 ]
Heterogeneity: Tau2 = 13.01; Chi2 = 2.34, df = 2 (P = 0.31); I2 =14%
Test for overall effect: Z = 0.30 (P = 0.76)
2 ICH
Ankolekar 2013 5 55.2 (43.37) 1 102.5 (0) Not estimable
ENOS 2015 249 60.09 (24.18) 267 59.58 (24.28) 15.7 % 0.51 [ -3.67, 4.69 ]
Willmot 2006 1 52.5 (0) 1 70 (0) Not estimable
Subtotal (95% CI) 255 269 15.7 % 0.51 [ -3.67, 4.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 1643 1626 100.0 % -0.54 [ -2.20, 1.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.62, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 1.31. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
31 Mood (Zung), end of trial, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 31 Mood (Zung), end of trial, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 6 hours
Ankolekar 2013 24 31.76 (28.49) 15 54.07 (41.21) 1.6 % -22.31 [ -46.08, 1.46 ]
ENOS 2015 123 52.2 (21.19) 106 62.5 (27.58) 13.0 % -10.30 [ -16.75, -3.85 ]
Subtotal (95% CI) 147 121 14.7 % -11.12 [ -17.35, -4.90 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 3.50 (P = 0.00046)
2 6.1 to 12 hours
Ankolekar 2013 1 102.5 (0) 1 25 (0) Not estimable
ENOS 2015 189 61.71 (25.84) 181 59.16 (24.51) 16.3 % 2.55 [ -2.58, 7.68 ]
Subtotal (95% CI) 190 182 16.3 % 2.55 [ -2.58, 7.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
3 12.1 to 24 hours
ENOS 2015 426 58.79 (24.18) 408 57.81 (24.76) 21.8 % 0.98 [ -2.34, 4.30 ]
Subtotal (95% CI) 426 408 21.8 % 0.98 [ -2.34, 4.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
4 24.1 to 36 hours
ENOS 2015 489 59.22 (23.9) 498 58.8 (24.13) 22.8 % 0.42 [ -2.58, 3.42 ]
Willmot 2006 1 52.5 (0) 1 82.5 (0) Not estimable
Subtotal (95% CI) 490 499 22.8 % 0.42 [ -2.58, 3.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
5 > 36 hours
ENOS 2015 406 56.95 (22.3) 427 58.67 (24.1) 22.4 % -1.72 [ -4.87, 1.43 ]
Willmot 2006 11 50.91 (17.58) 4 44.38 (18.97) 2.0 % 6.53 [ -14.77, 27.83 ]
Subtotal (95% CI) 417 431 24.4 % -1.54 [ -4.66, 1.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Total (95% CI) 1670 1641 100.0 % -1.24 [ -4.38, 1.91 ]
Heterogeneity: Tau2 = 8.91; Chi2 = 15.57, df = 6 (P = 0.02); I2 =61%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Chi2 = 14.10, df = 4 (P = 0.01), I2 =72%
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Analysis 1.32. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
32 Mood (Zung), end of trial, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 32 Mood (Zung), end of trial, by baseline SBP
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 160 mmHg
Ankolekar 2013 11 39 (33.9) 7 58.36 (41.72) 0.2 % -19.36 [ -56.19, 17.47 ]
ENOS 2015 655 58.37 (24.1) 662 58.56 (24.25) 39.9 % -0.19 [ -2.80, 2.42 ]
Willmot 2006 7 52.86 (15.3) 2 38.75 (12.37) 0.6 % 14.11 [ -6.44, 34.66 ]
Subtotal (95% CI) 673 671 40.7 % 1.19 [ -9.36, 11.75 ]
Heterogeneity: Tau2 = 37.98; Chi2 = 2.89, df = 2 (P = 0.24); I2 =31%
Test for overall effect: Z = 0.22 (P = 0.82)
2 160.1 to 180 mmHg
Ankolekar 2013 4 19.75 (2.63) 3 46.5 (48.56) 0.1 % -26.75 [ -81.76, 28.26 ]
ENOS 2015 590 57.73 (23.4) 576 58.02 (24.82) 35.4 % -0.29 [ -3.06, 2.48 ]
Willmot 2006 3 54.17 (23.23) 3 49.17 (28.98) 0.2 % 5.00 [ -37.03, 47.03 ]
Subtotal (95% CI) 597 582 35.7 % -0.33 [ -3.09, 2.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
3 180.1 to 200 mmHg
Ankolekar 2013 7 32.07 (31.71) 1 18 (0) Not estimable
ENOS 2015 295 59.09 (23.14) 276 59.28 (24.05) 18.1 % -0.19 [ -4.07, 3.69 ]
Willmot 2006 2 40 (17.68) 1 70 (0) Not estimable
Subtotal (95% CI) 304 278 18.1 % -0.19 [ -4.07, 3.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
4 > 200 mmHg
Ankolekar 2013 3 46.5 (48.56) 5 54 (44.33) 0.1 % -7.50 [ -74.80, 59.80 ]
ENOS 2015 93 58.95 (24.88) 106 63.23 (26.13) 5.4 % -4.28 [ -11.37, 2.81 ]
Subtotal (95% CI) 96 111 5.5 % -4.32 [ -11.37, 2.74 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 1.20 (P = 0.23)
Total (95% CI) 1670 1642 100.0 % -0.41 [ -2.06, 1.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.11, df = 8 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 1.25, df = 3 (P = 0.74), I2 =0.0%
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Analysis 1.33. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
33 EQ5D-3L, end of trial.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 33 EQ5D-3L, end of trial
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Overall
Ankolekar 2013 25 0.45 (0.33) 16 0.25 (0.26) 24.7 % 0.20 [ 0.02, 0.38 ]
ENOS 2015 1978 0.46 (0.4) 1974 0.45 (0.4) 35.6 % 0.01 [ -0.01, 0.03 ]
Rashid 2002 54 0.43 (0.39) 28 0.41 (0.35) 26.0 % 0.02 [ -0.15, 0.19 ]
Willmot 2006 9 0.38 (0.49) 4 0.9 (0.12) 13.7 % -0.52 [ -0.86, -0.18 ]
Total (95% CI) 2066 2022 100.0 % -0.01 [ -0.17, 0.15 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 13.49, df = 3 (P = 0.004); I2 =78%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 1.34. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
34 EQ5D-3L, end of trial, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 34 EQ5D-3L, end of trial, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic
Ankolekar 2013 16 0.5 (0.35) 11 0.21 (0.23) 10.7 % 0.29 [ 0.07, 0.51 ]
ENOS 2015 1664 0.47 (0.4) 1678 0.46 (0.41) 36.6 % 0.01 [ -0.02, 0.04 ]
Rashid 2002 48 0.43 (0.39) 28 0.41 (0.35) 14.9 % 0.02 [ -0.15, 0.19 ]
Willmot 2006 8 0.48 (0.42) 4 0.9 (0.12) 6.1 % -0.42 [ -0.73, -0.11 ]
Subtotal (95% CI) 1736 1721 68.3 % 0.01 [ -0.17, 0.18 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 13.50, df = 3 (P = 0.004); I2 =78%
Test for overall effect: Z = 0.07 (P = 0.95)
2 ICH
Ankolekar 2013 5 0.25 (0.26) 1 0 (0) Not estimable
ENOS 2015 309 0.42 (0.39) 312 0.44 (0.39) 31.7 % -0.02 [ -0.08, 0.04 ]
Subtotal (95% CI) 314 313 31.7 % -0.02 [ -0.08, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 2050 2034 100.0 % 0.01 [ -0.08, 0.09 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 14.34, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 0.13 (P = 0.89)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
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Analysis 1.35. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
35 EQ5D-3L, end of trial, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 35 EQ5D-3L, end of trial, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 6 hours
Ankolekar 2013 24 0.45 (0.38) 15 0.24 (0.29) 4.2 % 0.21 [ 0.00, 0.42 ]
ENOS 2015 144 0.53 (0.4) 129 0.44 (0.41) 12.3 % 0.09 [ -0.01, 0.19 ]
Subtotal (95% CI) 168 144 16.4 % 0.11 [ 0.02, 0.20 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 2.42 (P = 0.016)
2 6.1 to 12 hours
Ankolekar 2013 1 0 (0) 1 -0.17 (0) Not estimable
ENOS 2015 223 0.45 (0.4) 210 0.49 (0.4) 15.3 % -0.04 [ -0.12, 0.04 ]
Subtotal (95% CI) 224 211 15.3 % -0.04 [ -0.12, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
3 12.1 to 24 hours
ENOS 2015 530 0.44 (0.41) 519 0.45 (0.4) 19.8 % -0.01 [ -0.06, 0.04 ]
Rashid 2002 1 0 (0) 2 0.39 (0.43) Not estimable
Subtotal (95% CI) 531 521 19.8 % -0.01 [ -0.06, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
4 24.1 to 36 hours
ENOS 2015 587 0.46 (0.4) 597 0.45 (0.4) 20.4 % 0.01 [ -0.04, 0.06 ]
Rashid 2002 8 0.16 (0.37) 4 0.16 (0.39) 1.0 % 0.0 [ -0.46, 0.46 ]
Subtotal (95% CI) 595 601 21.4 % 0.01 [ -0.04, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
5 > 36 hours
ENOS 2015 494 0.47 (0.38) 519 0.44 (0.41) 19.8 % 0.03 [ -0.02, 0.08 ]
Rashid 2002 45 0.49 (0.38) 22 0.46 (0.33) 5.5 % 0.03 [ -0.15, 0.21 ]
Willmot 2006 9 0.38 (0.49) 3 0.94 (0.12) 1.7 % -0.56 [ -0.91, -0.21 ]
Subtotal (95% CI) 548 544 27.1 % -0.10 [ -0.33, 0.13 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 10.86, df = 2 (P = 0.004); I2 =82%
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.85 (P = 0.40)
Total (95% CI) 2066 2021 100.0 % 0.01 [ -0.04, 0.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 19.44, df = 8 (P = 0.01); I2 =59%
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Chi2 = 7.91, df = 4 (P = 0.10), I2 =49%
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Analysis 1.36. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
36 EQ5D-3L, end of trial, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 36 EQ5D-3L, end of trial, by baseline SBP
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 160 mmHg
Ankolekar 2013 11 0.33 (0.35) 7 0.19 (0.23) 4.5 % 0.14 [ -0.13, 0.41 ]
ENOS 2015 781 0.47 (0.4) 806 0.47 (0.4) 21.9 % 0.0 [ -0.04, 0.04 ]
Rashid 2002 29 0.32 (0.38) 21 0.45 (0.35) 6.9 % -0.13 [ -0.33, 0.07 ]
Willmot 2006 7 0.22 (0.44) 2 0.91 (0.13) 2.6 % -0.69 [ -1.06, -0.32 ]
Subtotal (95% CI) 828 836 35.8 % -0.12 [ -0.34, 0.10 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 15.59, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 1.08 (P = 0.28)
2 160.1 to 180 mmHg
Ankolekar 2013 4 0.69 (0.07) 3 0.3 (0.26) 3.7 % 0.39 [ 0.09, 0.69 ]
ENOS 2015 712 0.48 (0.39) 697 0.46 (0.41) 21.6 % 0.02 [ -0.02, 0.06 ]
Rashid 2002 14 0.59 (0.42) 5 0.23 (0.39) 2.2 % 0.36 [ -0.05, 0.77 ]
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Willmot 2006 1 0.85 (0) 2 0.89 (0.16) Not estimable
Subtotal (95% CI) 731 707 27.5 % 0.22 [ -0.08, 0.51 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 8.21, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 1.45 (P = 0.15)
3 180.1 to 200 mmHg
Ankolekar 2013 7 0.55 (0.35) 1 0.32 (0) Not estimable
ENOS 2015 368 0.42 (0.4) 343 0.43 (0.4) 19.8 % -0.01 [ -0.07, 0.05 ]
Rashid 2002 6 0.59 (0.31) 1 0.31 (0) Not estimable
Subtotal (95% CI) 381 345 19.8 % -0.01 [ -0.07, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
4 > 200 mmHg
Ankolekar 2013 3 0.28 (0.25) 5 0.3 (0.38) 1.9 % -0.02 [ -0.46, 0.42 ]
ENOS 2015 117 0.46 (0.38) 128 0.37 (0.42) 14.9 % 0.09 [ -0.01, 0.19 ]
Rashid 2002 4 0.43 (0.35) 1 0.62 (0) Not estimable
Subtotal (95% CI) 124 134 16.9 % 0.08 [ -0.01, 0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.090)
Total (95% CI) 2064 2022 100.0 % 0.02 [ -0.05, 0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 28.59, df = 9 (P = 0.00076); I2 =69%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 5.92, df = 3 (P = 0.12), I2 =49%
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Analysis 1.37. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
37 EQ VAS, end of trial.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 37 EQ VAS, end of trial
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Overall
Ankolekar 2013 25 49.59 (32.02) 16 40.5 (37.11) 0.8 % 9.09 [ -13.00, 31.18 ]
ENOS 2015 1720 56.45 (30.81) 1720 55.66 (31.56) 95.1 % 0.79 [ -1.29, 2.87 ]
Rashid 2002 50 60.98 (25.94) 28 52.29 (24.19) 3.1 % 8.69 [ -2.80, 20.18 ]
Willmot 2006 10 70.7 (15.38) 6 68.33 (24.22) 0.9 % 2.37 [ -19.23, 23.97 ]
Total (95% CI) 1805 1770 100.0 % 1.12 [ -0.91, 3.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.28, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 1.38. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
38 EQ VAS, end of trial, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 38 EQ VAS, end of trial, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic
Ankolekar 2013 16 49.5 (32.49) 11 41.36 (38.8) 0.5 % 8.14 [ -19.77, 36.05 ]
ENOS 2015 1435 56.86 (30.67) 1425 55.92 (31.54) 80.3 % 0.94 [ -1.34, 3.22 ]
Rashid 2002 44 61.05 (27.23) 28 52.29 (24.19) 2.9 % 8.76 [ -3.28, 20.80 ]
Willmot 2006 10 70.7 (15.38) 5 76 (17.1) 1.3 % -5.30 [ -23.06, 12.46 ]
Subtotal (95% CI) 1505 1469 85.1 % 1.15 [ -1.06, 3.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.31, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
2 ICH
Ankolekar 2013 5 32 (40.03) 1 -1 (0) Not estimable
ENOS 2015 262 54.63 (31.31) 281 55.06 (31.53) 14.9 % -0.43 [ -5.72, 4.86 ]
Subtotal (95% CI) 267 282 14.9 % -0.43 [ -5.72, 4.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Total (95% CI) 1772 1751 100.0 % 0.92 [ -1.13, 2.96 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.61, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
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Analysis 1.39. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
39 EQ VAS, end of trial, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 39 EQ VAS, end of trial, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 6 hours
Ankolekar 2013 24 52 (30.7) 15 39.2 (38.03) 1.8 % 12.80 [ -10.03, 35.63 ]
ENOS 2015 138 62.21 (28.9) 118 52.59 (34.71) 10.7 % 9.62 [ 1.72, 17.52 ]
Subtotal (95% CI) 162 133 12.5 % 9.96 [ 2.49, 17.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.61 (P = 0.0090)
2 6.1 to 12 hours
Ankolekar 2013 1 -1 (0) 1 60 (0) Not estimable
ENOS 2015 198 53.57 (33.45) 192 56.49 (32.38) 13.7 % -2.92 [ -9.45, 3.61 ]
Subtotal (95% CI) 199 193 13.7 % -2.92 [ -9.45, 3.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
3 12.1 to 24 hours
ENOS 2015 455 56.1 (31.55) 448 55.43 (31.17) 21.6 % 0.67 [ -3.42, 4.76 ]
Rashid 2002 1 -1 (0) 2 55 (7.07) Not estimable
Subtotal (95% CI) 456 450 21.6 % 0.67 [ -3.42, 4.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
4 24.1 to 36 hours
ENOS 2015 510 55.1 (31.04) 523 56.57 (30.63) 22.9 % -1.47 [ -5.23, 2.29 ]
Rashid 2002 6 31.5 (28.1) 4 42.25 (30.34) 0.7 % -10.75 [ -48.03, 26.53 ]
Willmot 2006 1 60 (0) 1 50 (0) Not estimable
Subtotal (95% CI) 517 528 23.6 % -1.56 [ -5.31, 2.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
5 > 36 hours
ENOS 2015 419 57.94 (28.81) 439 55.26 (31.89) 21.7 % 2.68 [ -1.38, 6.74 ]
Rashid 2002 43 66.53 (21.06) 22 53.86 (24.41) 5.7 % 12.67 [ 0.68, 24.66 ]
Willmot 2006 9 71.89 (15.82) 4 70 (28.58) 1.1 % 1.89 [ -27.96, 31.74 ]
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 471 465 28.5 % 4.63 [ -1.21, 10.48 ]
Heterogeneity: Tau2 = 7.32; Chi2 = 2.41, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 1.56 (P = 0.12)
Total (95% CI) 1805 1769 100.0 % 1.91 [ -1.21, 5.04 ]
Heterogeneity: Tau2 = 7.39; Chi2 = 13.30, df = 8 (P = 0.10); I2 =40%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Chi2 = 10.21, df = 4 (P = 0.04), I2 =61%
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Analysis 1.40. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
40 EQ VAS, end of trial, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 40 EQ VAS, end of trial, by baseline SBP
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 160 mmHg
Ankolekar 2013 11 42.56 (34.96) 7 31.71 (34.97) 0.4 % 10.85 [ -22.28, 43.98 ]
ENOS 2015 701 56.68 (31.27) 708 56.46 (31.22) 39.1 % 0.22 [ -3.04, 3.48 ]
Rashid 2002 25 59.96 (28.44) 21 54.33 (24.83) 1.8 % 5.63 [ -9.77, 21.03 ]
Willmot 2006 5 73 (13.51) 2 82.5 (17.68) 0.6 % -9.50 [ -36.71, 17.71 ]
Subtotal (95% CI) 742 738 41.8 % 0.41 [ -2.74, 3.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.35, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
2 160.1 to 180 mmHg
Ankolekar 2013 4 58.75 (30.1) 3 59.33 (52.25) 0.1 % -0.58 [ -66.66, 65.50 ]
ENOS 2015 612 57.31 (30.47) 614 56.75 (31.39) 34.7 % 0.56 [ -2.90, 4.02 ]
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rashid 2002 14 66.07 (26.4) 5 42.6 (24.71) 0.6 % 23.47 [ -2.23, 49.17 ]
Willmot 2006 3 62.67 (16.17) 3 71.67 (18.93) 0.5 % -9.00 [ -37.17, 19.17 ]
Subtotal (95% CI) 633 625 36.0 % 2.02 [ -6.59, 10.64 ]
Heterogeneity: Tau2 = 21.09; Chi2 = 3.47, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.46 (P = 0.65)
3 180.1 to 200 mmHg
Ankolekar 2013 7 58.17 (30.99) 1 40 (0) Not estimable
ENOS 2015 312 55.56 (29.95) 287 54.79 (32.02) 16.8 % 0.77 [ -4.21, 5.75 ]
Rashid 2002 6 62.5 (20.19) 1 40 (0) Not estimable
Willmot 2006 2 77 (24.04) 1 30 (0) Not estimable
Subtotal (95% CI) 327 290 16.8 % 0.77 [ -4.21, 5.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
4 > 200 mmHg
Ankolekar 2013 3 41.33 (37.42) 5 41.6 (39.53) 0.1 % -0.27 [ -54.98, 54.44 ]
ENOS 2015 95 52.12 (32.44) 111 46.75 (32.47) 5.3 % 5.37 [ -3.52, 14.26 ]
Rashid 2002 4 68.75 (20.97) 1 70 (0) Not estimable
Subtotal (95% CI) 102 117 5.4 % 5.22 [ -3.55, 14.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Total (95% CI) 1804 1770 100.0 % 0.88 [ -1.16, 2.92 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.89, df = 10 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 1.09, df = 3 (P = 0.78), I2 =0.0%
-50 -25 0 25 50
Favours control Favours NO donor
93Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.41. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
41 t-MMSE, end of trial.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 41 t-MMSE, end of trial
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Overall
Ankolekar 2013 23 11.83 (8.3) 16 7.81 (8.86) 20.8 % 4.02 [ -1.49, 9.53 ]
ENOS 2015 1006 11.21 (7.45) 1026 10.84 (7.7) 79.2 % 0.37 [ -0.29, 1.03 ]
Willmot 2006 6 14.5 (3.99) 1 12 (0) Not estimable
Total (95% CI) 1035 1043 100.0 % 1.13 [ -1.77, 4.03 ]
Heterogeneity: Tau2 = 2.65; Chi2 = 1.66, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 1.42. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
42 t-MMSE, end of trial, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 42 t-MMSE, end of trial, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic
Ankolekar 2013 14 14.07 (7.38) 11 6.73 (8.46) 6.3 % 7.34 [ 1.02, 13.66 ]
ENOS 2015 836 11.45 (7.38) 861 11 (7.64) 56.5 % 0.45 [ -0.26, 1.16 ]
Willmot 2006 6 14.5 (3.99) 1 12 (0) Not estimable
Subtotal (95% CI) 856 873 62.9 % 3.15 [ -3.44, 9.74 ]
Heterogeneity: Tau2 = 18.47; Chi2 = 4.51, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.94 (P = 0.35)
2 ICH
Ankolekar 2013 5 6.8 (9.81) 1 -1 (0) Not estimable
ENOS 2015 153 10.13 (7.8) 153 9.98 (7.94) 37.1 % 0.15 [ -1.61, 1.91 ]
Subtotal (95% CI) 158 154 37.1 % 0.15 [ -1.61, 1.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Total (95% CI) 1014 1027 100.0 % 0.78 [ -0.90, 2.45 ]
Heterogeneity: Tau2 = 1.17; Chi2 = 4.67, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 0.91 (P = 0.37)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
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Analysis 1.43. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
43 t-MMSE, end of trial, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 43 t-MMSE, end of trial, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 6 hours
Ankolekar 2013 22 12.41 (8) 15 8.07 (9.11) 4.3 % 4.34 [ -1.35, 10.03 ]
ENOS 2015 92 13.75 (6.22) 90 10.23 (7.8) 15.9 % 3.52 [ 1.47, 5.57 ]
Subtotal (95% CI) 114 105 20.1 % 3.61 [ 1.68, 5.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 3.67 (P = 0.00024)
2 6.1 to 12 hours
Ankolekar 2013 1 -1 (0) 1 4 (0) Not estimable
ENOS 2015 124 10.02 (8.08) 128 11.77 (7.55) 16.7 % -1.75 [ -3.68, 0.18 ]
Subtotal (95% CI) 125 129 16.7 % -1.75 [ -3.68, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.076)
3 12.1 to -24 hours
ENOS 2015 278 11.09 (7.37) 278 11.09 (7.53) 21.4 % 0.0 [ -1.24, 1.24 ]
Subtotal (95% CI) 278 278 21.4 % 0.0 [ -1.24, 1.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 24.1 to 36 hours
ENOS 2015 293 10.73 (7.5) 294 10.4 (7.74) 21.5 % 0.33 [ -0.90, 1.56 ]
Subtotal (95% CI) 293 294 21.5 % 0.33 [ -0.90, 1.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
5 > 36 hours
ENOS 2015 219 11.63 (7.4) 236 10.81 (7.88) 20.3 % 0.82 [ -0.58, 2.22 ]
Willmot 2006 6 14.5 (3.99) 1 12 (0) Not estimable
Subtotal (95% CI) 225 237 20.3 % 0.82 [ -0.58, 2.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Total (95% CI) 1035 1043 100.0 % 0.69 [ -0.59, 1.97 ]
Heterogeneity: Tau2 = 1.59; Chi2 = 16.17, df = 5 (P = 0.01); I2 =69%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi2 = 16.10, df = 4 (P = 0.00), I2 =75%
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Analysis 1.44. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
44 t-MMSE, end of trial, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 44 t-MMSE, end of trial, by baseline SBP
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 160 mmHg
Ankolekar 2013 9 10.56 (8.13) 7 7.29 (10.05) 1.1 % 3.27 [ -5.88, 12.42 ]
ENOS 2015 417 11.06 (7.49) 427 11.3 (7.66) 33.9 % -0.24 [ -1.26, 0.78 ]
Subtotal (95% CI) 426 434 35.0 % -0.20 [ -1.21, 0.82 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
2 160.1 to 180 mmHg
Ankolekar 2013 4 18 (0.82) 3 7 (8.54) 1.0 % 11.00 [ 1.30, 20.70 ]
ENOS 2015 368 11.8 (7.31) 367 10.84 (7.6) 32.5 % 0.96 [ -0.12, 2.04 ]
Willmot 2006 1 18 (0) 1 12 (0) Not estimable
Subtotal (95% CI) 373 371 33.5 % 4.78 [ -4.78, 14.33 ]
Heterogeneity: Tau2 = 38.01; Chi2 = 4.07, df = 1 (P = 0.04); I2 =75%
Test for overall effect: Z = 0.98 (P = 0.33)
3 180.1 to 200 mmHg
Ankolekar 2013 7 13.29 (9.11) 1 17 (0) Not estimable
ENOS 2015 169 10.71 (7.38) 169 10.67 (7.66) 22.0 % 0.04 [ -1.56, 1.64 ]
Subtotal (95% CI) 176 170 22.0 % 0.04 [ -1.56, 1.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
4 > 200 mmHg
Ankolekar 2013 3 4 (7.81) 5 7.2 (9.18) 0.7 % -3.20 [ -15.15, 8.75 ]
ENOS 2015 52 9.9 (8.17) 63 8.17 (8.26) 8.8 % 1.73 [ -1.29, 4.75 ]
Subtotal (95% CI) 55 68 9.5 % 1.44 [ -1.49, 4.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 1030 1043 100.0 % 0.52 [ -0.46, 1.50 ]
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.46; Chi2 = 8.80, df = 6 (P = 0.19); I2 =32%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 2.03, df = 3 (P = 0.57), I2 =0.0%
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Analysis 1.45. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
45 TICS, end of trial.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 45 TICS, end of trial
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Overall
ENOS 2015 995 14.88 (10.47) 1018 14.58 (10.84) 100.0 % 0.30 [ -0.63, 1.23 ]
Total (95% CI) 995 1018 100.0 % 0.30 [ -0.63, 1.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 1.46. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
46 TICS, end of trial, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 46 TICS, end of trial, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic
ENOS 2015 830 15.16 (10.4) 853 14.74 (10.76) 86.2 % 0.42 [ -0.59, 1.43 ]
Subtotal (95% CI) 830 853 86.2 % 0.42 [ -0.59, 1.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
2 ICH
ENOS 2015 149 13.67 (11.14) 153 13.79 (11.28) 13.8 % -0.12 [ -2.65, 2.41 ]
Subtotal (95% CI) 149 153 13.8 % -0.12 [ -2.65, 2.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 979 1006 100.0 % 0.35 [ -0.59, 1.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 1.47. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
47 TICS, end of trial, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 47 TICS, end of trial, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 6 hours
ENOS 2015 92 19 (9.62) 90 13.41 (10.72) 16.7 % 5.59 [ 2.63, 8.55 ]
Subtotal (95% CI) 92 90 16.7 % 5.59 [ 2.63, 8.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.70 (P = 0.00022)
2 6.1 to 12 hours
ENOS 2015 122 13.28 (11.27) 126 15.47 (10.84) 17.6 % -2.19 [ -4.94, 0.56 ]
Subtotal (95% CI) 122 126 17.6 % -2.19 [ -4.94, 0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
3 12.1 to 24 hours
ENOS 2015 275 14.57 (10.2) 274 15.13 (10.8) 22.2 % -0.56 [ -2.32, 1.20 ]
Subtotal (95% CI) 275 274 22.2 % -0.56 [ -2.32, 1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
4 24.1 to 36 hours
ENOS 2015 290 14.25 (10.39) 293 14 (10.73) 22.4 % 0.25 [ -1.46, 1.96 ]
Subtotal (95% CI) 290 293 22.4 % 0.25 [ -1.46, 1.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.78)
5 > 36 hours
ENOS 2015 216 15.28 (10.42) 235 14.62 (11.07) 21.2 % 0.66 [ -1.32, 2.64 ]
Subtotal (95% CI) 216 235 21.2 % 0.66 [ -1.32, 2.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Total (95% CI) 995 1018 100.0 % 0.62 [ -1.33, 2.56 ]
Heterogeneity: Tau2 = 3.62; Chi2 = 16.43, df = 4 (P = 0.002); I2 =76%
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Chi2 = 16.43, df = 4 (P = 0.00), I2 =76%
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Analysis 1.48. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
48 TICS, end of trial, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 48 TICS, end of trial, by baseline SBP
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 160 mmHg
ENOS 2015 413 14.61 (10.63) 425 15.27 (10.78) 38.7 % -0.66 [ -2.11, 0.79 ]
Subtotal (95% CI) 413 425 38.7 % -0.66 [ -2.11, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
2 160.1 to 180 mmHg
ENOS 2015 366 15.79 (10.16) 362 14.48 (10.76) 36.1 % 1.31 [ -0.21, 2.83 ]
Subtotal (95% CI) 366 362 36.1 % 1.31 [ -0.21, 2.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
3 180.1 to 200 mmHg
ENOS 2015 164 14.12 (10.25) 168 14.07 (10.65) 19.3 % 0.05 [ -2.20, 2.30 ]
Subtotal (95% CI) 164 168 19.3 % 0.05 [ -2.20, 2.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
4 > 200 mmHg
ENOS 2015 52 13.1 (11.64) 63 11.78 (11.91) 5.8 % 1.32 [ -3.00, 5.64 ]
Subtotal (95% CI) 52 63 5.8 % 1.32 [ -3.00, 5.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 995 1018 100.0 % 0.30 [ -0.76, 1.37 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 3.64, df = 3 (P = 0.30); I2 =18%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 3.64, df = 3 (P = 0.30), I2 =18%
-4 -2 0 2 4
Favours control Favours NO donor
101Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.49. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
49 Animal naming, end of trial.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 49 Animal naming, end of trial
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Overall
ENOS 2015 1175 9.31 (7.73) 1191 9.21 (7.93) 100.0 % 0.10 [ -0.53, 0.73 ]
Total (95% CI) 1175 1191 100.0 % 0.10 [ -0.53, 0.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 1.50. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
50 Animal naming, end of trial, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 50 Animal naming, end of trial, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic
ENOS 2015 978 9.54 (7.71) 982 9.45 (7.96) 83.0 % 0.09 [ -0.60, 0.78 ]
Subtotal (95% CI) 978 982 83.0 % 0.09 [ -0.60, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
2 ICH
ENOS 2015 179 8.16 (7.77) 197 7.88 (7.36) 17.0 % 0.28 [ -1.25, 1.81 ]
Subtotal (95% CI) 179 197 17.0 % 0.28 [ -1.25, 1.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 1157 1179 100.0 % 0.12 [ -0.51, 0.75 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 1.51. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
51 Animal naming, end of trial, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 51 Animal naming, end of trial, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 6 hours
ENOS 2015 97 11.69 (6.72) 95 8.75 (7.76) 14.7 % 2.94 [ 0.88, 5.00 ]
Subtotal (95% CI) 97 95 14.7 % 2.94 [ 0.88, 5.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0050)
2 6.1 to 12 hours
ENOS 2015 146 8.62 (8.35) 140 9.95 (8.29) 15.8 % -1.33 [ -3.26, 0.60 ]
Subtotal (95% CI) 146 140 15.8 % -1.33 [ -3.26, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
3 12.1 to 24 hours
ENOS 2015 314 9.28 (7.76) 311 9.26 (7.89) 23.1 % 0.02 [ -1.21, 1.25 ]
Subtotal (95% CI) 314 311 23.1 % 0.02 [ -1.21, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
4 24.1 to 36 hours
ENOS 2015 346 8.68 (7.49) 349 9.02 (7.9) 24.1 % -0.34 [ -1.48, 0.80 ]
Subtotal (95% CI) 346 349 24.1 % -0.34 [ -1.48, 0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
5 > 36 hours
ENOS 2015 272 9.67 (7.85) 296 9.19 (7.9) 22.3 % 0.48 [ -0.82, 1.78 ]
Subtotal (95% CI) 272 296 22.3 % 0.48 [ -0.82, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 1175 1191 100.0 % 0.25 [ -0.80, 1.30 ]
Heterogeneity: Tau2 = 0.85; Chi2 = 10.34, df = 4 (P = 0.04); I2 =61%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 10.34, df = 4 (P = 0.04), I2 =61%
-4 -2 0 2 4
Favours control Favours NO donor
104Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.52. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
52 Animal naming, end of trial, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 52 Animal naming, end of trial, by baseline SBP
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 160 mmHg
ENOS 2015 477 9.17 (7.74) 489 9.53 (8.11) 39.7 % -0.36 [ -1.36, 0.64 ]
Subtotal (95% CI) 477 489 39.7 % -0.36 [ -1.36, 0.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 160.1 to 180 mmHg
ENOS 2015 425 9.79 (7.78) 425 9.39 (7.63) 37.0 % 0.40 [ -0.64, 1.44 ]
Subtotal (95% CI) 425 425 37.0 % 0.40 [ -0.64, 1.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
3 180.1 to 200 mmHg
ENOS 2015 204 9.06 (7.66) 206 8.8 (7.92) 17.5 % 0.26 [ -1.25, 1.77 ]
Subtotal (95% CI) 204 206 17.5 % 0.26 [ -1.25, 1.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
4 > 200 mmHg
ENOS 2015 69 8.07 (7.49) 71 7.15 (8.26) 5.8 % 0.92 [ -1.69, 3.53 ]
Subtotal (95% CI) 69 71 5.8 % 0.92 [ -1.69, 3.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 1175 1191 100.0 % 0.10 [ -0.53, 0.73 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.56, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Chi2 = 1.56, df = 3 (P = 0.67), I2 =0.0%
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Analysis 1.53. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
53 Physiotherapy.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 53 Physiotherapy
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overall
Ankolekar 2013 16/25 9/16 1.9 % 1.38 [ 0.38, 4.98 ]
ENOS 2015 1693/1987 1718/1997 98.1 % 0.94 [ 0.78, 1.12 ]
Willmot 2006 11/11 6/6 Not estimable
Total (95% CI) 2023 2019 100.0 % 0.94 [ 0.79, 1.12 ]
Total events: 1720 (NO donor), 1733 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 1.54. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
54 Physiotherapy, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 54 Physiotherapy, by stroke type
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic
Ankolekar 2013 11/16 7/11 1.2 % 1.26 [ 0.25, 6.36 ]
ENOS 2015 1430/1653 1462/1668 76.8 % 0.90 [ 0.74, 1.11 ]
Willmot 2006 10/10 5/5 Not estimable
Subtotal (95% CI) 1679 1684 78.0 % 0.91 [ 0.74, 1.11 ]
Total events: 1451 (NO donor), 1474 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
2 ICH
Ankolekar 2013 3/5 1/1 0.2 % 0.47 [ 0.01, 16.89 ]
ENOS 2015 245/308 242/315 21.8 % 1.17 [ 0.80, 1.72 ]
Willmot 2006 1/1 1/1 Not estimable
Subtotal (95% CI) 314 317 22.0 % 1.16 [ 0.79, 1.70 ]
Total events: 249 (NO donor), 244 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI) 1993 2001 100.0 % 0.96 [ 0.80, 1.15 ]
Total events: 1700 (NO donor), 1718 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 1.26, df = 1 (P = 0.26), I2 =21%
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Analysis 1.55. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
55 Physiotherapy, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 55 Physiotherapy, by time to randomisation
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 6 hours
Ankolekar 2013 16/24 8/15 1.8 % 1.75 [ 0.47, 6.57 ]
ENOS 2015 105/143 100/125 9.5 % 0.69 [ 0.39, 1.23 ]
Subtotal (95% CI) 167 140 11.3 % 0.90 [ 0.40, 2.05 ]
Total events: 121 (NO donor), 108 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 1.60, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.25 (P = 0.80)
2 6.1 to 12 hours
Ankolekar 2013 0/1 1/1 0.2 % 0.11 [ 0.00, 10.27 ]
ENOS 2015 170/224 166/213 15.8 % 0.89 [ 0.57, 1.39 ]
Subtotal (95% CI) 225 214 16.0 % 0.87 [ 0.56, 1.36 ]
Total events: 170 (NO donor), 167 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
3 12.1 to 24 hours
ENOS 2015 462/539 445/525 27.3 % 1.08 [ 0.77, 1.51 ]
Subtotal (95% CI) 539 525 27.3 % 1.08 [ 0.77, 1.51 ]
Total events: 462 (NO donor), 445 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
4 24.1 to 36 hours
ENOS 2015 512/588 525/608 28.1 % 1.07 [ 0.76, 1.49 ]
Willmot 2006 1/1 1/1 Not estimable
Subtotal (95% CI) 589 609 28.1 % 1.07 [ 0.76, 1.49 ]
Total events: 513 (NO donor), 526 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
5 > 36 hours
ENOS 2015 444/493 482/526 17.2 % 0.83 [ 0.54, 1.27 ]
Willmot 2006 10/10 4/4 Not estimable
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 503 530 17.2 % 0.83 [ 0.54, 1.27 ]
Total events: 454 (NO donor), 486 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Total (95% CI) 2023 2018 100.0 % 0.96 [ 0.80, 1.15 ]
Total events: 1720 (NO donor), 1732 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.32, df = 6 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 1.45, df = 4 (P = 0.84), I2 =0.0%
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Analysis 1.56. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
56 Physiotherapy, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 56 Physiotherapy, by baseline SBP
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 160 mmHg
Ankolekar 2013 8/11 4/7 0.9 % 2.00 [ 0.27, 14.78 ]
ENOS 2015 670/782 700/815 38.5 % 0.98 [ 0.74, 1.30 ]
Willmot 2006 7/7 2/2 Not estimable
Subtotal (95% CI) 800 824 39.4 % 1.00 [ 0.75, 1.32 ]
Total events: 685 (NO donor), 706 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
2 160.1 to 180 mmHg
Ankolekar 2013 1/4 2/3 0.3 % 0.17 [ 0.01, 4.51 ]
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ENOS 2015 604/713 604/708 36.1 % 0.95 [ 0.71, 1.28 ]
Willmot 2006 2/2 3/3 Not estimable
Subtotal (95% CI) 719 714 36.4 % 0.89 [ 0.46, 1.72 ]
Total events: 607 (NO donor), 609 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 1.07, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 0.34 (P = 0.73)
3 180.1 to 200 mmHg
Ankolekar 2013 4/7 1/1 0.3 % 0.43 [ 0.01, 14.08 ]
ENOS 2015 315/374 306/345 17.3 % 0.68 [ 0.44, 1.05 ]
Willmot 2006 2/2 1/1 Not estimable
Subtotal (95% CI) 383 347 17.6 % 0.68 [ 0.44, 1.04 ]
Total events: 321 (NO donor), 308 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.074)
4 > 200 mmHg
Ankolekar 2013 3/3 2/5 0.3 % 9.80 [ 0.33, 287.42 ]
ENOS 2015 104/118 108/129 6.4 % 1.44 [ 0.70, 2.99 ]
Subtotal (95% CI) 121 134 6.7 % 1.80 [ 0.54, 5.98 ]
Total events: 107 (NO donor), 110 (Control)
Heterogeneity: Tau2 = 0.29; Chi2 = 1.18, df = 1 (P = 0.28); I2 =16%
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 2023 2019 100.0 % 0.94 [ 0.78, 1.13 ]
Total events: 1720 (NO donor), 1733 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 7.22, df = 7 (P = 0.41); I2 =3%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Chi2 = 3.49, df = 3 (P = 0.32), I2 =14%
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Analysis 1.57. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
57 Occupational therapy.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 57 Occupational therapy
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overall
Ankolekar 2013 15/25 7/16 6.5 % 1.93 [ 0.54, 6.88 ]
ENOS 2015 1310/1987 1332/1997 93.5 % 0.97 [ 0.85, 1.10 ]
Willmot 2006 11/11 6/6 Not estimable
Total (95% CI) 2023 2019 100.0 % 1.01 [ 0.72, 1.41 ]
Total events: 1336 (NO donor), 1345 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.12, df = 1 (P = 0.29); I2 =11%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 1.58. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
58 Occupational therapy, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 58 Occupational therapy, by stroke type
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic
Ankolekar 2013 10/16 6/11 1.6 % 1.39 [ 0.29, 6.61 ]
ENOS 2015 1112/1653 1149/1668 69.6 % 0.93 [ 0.80, 1.07 ]
Willmot 2006 10/10 5/5 Not estimable
Subtotal (95% CI) 1679 1684 71.1 % 0.93 [ 0.81, 1.08 ]
Total events: 1132 (NO donor), 1160 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
2 ICH
Ankolekar 2013 3/5 0/1 0.3 % 4.20 [ 0.12, 151.97 ]
ENOS 2015 183/308 170/315 28.6 % 1.25 [ 0.91, 1.72 ]
Willmot 2006 1/1 1/1 Not estimable
Subtotal (95% CI) 314 317 28.9 % 1.26 [ 0.92, 1.73 ]
Total events: 187 (NO donor), 171 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
Total (95% CI) 1993 2001 100.0 % 1.02 [ 0.84, 1.24 ]
Total events: 1319 (NO donor), 1331 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.59, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 2.90, df = 1 (P = 0.09), I2 =65%
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Analysis 1.59. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
59 Occupational therapy, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 59 Occupational therapy, by time to randomisation
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 6 hours
Ankolekar 2013 15/24 6/15 1.0 % 2.50 [ 0.67, 9.39 ]
ENOS 2015 81/143 80/125 7.2 % 0.73 [ 0.45, 1.20 ]
Subtotal (95% CI) 167 140 8.2 % 1.15 [ 0.36, 3.68 ]
Total events: 96 (NO donor), 86 (Control)
Heterogeneity: Tau2 = 0.49; Chi2 = 2.89, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.24 (P = 0.81)
2 6.1 to 12 hours
Ankolekar 2013 0/1 1/1 0.1 % 0.11 [ 0.00, 10.27 ]
ENOS 2015 110/224 107/213 12.5 % 0.96 [ 0.66, 1.39 ]
Subtotal (95% CI) 225 214 12.6 % 0.94 [ 0.65, 1.37 ]
Total events: 110 (NO donor), 108 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
3 12.1 to 24 hours
ENOS 2015 351/539 335/525 27.8 % 1.06 [ 0.82, 1.36 ]
Subtotal (95% CI) 539 525 27.8 % 1.06 [ 0.82, 1.36 ]
Total events: 351 (NO donor), 335 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
4 24.1 to 36 hours
ENOS 2015 395/588 408/608 30.1 % 1.00 [ 0.79, 1.28 ]
Willmot 2006 1/1 1/1 Not estimable
Subtotal (95% CI) 589 609 30.1 % 1.00 [ 0.79, 1.28 ]
Total events: 396 (NO donor), 409 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
5 > 36 hours
ENOS 2015 373/493 402/526 21.2 % 0.96 [ 0.72, 1.28 ]
Willmot 2006 10/10 4/4 Not estimable
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 503 530 21.2 % 0.96 [ 0.72, 1.28 ]
Total events: 383 (NO donor), 406 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 2023 2018 100.0 % 0.99 [ 0.86, 1.13 ]
Total events: 1336 (NO donor), 1344 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.55, df = 6 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 0.44, df = 4 (P = 0.98), I2 =0.0%
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Analysis 1.60. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
60 Occupational therapy, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 60 Occupational therapy, by baseline SBP
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 160 mmHg
Ankolekar 2013 7/11 3/7 1.5 % 2.33 [ 0.34, 16.18 ]
ENOS 2015 527/782 551/815 30.1 % 0.99 [ 0.80, 1.22 ]
Willmot 2006 7/7 2/2 Not estimable
Subtotal (95% CI) 800 824 31.6 % 1.00 [ 0.81, 1.23 ]
Total events: 541 (NO donor), 556 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
2 160.1 to 180 mmHg
Ankolekar 2013 2/4 1/3 0.6 % 2.00 [ 0.09, 44.35 ]
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ENOS 2015 464/713 471/708 29.5 % 0.94 [ 0.75, 1.17 ]
Willmot 2006 2/2 3/3 Not estimable
Subtotal (95% CI) 719 714 30.1 % 0.94 [ 0.76, 1.17 ]
Total events: 468 (NO donor), 475 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
3 180.1 to 200 mmHg
Ankolekar 2013 4/7 1/1 0.5 % 0.43 [ 0.01, 14.08 ]
ENOS 2015 235/374 240/345 23.6 % 0.74 [ 0.54, 1.01 ]
Willmot 2006 2/2 1/1 Not estimable
Subtotal (95% CI) 383 347 24.1 % 0.74 [ 0.54, 1.00 ]
Total events: 241 (NO donor), 242 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
4 > 200 mmHg
Ankolekar 2013 2/3 2/5 0.6 % 3.00 [ 0.15, 59.89 ]
ENOS 2015 84/118 70/129 13.5 % 2.08 [ 1.23, 3.53 ]
Subtotal (95% CI) 121 134 14.2 % 2.11 [ 1.25, 3.54 ]
Total events: 86 (NO donor), 72 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0050)
Total (95% CI) 2023 2019 100.0 % 1.03 [ 0.81, 1.30 ]
Total events: 1336 (NO donor), 1345 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 12.85, df = 7 (P = 0.08); I2 =46%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 11.73, df = 3 (P = 0.01), I2 =74%
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Analysis 1.61. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
61 Speech and language therapy.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 61 Speech and language therapy
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overall
Ankolekar 2013 12/25 6/16 0.9 % 1.54 [ 0.43, 5.54 ]
ENOS 2015 974/1987 1005/1997 98.8 % 0.95 [ 0.84, 1.07 ]
Willmot 2006 2/11 2/6 0.3 % 0.44 [ 0.05, 4.37 ]
Total (95% CI) 2023 2019 100.0 % 0.95 [ 0.84, 1.08 ]
Total events: 988 (NO donor), 1013 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 1.62. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
62 Speech and language therapy, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 62 Speech and language therapy, by stroke type
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic
Ankolekar 2013 9/16 5/11 0.6 % 1.54 [ 0.33, 7.23 ]
ENOS 2015 828/1653 861/1668 83.6 % 0.94 [ 0.82, 1.08 ]
Willmot 2006 1/10 1/5 0.2 % 0.44 [ 0.02, 9.03 ]
Subtotal (95% CI) 1679 1684 84.4 % 0.94 [ 0.82, 1.08 ]
Total events: 838 (NO donor), 867 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
2 ICH
Ankolekar 2013 1/5 1/1 0.1 % 0.11 [ 0.00, 4.48 ]
ENOS 2015 141/308 135/315 15.5 % 1.13 [ 0.82, 1.54 ]
Willmot 2006 1/1 1/1 Not estimable
Subtotal (95% CI) 314 317 15.6 % 0.76 [ 0.14, 4.19 ]
Total events: 143 (NO donor), 137 (Control)
Heterogeneity: Tau2 = 0.89; Chi2 = 1.50, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 1993 2001 100.0 % 0.97 [ 0.85, 1.09 ]
Total events: 981 (NO donor), 1004 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.97, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 1.63. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
63 Speech and language therapy, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 63 Speech and language therapy, by time to randomisation
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 6 hours
Ankolekar 2013 12/24 5/15 0.9 % 2.00 [ 0.52, 7.63 ]
ENOS 2015 70/143 69/125 6.7 % 0.78 [ 0.48, 1.26 ]
Subtotal (95% CI) 167 140 7.5 % 1.01 [ 0.44, 2.29 ]
Total events: 82 (NO donor), 74 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 1.69, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.01 (P = 0.99)
2 6.1 to 12 hours
Ankolekar 2013 0/1 1/1 0.1 % 0.11 [ 0.00, 10.27 ]
ENOS 2015 79/224 77/213 10.1 % 0.96 [ 0.65, 1.42 ]
Subtotal (95% CI) 225 214 10.2 % 0.95 [ 0.64, 1.40 ]
Total events: 79 (NO donor), 78 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.78)
3 12.1 to 24 hours
ENOS 2015 259/539 259/525 26.7 % 0.95 [ 0.75, 1.21 ]
Subtotal (95% CI) 539 525 26.7 % 0.95 [ 0.75, 1.21 ]
Total events: 259 (NO donor), 259 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
4 24.1 to 36 hours
ENOS 2015 287/588 304/608 30.1 % 0.95 [ 0.76, 1.20 ]
Willmot 2006 1/1 0/1 0.1 % 9.00 [ 0.10, 831.78 ]
Subtotal (95% CI) 589 609 30.2 % 0.96 [ 0.76, 1.20 ]
Total events: 288 (NO donor), 304 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
5 > 36 hours
ENOS 2015 279/493 296/526 25.2 % 1.01 [ 0.79, 1.30 ]
Willmot 2006 2/10 1/4 0.2 % 0.75 [ 0.05, 11.65 ]
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 503 530 25.4 % 1.01 [ 0.79, 1.29 ]
Total events: 281 (NO donor), 297 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
Total (95% CI) 2023 2018 100.0 % 0.96 [ 0.85, 1.09 ]
Total events: 989 (NO donor), 1012 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.92, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 0.17, df = 4 (P = 1.00), I2 =0.0%
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Analysis 1.64. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
64 Speech and language therapy, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 64 Speech and language therapy, by baseline SBP
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 160 mmHg
Ankolekar 2013 8/11 3/7 0.4 % 3.56 [ 0.48, 26.28 ]
ENOS 2015 379/782 423/815 39.7 % 0.87 [ 0.72, 1.06 ]
Willmot 2006 2/7 0/2 0.1 % 2.27 [ 0.08, 67.05 ]
Subtotal (95% CI) 800 824 40.2 % 0.98 [ 0.58, 1.66 ]
Total events: 389 (NO donor), 426 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 2.18, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 0.09 (P = 0.93)
2 160.1 to 180 mmHg
Ankolekar 2013 0/4 1/3 0.1 % 0.19 [ 0.01, 6.48 ]
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ENOS 2015 344/713 351/708 35.3 % 0.95 [ 0.77, 1.17 ]
Willmot 2006 0/2 1/3 0.1 % 0.33 [ 0.01, 12.82 ]
Subtotal (95% CI) 719 714 35.6 % 0.94 [ 0.76, 1.16 ]
Total events: 344 (NO donor), 353 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
3 180.1 to 200 mmHg
Ankolekar 2013 2/7 0/1 0.1 % 1.36 [ 0.04, 46.65 ]
ENOS 2015 192/374 176/345 17.8 % 1.01 [ 0.76, 1.36 ]
Willmot 2006 0/2 1/1 0.1 % 0.07 [ 0.00, 5.49 ]
Subtotal (95% CI) 383 347 18.0 % 1.00 [ 0.75, 1.34 ]
Total events: 194 (NO donor), 177 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.48, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
4 > 200 mmHg
Ankolekar 2013 2/3 2/5 0.2 % 3.00 [ 0.15, 59.89 ]
ENOS 2015 59/118 55/129 6.1 % 1.35 [ 0.81, 2.22 ]
Subtotal (95% CI) 121 134 6.2 % 1.38 [ 0.84, 2.26 ]
Total events: 61 (NO donor), 57 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Total (95% CI) 2023 2019 100.0 % 0.95 [ 0.84, 1.08 ]
Total events: 988 (NO donor), 1013 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.83, df = 10 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
Test for subgroup differences: Chi2 = 1.94, df = 3 (P = 0.58), I2 =0.0%
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Analysis 1.65. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
65 Feeding route (non-oral feeding at day 7).
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 65 Feeding route (non-oral feeding at day 7)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overall
Ankolekar 2013 6/24 5/15 1.4 % 0.67 [ 0.16, 2.75 ]
ENOS 2015 315/1970 323/1982 98.3 % 0.98 [ 0.83, 1.16 ]
Willmot 2006 1/12 0/6 0.3 % 1.70 [ 0.06, 47.95 ]
Total (95% CI) 2006 2003 100.0 % 0.97 [ 0.82, 1.15 ]
Total events: 322 (NO donor), 328 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 1.66. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
66 Feeding route (non-oral feeding at day 7), by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 66 Feeding route (non-oral feeding at day 7), by stroke type
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic
Ankolekar 2013 3/16 4/10 1.4 % 0.35 [ 0.06, 2.06 ]
ENOS 2015 239/1640 261/1657 71.2 % 0.91 [ 0.75, 1.10 ]
Willmot 2006 1/11 0/5 0.4 % 1.57 [ 0.05, 45.37 ]
Subtotal (95% CI) 1667 1672 73.1 % 0.90 [ 0.75, 1.09 ]
Total events: 243 (NO donor), 265 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
2 ICH
Ankolekar 2013 2/4 1/1 0.3 % 0.33 [ 0.01, 12.82 ]
ENOS 2015 75/307 62/311 26.6 % 1.30 [ 0.89, 1.90 ]
Subtotal (95% CI) 311 312 26.9 % 1.28 [ 0.88, 1.87 ]
Total events: 77 (NO donor), 63 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 1978 1984 100.0 % 0.99 [ 0.80, 1.22 ]
Total events: 320 (NO donor), 328 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.34, df = 4 (P = 0.36); I2 =8%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Chi2 = 2.58, df = 1 (P = 0.11), I2 =61%
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Analysis 1.67. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
67 Feeding route (non-oral feeding at day 7), by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 67 Feeding route (non-oral feeding at day 7), by time to randomisation
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 6 hours
Ankolekar 2013 6/23 5/14 1.5 % 0.64 [ 0.15, 2.67 ]
ENOS 2015 18/143 24/121 6.8 % 0.58 [ 0.30, 1.13 ]
Subtotal (95% CI) 166 135 8.4 % 0.59 [ 0.32, 1.08 ]
Total events: 24 (NO donor), 29 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.088)
2 6.1 to 12 hours
ENOS 2015 34/221 32/214 10.9 % 1.03 [ 0.61, 1.75 ]
Subtotal (95% CI) 221 214 10.9 % 1.03 [ 0.61, 1.75 ]
Total events: 34 (NO donor), 32 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
3 12.1 to 24 hours
ENOS 2015 84/528 72/515 24.4 % 1.16 [ 0.83, 1.64 ]
Subtotal (95% CI) 528 515 24.4 % 1.16 [ 0.83, 1.64 ]
Total events: 84 (NO donor), 72 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
4 24.1 to 36 hours
ENOS 2015 99/585 92/607 29.0 % 1.14 [ 0.84, 1.55 ]
Subtotal (95% CI) 585 607 29.0 % 1.14 [ 0.84, 1.55 ]
Total events: 99 (NO donor), 92 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
5 > 36 hours
ENOS 2015 80/493 103/525 27.1 % 0.79 [ 0.58, 1.10 ]
Willmot 2006 1/11 0/4 0.3 % 1.29 [ 0.04, 37.98 ]
Subtotal (95% CI) 504 529 27.3 % 0.80 [ 0.58, 1.10 ]
Total events: 81 (NO donor), 103 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
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Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.39 (P = 0.17)
Total (95% CI) 2004 2000 100.0 % 0.97 [ 0.82, 1.16 ]
Total events: 322 (NO donor), 328 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.31, df = 6 (P = 0.39); I2 =5%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 6.22, df = 4 (P = 0.18), I2 =36%
0.02 0.1 1 10 50
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Analysis 1.68. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
68 Feeding route (non-oral feeding at day 7), by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 68 Feeding route (non-oral feeding at day 7), by baseline SBP
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 160 mmHg
Ankolekar 2013 3/11 2/7 0.6 % 0.94 [ 0.11, 7.73 ]
ENOS 2015 110/776 117/810 36.1 % 0.98 [ 0.74, 1.30 ]
Willmot 2006 1/7 0/2 0.2 % 1.15 [ 0.03, 38.88 ]
Subtotal (95% CI) 794 819 37.0 % 0.98 [ 0.74, 1.29 ]
Total events: 114 (NO donor), 119 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
2 160.1 to 180 mmHg
Ankolekar 2013 0/4 1/2 0.2 % 0.11 [ 0.00, 4.48 ]
ENOS 2015 106/707 122/700 35.3 % 0.84 [ 0.63, 1.11 ]
Subtotal (95% CI) 711 702 35.5 % 0.73 [ 0.27, 1.95 ]
0.005 0.1 1 10 200
Favours NO donor Favours control
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Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 106 (NO donor), 123 (Control)
Heterogeneity: Tau2 = 0.25; Chi2 = 1.14, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.62 (P = 0.53)
3 180.1 to 200 mmHg
Ankolekar 2013 1/6 0/1 0.2 % 0.82 [ 0.02, 32.27 ]
ENOS 2015 76/370 55/343 19.4 % 1.35 [ 0.92, 1.99 ]
Subtotal (95% CI) 376 344 19.6 % 1.35 [ 0.92, 1.97 ]
Total events: 77 (NO donor), 55 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
4 > 200 mmHg
Ankolekar 2013 2/3 2/5 0.3 % 3.00 [ 0.15, 59.89 ]
ENOS 2015 23/117 29/129 7.5 % 0.84 [ 0.46, 1.56 ]
Subtotal (95% CI) 120 134 7.9 % 0.89 [ 0.49, 1.62 ]
Total events: 25 (NO donor), 31 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 2001 1999 100.0 % 0.97 [ 0.82, 1.15 ]
Total events: 322 (NO donor), 328 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.05, df = 8 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
Test for subgroup differences: Chi2 = 2.70, df = 3 (P = 0.44), I2 =0.0%
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Analysis 1.69. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
69 Length of stay.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 69 Length of stay
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Overall
Ankolekar 2013 25 20.64 (27.78) 16 17.81 (20.57) 18.7 % 2.83 [ -12.01, 17.67 ]
Bath 2001 14 39.21 (40.31) 21 49.9 (44.59) 6.3 % -10.69 [ -39.14, 17.76 ]
ENOS 2015 1988 20.71 (23.4) 1997 21.05 (23.78) 68.7 % -0.34 [ -1.80, 1.12 ]
Willmot 2006 11 42.73 (40.18) 6 16 (20.06) 6.2 % 26.73 [ -1.93, 55.39 ]
Total (95% CI) 2038 2040 100.0 % 1.29 [ -6.21, 8.78 ]
Heterogeneity: Tau2 = 20.71; Chi2 = 4.10, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
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Analysis 1.70. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
70 Length of stay, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 70 Length of stay, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ischaemic
Ankolekar 2013 16 19.19 (25.19) 11 23.55 (22.25) 5.8 % -4.36 [ -22.39, 13.67 ]
Bath 2001 12 42.33 (42.73) 18 52.83 (45.93) 2.0 % -10.50 [ -42.67, 21.67 ]
ENOS 2015 1664 20.16 (22.71) 1678 20.94 (23.59) 48.9 % -0.78 [ -2.35, 0.79 ]
Willmot 2006 10 34.8 (32.03) 5 8 (4.8) 4.7 % 26.80 [ 6.51, 47.09 ]
Subtotal (95% CI) 1702 1712 61.4 % 2.99 [ -9.65, 15.63 ]
Heterogeneity: Tau2 = 93.11; Chi2 = 7.58, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 0.46 (P = 0.64)
2 ICH
Ankolekar 2013 5 20.8 (25.06) 1 19 (0) Not estimable
Bath 2001 2 20.5 (14.85) 2 23.5 (19.09) 1.8 % -3.00 [ -36.52, 30.52 ]
ENOS 2015 310 24.64 (27.14) 319 22.01 (25.14) 36.8 % 2.63 [ -1.46, 6.72 ]
Willmot 2006 1 122 (0) 1 56 (0) Not estimable
Subtotal (95% CI) 318 323 38.6 % 2.55 [ -1.51, 6.61 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 2020 2035 100.0 % 1.33 [ -3.28, 5.93 ]
Heterogeneity: Tau2 = 10.63; Chi2 = 9.78, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 1.71. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
71 Length of stay by time, to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 71 Length of stay by time, to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 6 hours
Ankolekar 2013 24 21.38 (28.13) 15 16 (19.93) 0.9 % 5.38 [ -9.73, 20.49 ]
ENOS 2015 143 15.53 (20.38) 125 17.84 (21.29) 8.1 % -2.31 [ -7.32, 2.70 ]
Subtotal (95% CI) 167 140 9.0 % -1.55 [ -6.30, 3.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
2 6.1 to 12 hours
Ankolekar 2013 1 3 (0) 1 45 (0) Not estimable
ENOS 2015 224 15.44 (16.81) 213 17.08 (20.19) 16.7 % -1.64 [ -5.13, 1.85 ]
Subtotal (95% CI) 225 214 16.7 % -1.64 [ -5.13, 1.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
3 12.1 to 24 hours
ENOS 2015 539 19.88 (22.41) 525 20.64 (24.14) 25.9 % -0.76 [ -3.56, 2.04 ]
Subtotal (95% CI) 539 525 25.9 % -0.76 [ -3.56, 2.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
4 24.1 to 36 hours
ENOS 2015 588 21.49 (24.2) 607 21.45 (23.84) 27.4 % 0.04 [ -2.68, 2.76 ]
Willmot 2006 1 16 (0) 1 7 (0) Not estimable
Subtotal (95% CI) 589 608 27.4 % 0.04 [ -2.68, 2.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
5 > 36 hours
Bath 2001 16 39.21 (40.31) 19 51.79 (44.98) 0.3 % -12.58 [ -40.85, 15.69 ]
ENOS 2015 494 24.59 (26.04) 527 23.37 (25.01) 20.7 % 1.22 [ -1.92, 4.36 ]
Willmot 2006 10 45.4 (41.31) 4 21.5 (23.39) 0.2 % 23.90 [ -10.47, 58.27 ]
Subtotal (95% CI) 520 550 21.1 % 1.52 [ -9.40, 12.44 ]
Heterogeneity: Tau2 = 37.08; Chi2 = 2.59, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.27 (P = 0.79)
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Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 2040 2037 100.0 % -0.34 [ -1.76, 1.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.42, df = 7 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 0.84, df = 4 (P = 0.93), I2 =0.0%
-50 -25 0 25 50
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Analysis 1.72. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
72 Length of stay, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 72 Length of stay, by baseline SBP
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 160 mmHg
Ankolekar 2013 11 25.18 (28.61) 7 21.14 (25.65) 1.3 % 4.04 [ -21.39, 29.47 ]
Bath 2001 5 36.4 (26.64) 13 31.31 (30.41) 1.0 % 5.09 [ -23.52, 33.70 ]
ENOS 2015 783 18.8 (20.89) 816 20.26 (23.12) 29.6 % -1.46 [ -3.62, 0.70 ]
Willmot 2006 7 57.29 (43.75) 2 11.5 (6.36) 0.8 % 45.79 [ 12.20, 79.38 ]
Subtotal (95% CI) 806 838 32.7 % 8.63 [ -8.44, 25.71 ]
Heterogeneity: Tau2 = 177.38; Chi2 = 7.92, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 0.99 (P = 0.32)
2 160.1 to 180 mmHg
Ankolekar 2013 4 2.5 (1.91) 3 17.67 (16.07) 2.4 % -15.17 [ -33.45, 3.11 ]
Bath 2001 6 19.5 (9.93) 4 65.5 (51.33) 0.3 % -46.00 [ -96.93, 4.93 ]
ENOS 2015 713 20.78 (23.99) 708 20.38 (23.08) 28.3 % 0.40 [ -2.05, 2.85 ]
Willmot 2006 2 24 (18.38) 3 5.67 (2.31) 1.3 % 18.33 [ -7.28, 43.94 ]
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Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 725 718 32.4 % -3.77 [ -18.94, 11.40 ]
Heterogeneity: Tau2 = 130.93; Chi2 = 7.83, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 0.49 (P = 0.63)
3 180.1 to 200 mmHg
Ankolekar 2013 7 16.86 (21.74) 1 3 (0) Not estimable
Bath 2001 2 121.5 (28.99) 2 124 (36.77) 0.2 % -2.50 [ -67.39, 62.39 ]
ENOS 2015 374 22.87 (24.5) 344 24.04 (25.82) 22.7 % -1.17 [ -4.86, 2.52 ]
Willmot 2006 2 10.5 (7.78) 1 56 (0) Not estimable
Subtotal (95% CI) 385 348 22.9 % -1.17 [ -4.86, 2.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
4 > 200 mmHg
Ankolekar 2013 3 37 (50.24) 5 16.2 (19.82) 0.2 % 20.80 [ -38.65, 80.25 ]
Bath 2001 1 7 (0) 1 81 (0) Not estimable
ENOS 2015 118 26.08 (30.03) 129 21.81 (25.66) 11.8 % 4.27 [ -2.73, 11.27 ]
Subtotal (95% CI) 122 135 12.0 % 4.50 [ -2.45, 11.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 2038 2039 100.0 % 0.13 [ -2.82, 3.07 ]
Heterogeneity: Tau2 = 6.40; Chi2 = 18.87, df = 11 (P = 0.06); I2 =42%
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Chi2 = 3.20, df = 3 (P = 0.36), I2 =6%
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Analysis 1.73. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
73 Headache, on treatment.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 73 Headache, on treatment
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overall
Ankolekar 2013 8/25 1/16 3.6 % 7.06 [ 0.79, 63.18 ]
Bath 2001 2/16 4/21 5.0 % 0.61 [ 0.10, 3.82 ]
ENOS 2015 360/1996 170/2004 87.7 % 2.37 [ 1.95, 2.88 ]
Rashid 2002 9/60 0/30 2.1 % 11.25 [ 0.63, 200.22 ]
Willmot 2006 1/12 0/6 1.6 % 1.70 [ 0.06, 47.95 ]
Total (95% CI) 2109 2077 100.0 % 2.37 [ 1.55, 3.62 ]
Total events: 380 (NO donor), 175 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 4.23, df = 4 (P = 0.38); I2 =6%
Test for overall effect: Z = 4.00 (P = 0.000063)
Test for subgroup differences: Not applicable
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Analysis 1.74. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
74 Headache, on treatment, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 74 Headache, on treatment, by stroke type
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic
Ankolekar 2013 5/16 0/11 0.4 % 11.00 [ 0.54, 222.77 ]
Bath 2001 2/14 4/19 1.1 % 0.63 [ 0.10, 4.01 ]
ENOS 2015 287/1660 129/1673 77.7 % 2.50 [ 2.01, 3.12 ]
Willmot 2006 1/11 0/5 0.3 % 1.57 [ 0.05, 45.37 ]
Subtotal (95% CI) 1701 1708 79.5 % 2.39 [ 1.59, 3.61 ]
Total events: 295 (NO donor), 133 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.13, df = 3 (P = 0.37); I2 =4%
Test for overall effect: Z = 4.17 (P = 0.000031)
2 ICH
Ankolekar 2013 1/5 0/1 0.3 % 1.00 [ 0.02, 40.28 ]
Bath 2001 0/2 0/2 Not estimable
ENOS 2015 66/310 39/317 20.2 % 1.93 [ 1.25, 2.97 ]
Willmot 2006 0/1 0/1 Not estimable
Subtotal (95% CI) 318 321 20.5 % 1.91 [ 1.24, 2.93 ]
Total events: 67 (NO donor), 39 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.96 (P = 0.0031)
Total (95% CI) 2019 2029 100.0 % 2.34 [ 1.93, 2.84 ]
Total events: 362 (NO donor), 172 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.34, df = 5 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 8.60 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.55, df = 1 (P = 0.46), I2 =0.0%
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Analysis 1.75. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
75 Headache, on treatment, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 75 Headache, on treatment, by time to randomisation
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 6 hours
Ankolekar 2013 7/24 1/15 0.8 % 5.76 [ 0.63, 52.63 ]
ENOS 2015 25/144 12/126 6.8 % 2.00 [ 0.96, 4.16 ]
Subtotal (95% CI) 168 141 7.6 % 2.22 [ 1.10, 4.45 ]
Total events: 32 (NO donor), 13 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 2.24 (P = 0.025)
2 6.1 to 12 hours
Ankolekar 2013 1/1 0/1 0.2 % 9.00 [ 0.10, 831.78 ]
ENOS 2015 37/224 19/214 10.7 % 2.03 [ 1.13, 3.66 ]
Subtotal (95% CI) 225 215 10.8 % 2.08 [ 1.16, 3.73 ]
Total events: 38 (NO donor), 19 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
3 12.1 to 24 hours
ENOS 2015 109/540 47/525 27.6 % 2.57 [ 1.78, 3.71 ]
Subtotal (95% CI) 540 525 27.6 % 2.57 [ 1.78, 3.71 ]
Total events: 109 (NO donor), 47 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 5.06 (P < 0.00001)
4 24.1 to 36 hours
ENOS 2015 105/591 53/609 29.8 % 2.27 [ 1.59, 3.22 ]
Willmot 2006 0/1 0/1 Not estimable
Subtotal (95% CI) 592 610 29.8 % 2.27 [ 1.59, 3.22 ]
Total events: 105 (NO donor), 53 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.56 (P < 0.00001)
5 > 36 hours
Bath 2001 2/16 3/20 1.0 % 0.81 [ 0.12, 5.54 ]
ENOS 2015 84/497 39/530 22.9 % 2.56 [ 1.71, 3.83 ]
Willmot 2006 1/11 0/4 0.3 % 1.29 [ 0.04, 37.98 ]
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 524 554 24.2 % 2.42 [ 1.64, 3.58 ]
Total events: 87 (NO donor), 42 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.45, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.43 (P < 0.00001)
Total (95% CI) 2049 2045 100.0 % 2.36 [ 1.95, 2.86 ]
Total events: 371 (NO donor), 174 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.15, df = 8 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 8.75 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.49, df = 4 (P = 0.97), I2 =0.0%
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Analysis 1.76. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
76 Headache, on treatment, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 76 Headache, on treatment, by baseline SBP
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 160 mmHg
Ankolekar 2013 3/11 1/7 0.8 % 2.25 [ 0.18, 27.37 ]
Bath 2001 1/5 2/13 0.7 % 1.38 [ 0.10, 19.64 ]
ENOS 2015 137/787 66/817 35.4 % 2.40 [ 1.76, 3.28 ]
Willmot 2006 1/7 0/2 0.4 % 1.15 [ 0.03, 38.88 ]
Subtotal (95% CI) 810 839 37.3 % 2.37 [ 1.74, 3.21 ]
Total events: 142 (NO donor), 69 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 5.51 (P < 0.00001)
2 160.1 to 180 mmHg
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ankolekar 2013 2/4 0/3 0.4 % 7.00 [ 0.22, 218.95 ]
Bath 2001 1/7 1/5 0.5 % 0.67 [ 0.03, 14.03 ]
ENOS 2015 144/717 55/711 32.6 % 3.00 [ 2.15, 4.17 ]
Willmot 2006 0/3 0/3 Not estimable
Subtotal (95% CI) 731 722 33.6 % 2.97 [ 2.14, 4.12 ]
Total events: 147 (NO donor), 56 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 6.52 (P < 0.00001)
3 180.1 to 200 mmHg
Ankolekar 2013 3/7 0/1 0.4 % 2.33 [ 0.07, 76.67 ]
Bath 2001 0/3 0/1 Not estimable
ENOS 2015 58/374 40/347 21.6 % 1.41 [ 0.91, 2.17 ]
Willmot 2006 0/2 0/1 Not estimable
Subtotal (95% CI) 386 350 22.0 % 1.42 [ 0.92, 2.18 ]
Total events: 61 (NO donor), 40 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
4 > 200 mmHg
Ankolekar 2013 0/3 0/5 Not estimable
Bath 2001 0/1 1/1 0.2 % 0.11 [ 0.00, 10.27 ]
ENOS 2015 21/118 9/129 6.9 % 2.89 [ 1.26, 6.59 ]
Subtotal (95% CI) 122 135 7.1 % 1.25 [ 0.08, 20.46 ]
Total events: 21 (NO donor), 10 (Control)
Heterogeneity: Tau2 = 2.57; Chi2 = 1.93, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 0.15 (P = 0.88)
Total (95% CI) 2049 2046 100.0 % 2.29 [ 1.83, 2.86 ]
Total events: 371 (NO donor), 175 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 10.81, df = 10 (P = 0.37); I2 =8%
Test for overall effect: Z = 7.28 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.42, df = 3 (P = 0.06), I2 =60%
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Analysis 1.77. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
77 Treatment stopped early.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 77 Treatment stopped early
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Overall
Ankolekar 2013 8/25 10/16 23.0 % 0.28 [ 0.08, 1.05 ]
Bath 2001 3/16 2/21 20.5 % 2.19 [ 0.32, 15.00 ]
ENOS 2015 416/2000 58/2011 25.7 % 8.84 [ 6.67, 11.73 ]
Rashid 2002 12/57 0/29 16.4 % 16.21 [ 0.92, 284.28 ]
Willmot 2006 0/12 1/6 14.4 % 0.15 [ 0.01, 4.20 ]
Total (95% CI) 2110 2083 100.0 % 1.84 [ 0.27, 12.42 ]
Total events: 439 (NO donor), 71 (Control)
Heterogeneity: Tau2 = 3.67; Chi2 = 32.27, df = 4 (P<0.00001); I2 =88%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 1.78. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
78 Treatment stopped early, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 78 Treatment stopped early, by stroke type
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic
Ankolekar 2013 2/16 7/11 16.9 % 0.08 [ 0.01, 0.56 ]
ENOS 2015 344/1664 48/1678 28.0 % 8.85 [ 6.49, 12.07 ]
Rashid 2002 12/51 0/29 11.3 % 18.67 [ 1.06, 328.20 ]
Willmot 2006 0/11 1/5 9.1 % 0.13 [ 0.00, 3.84 ]
Subtotal (95% CI) 1742 1723 65.4 % 1.26 [ 0.07, 21.87 ]
Total events: 358 (NO donor), 56 (Control)
Heterogeneity: Tau2 = 7.09; Chi2 = 28.29, df = 3 (P<0.00001); I2 =89%
Test for overall effect: Z = 0.16 (P = 0.87)
2 ICH
Ankolekar 2013 2/5 0/1 8.4 % 2.14 [ 0.06, 77.54 ]
ENOS 2015 58/310 10/319 26.2 % 7.11 [ 3.56, 14.20 ]
Willmot 2006 0/1 0/1 Not estimable
Subtotal (95% CI) 316 321 34.6 % 6.81 [ 3.46, 13.43 ]
Total events: 60 (NO donor), 10 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 5.54 (P < 0.00001)
Total (95% CI) 2058 2044 100.0 % 2.49 [ 0.72, 8.59 ]
Total events: 418 (NO donor), 66 (Control)
Heterogeneity: Tau2 = 1.40; Chi2 = 28.78, df = 5 (P = 0.00003); I2 =83%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Chi2 = 1.27, df = 1 (P = 0.26), I2 =21%
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Analysis 1.79. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
79 Treatment stopped early, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 79 Treatment stopped early, by time to randomisation
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 6 hours
Ankolekar 2013 7/24 10/15 10.5 % 0.21 [ 0.05, 0.83 ]
ENOS 2015 27/144 6/129 13.0 % 4.73 [ 1.89, 11.87 ]
Subtotal (95% CI) 168 144 23.5 % 1.03 [ 0.05, 22.27 ]
Total events: 34 (NO donor), 16 (Control)
Heterogeneity: Tau2 = 4.55; Chi2 = 13.62, df = 1 (P = 0.00022); I2 =93%
Test for overall effect: Z = 0.02 (P = 0.98)
2 6.1 to 12 hours
Ankolekar 2013 0/1 0/1 Not estimable
ENOS 2015 42/224 4/214 12.3 % 12.12 [ 4.26, 34.44 ]
Subtotal (95% CI) 225 215 12.3 % 12.12 [ 4.26, 34.44 ]
Total events: 42 (NO donor), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.68 (P < 0.00001)
3 12.1 to 24 hours
ENOS 2015 127/541 24/526 15.1 % 6.42 [ 4.07, 10.12 ]
Rashid 2002 0/1 0/2 Not estimable
Subtotal (95% CI) 542 528 15.1 % 6.42 [ 4.07, 10.12 ]
Total events: 127 (NO donor), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 8.00 (P < 0.00001)
4 24.1 to 36 hours
ENOS 2015 124/593 11/610 14.4 % 14.40 [ 7.68, 26.99 ]
Rashid 2002 1/9 0/4 3.9 % 1.59 [ 0.05, 47.52 ]
Willmot 2006 0/1 0/1 Not estimable
Subtotal (95% CI) 603 615 18.3 % 9.23 [ 1.63, 52.33 ]
Total events: 125 (NO donor), 11 (Control)
Heterogeneity: Tau2 = 0.88; Chi2 = 1.57, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 2.51 (P = 0.012)
5 > 36 hours
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bath 2001 3/16 2/21 8.0 % 2.19 [ 0.32, 15.00 ]
ENOS 2015 96/498 8/532 13.9 % 15.64 [ 7.52, 32.55 ]
Rashid 2002 11/47 0/23 5.0 % 14.81 [ 0.83, 263.40 ]
Willmot 2006 0/11 1/4 3.9 % 0.10 [ 0.00, 3.09 ]
Subtotal (95% CI) 572 580 30.8 % 3.86 [ 0.58, 25.79 ]
Total events: 110 (NO donor), 11 (Control)
Heterogeneity: Tau2 = 2.50; Chi2 = 10.83, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 1.39 (P = 0.16)
Total (95% CI) 2110 2082 100.0 % 4.56 [ 2.10, 9.87 ]
Total events: 438 (NO donor), 66 (Control)
Heterogeneity: Tau2 = 0.98; Chi2 = 44.72, df = 9 (P<0.00001); I2 =80%
Test for overall effect: Z = 3.85 (P = 0.00012)
Test for subgroup differences: Chi2 = 3.15, df = 4 (P = 0.53), I2 =0.0%
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Analysis 1.80. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
80 Treatment stopped early, by baseline SBP.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 80 Treatment stopped early, by baseline SBP
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 < 160 mmHg
Ankolekar 2013 2/11 4/7 7.0 % 0.17 [ 0.02, 1.42 ]
ENOS 2015 176/788 20/819 16.3 % 11.49 [ 7.15, 18.46 ]
Rashid 2002 6/32 0/21 4.6 % 10.55 [ 0.56, 197.95 ]
Willmot 2006 0/7 1/2 3.3 % 0.07 [ 0.00, 2.56 ]
Subtotal (95% CI) 838 849 31.1 % 1.33 [ 0.09, 20.26 ]
Total events: 184 (NO donor), 25 (Control)
Heterogeneity: Tau2 = 6.19; Chi2 = 21.33, df = 3 (P = 0.00009); I2 =86%
Test for overall effect: Z = 0.20 (P = 0.84)
2 160.1 to 180 mmHg
Ankolekar 2013 0/4 2/3 3.4 % 0.07 [ 0.00, 2.33 ]
ENOS 2015 150/720 24/714 16.5 % 7.57 [ 4.85, 11.81 ]
Rashid 2002 4/14 0/6 4.2 % 5.57 [ 0.26, 121.36 ]
Willmot 2006 0/3 0/3 Not estimable
Subtotal (95% CI) 741 726 24.1 % 2.17 [ 0.17, 27.08 ]
Total events: 154 (NO donor), 26 (Control)
Heterogeneity: Tau2 = 3.46; Chi2 = 6.77, df = 2 (P = 0.03); I2 =70%
Test for overall effect: Z = 0.60 (P = 0.55)
3 180.1 to 200 mmHg
Ankolekar 2013 4/7 1/1 3.5 % 0.43 [ 0.01, 14.08 ]
ENOS 2015 66/374 11/349 15.4 % 6.58 [ 3.41, 12.70 ]
Rashid 2002 1/6 0/2 3.4 % 1.36 [ 0.04, 46.65 ]
Willmot 2006 0/2 1/1 2.4 % 0.07 [ 0.00, 5.49 ]
Subtotal (95% CI) 389 353 24.6 % 1.38 [ 0.17, 11.13 ]
Total events: 71 (NO donor), 13 (Control)
Heterogeneity: Tau2 = 2.43; Chi2 = 6.77, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.30 (P = 0.76)
4 > 200 mmHg
Ankolekar 2013 1/3 3/5 4.4 % 0.33 [ 0.02, 6.65 ]
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(. . . Continued)
Study or subgroup NO donor Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ENOS 2015 24/118 3/129 11.7 % 10.72 [ 3.14, 36.67 ]
Rashid 2002 1/4 1/4 4.0 % 1.00 [ 0.04, 24.55 ]
Subtotal (95% CI) 125 138 20.1 % 2.16 [ 0.21, 22.44 ]
Total events: 26 (NO donor), 7 (Control)
Heterogeneity: Tau2 = 2.74; Chi2 = 5.60, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 0.65 (P = 0.52)
Total (95% CI) 2093 2066 100.0 % 2.84 [ 1.37, 5.88 ]
Total events: 435 (NO donor), 71 (Control)
Heterogeneity: Tau2 = 0.79; Chi2 = 42.42, df = 13 (P = 0.00006); I2 =69%
Test for overall effect: Z = 2.80 (P = 0.0051)
Test for subgroup differences: Chi2 = 0.15, df = 3 (P = 0.99), I2 =0.0%
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Analysis 1.81. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
81 Systolic BP, first treatment measurement.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 81 Systolic BP, first treatment measurement
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall
Ankolekar 2013 25 156.78 (23.64) 16 171.72 (23.43) 0.9 % -14.94 [ -29.69, -0.19 ]
Bath 2001 16 153.8 (23.3) 21 156.2 (20.9) 0.9 % -2.40 [ -16.90, 12.10 ]
ENOS 2015 2000 156.61 (22.6) 2011 163.64 (22.45) 95.6 % -7.03 [ -8.42, -5.64 ]
Rashid 2002 60 140.88 (18) 30 151.13 (22.65) 2.2 % -10.25 [ -19.55, -0.95 ]
Willmot 2006 12 159.46 (22.92) 6 185.17 (18.82) 0.5 % -25.71 [ -45.58, -5.84 ]
Total (95% CI) 2113 2084 100.0 % -7.21 [ -8.58, -5.85 ]
Heterogeneity: Chi2 = 5.28, df = 4 (P = 0.26); I2 =24%
Test for overall effect: Z = 10.37 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.82. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
82 Systolic BP, first treatment measurement, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 82 Systolic BP, first treatment measurement, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ischaemic
Ankolekar 2013 16 147.13 (10.8) 11 176.09 (22.47) 0.9 % -28.96 [ -43.25, -14.67 ]
Bath 2001 14 152.71 (24.76) 19 157.16 (21.55) 0.7 % -4.45 [ -20.64, 11.74 ]
ENOS 2015 1664 155.77 (22.02) 1678 162.41 (22.06) 82.4 % -6.64 [ -8.13, -5.15 ]
Rashid 2002 54 139.89 (18.43) 30 151.13 (22.65) 2.0 % -11.24 [ -20.72, -1.76 ]
Willmot 2006 11 159.68 (24.03) 5 187.6 (19.96) 0.4 % -27.92 [ -50.45, -5.39 ]
Subtotal (95% CI) 1759 1743 86.4 % -7.05 [ -8.51, -5.59 ]
Heterogeneity: Chi2 = 13.46, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 9.47 (P < 0.00001)
2 ICH
Ankolekar 2013 5 193.8 (21.39) 1 172 (0) Not estimable
Bath 2001 2 161.5 (3.54) 2 147 (14.14) 0.5 % 14.50 [ -5.70, 34.70 ]
ENOS 2015 310 162.72 (24.57) 319 170.22 (23.25) 13.2 % -7.50 [ -11.24, -3.76 ]
Willmot 2006 1 157 (0) 1 173 (0) Not estimable
Subtotal (95% CI) 318 323 13.6 % -6.77 [ -10.45, -3.09 ]
Heterogeneity: Chi2 = 4.40, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 3.61 (P = 0.00031)
Total (95% CI) 2077 2066 100.0 % -7.01 [ -8.37, -5.66 ]
Heterogeneity: Chi2 = 17.88, df = 6 (P = 0.01); I2 =66%
Test for overall effect: Z = 10.14 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 1.83. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
83 Systolic BP, first treatment measurement, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 83 Systolic BP, first treatment measurement, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 < 6 hours
Ankolekar 2013 24 157.73 (23.66) 15 168.5 (20.26) 1.0 % -10.77 [ -24.72, 3.18 ]
ENOS 2015 144 154.44 (22.29) 129 163.79 (20.4) 7.3 % -9.35 [ -14.41, -4.29 ]
Subtotal (95% CI) 168 144 8.2 % -9.52 [ -14.28, -4.75 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.92 (P = 0.000089)
2 6.1 to 12 hours
Ankolekar 2013 1 134 (0) 1 220 (0) Not estimable
ENOS 2015 224 157.39 (23.32) 214 165.31 (22.19) 10.3 % -7.92 [ -12.18, -3.66 ]
Subtotal (95% CI) 225 215 10.3 % -7.92 [ -12.18, -3.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.64 (P = 0.00027)
3 12.1 to 24 hours
ENOS 2015 541 157.63 (22.97) 526 162.96 (22.68) 24.8 % -5.33 [ -8.07, -2.59 ]
Rashid 2002 1 159 (0) 2 149.5 (6.36) Not estimable
Subtotal (95% CI) 542 528 24.8 % -5.33 [ -8.07, -2.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.81 (P = 0.00014)
4 24.1 to 36 hours
ENOS 2015 593 156.21 (21.84) 610 163.41 (22.34) 29.9 % -7.20 [ -9.70, -4.70 ]
Rashid 2002 9 150.89 (10.36) 4 154 (29.71) 0.2 % -3.11 [ -33.00, 26.78 ]
Willmot 2006 1 198 (0) 1 168 (0) Not estimable
Subtotal (95% CI) 603 615 30.1 % -7.17 [ -9.66, -4.68 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 5.65 (P < 0.00001)
5 > 36 hours
Bath 2001 16 153.8 (23.3) 20 156 (21.44) 0.9 % -2.20 [ -16.99, 12.59 ]
ENOS 2015 498 156.24 (22.85) 532 163.87 (22.96) 23.8 % -7.63 [ -10.43, -4.83 ]
Rashid 2002 50 138.72 (18.51) 24 150.79 (22.98) 1.7 % -12.07 [ -22.60, -1.54 ]
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Willmot 2006 11 155.95 (20.4) 4 187.5 (21.55) 0.3 % -31.55 [ -55.87, -7.23 ]
Subtotal (95% CI) 575 580 26.6 % -8.02 [ -10.66, -5.37 ]
Heterogeneity: Chi2 = 4.83, df = 3 (P = 0.18); I2 =38%
Test for overall effect: Z = 5.94 (P < 0.00001)
Total (95% CI) 2113 2082 100.0 % -7.21 [ -8.57, -5.84 ]
Heterogeneity: Chi2 = 8.12, df = 9 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 10.35 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.18, df = 4 (P = 0.53), I2 =0.0%
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Analysis 1.84. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
84 Diastolic BP, first treatment measurement.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 84 Diastolic BP, first treatment measurement
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall
Ankolekar 2013 25 85.84 (15.03) 16 82.34 (13.35) 1.0 % 3.50 [ -5.30, 12.30 ]
Bath 2001 16 90.5 (14.4) 21 86.7 (16.4) 0.8 % 3.80 [ -6.15, 13.75 ]
ENOS 2015 2000 84.31 (14.08) 2011 87.78 (14.54) 95.2 % -3.47 [ -4.36, -2.58 ]
Rashid 2002 60 82.15 (12.45) 30 84.43 (11.71) 2.7 % -2.28 [ -7.52, 2.96 ]
Willmot 2006 12 88.96 (11.08) 6 91 (16.92) 0.3 % -2.04 [ -16.96, 12.88 ]
Total (95% CI) 2113 2084 100.0 % -3.31 [ -4.18, -2.45 ]
Heterogeneity: Chi2 = 4.56, df = 4 (P = 0.34); I2 =12%
Test for overall effect: Z = 7.51 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
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Analysis 1.85. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
85 Diastolic BP, first treatment measurement, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 85 Diastolic BP, first treatment measurement, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ischaemic
Ankolekar 2013 16 80.63 (11.59) 11 81.91 (15.63) 0.6 % -1.28 [ -12.12, 9.56 ]
Bath 2001 14 88.86 (14.62) 19 85.68 (16.73) 0.6 % 3.18 [ -7.55, 13.91 ]
ENOS 2015 1664 83.73 (13.73) 1678 86.94 (14.16) 83.1 % -3.21 [ -4.16, -2.26 ]
Rashid 2002 54 81.83 (12.85) 30 84.43 (11.71) 2.5 % -2.60 [ -8.01, 2.81 ]
Willmot 2006 11 88.95 (11.62) 5 92.2 (18.63) 0.2 % -3.25 [ -20.96, 14.46 ]
Subtotal (95% CI) 1759 1743 87.1 % -3.13 [ -4.05, -2.21 ]
Heterogeneity: Chi2 = 1.50, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 6.65 (P < 0.00001)
2 ICH
Ankolekar 2013 5 101.3 (17.08) 1 93 (0) Not estimable
Bath 2001 2 102 (4.24) 2 96.5 (10.61) 0.3 % 5.50 [ -10.34, 21.34 ]
ENOS 2015 310 88.12 (15.52) 319 92.3 (15.6) 12.6 % -4.18 [ -6.61, -1.75 ]
Willmot 2006 1 89 (0) 1 85 (0) Not estimable
Subtotal (95% CI) 318 323 12.9 % -3.96 [ -6.36, -1.55 ]
Heterogeneity: Chi2 = 1.40, df = 1 (P = 0.24); I2 =29%
Test for overall effect: Z = 3.23 (P = 0.0013)
Total (95% CI) 2077 2066 100.0 % -3.24 [ -4.10, -2.38 ]
Heterogeneity: Chi2 = 3.30, df = 6 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 7.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.40, df = 1 (P = 0.53), I2 =0.0%
-20 -10 0 10 20
NO donor BP lower Control BP lower
146Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.86. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
86 Diastolic BP, first treatment measurement, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 86 Diastolic BP, first treatment measurement, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 < 6 hours
Ankolekar 2013 24 85.77 (15.35) 15 81.13 (12.88) 0.9 % 4.64 [ -4.32, 13.60 ]
ENOS 2015 144 84.46 (15.01) 129 87.8 (14.02) 6.3 % -3.34 [ -6.78, 0.10 ]
Subtotal (95% CI) 168 144 7.2 % -2.31 [ -5.53, 0.90 ]
Heterogeneity: Chi2 = 2.66, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 1.41 (P = 0.16)
2 6.1 to 12 hours
Ankolekar 2013 1 87.5 (0) 1 100.5 (0) Not estimable
ENOS 2015 224 85.36 (14.38) 214 89.86 (15.2) 9.7 % -4.50 [ -7.27, -1.73 ]
Subtotal (95% CI) 225 215 9.7 % -4.50 [ -7.27, -1.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
3 12.1 to 24 hours
ENOS 2015 541 83.87 (13.86) 526 87.2 (13.95) 26.8 % -3.33 [ -5.00, -1.66 ]
Rashid 2002 1 107 (0) 2 82.5 (4.95) Not estimable
Subtotal (95% CI) 542 528 26.8 % -3.33 [ -5.00, -1.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.91 (P = 0.000092)
4 24.1 to 36 hours
ENOS 2015 593 85.18 (13.81) 610 87.06 (14.6) 29.0 % -1.88 [ -3.49, -0.27 ]
Rashid 2002 9 82 (10.82) 4 85 (11.17) 0.4 % -3.00 [ -16.03, 10.03 ]
Willmot 2006 1 106 (0) 1 71 (0) Not estimable
Subtotal (95% CI) 603 615 29.4 % -1.90 [ -3.49, -0.30 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
5 > 36 hours
Bath 2001 16 90.5 (14.4) 20 87.15 (16.67) 0.7 % 3.35 [ -6.81, 13.51 ]
ENOS 2015 498 83.25 (14.18) 532 88.34 (14.84) 23.8 % -5.09 [ -6.86, -3.32 ]
Rashid 2002 50 81.68 (12.44) 24 84.5 (12.46) 2.0 % -2.82 [ -8.88, 3.24 ]
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Willmot 2006 11 87.41 (10.16) 4 91.5 (15.35) 0.3 % -4.09 [ -20.29, 12.11 ]
Subtotal (95% CI) 575 580 26.8 % -4.68 [ -6.35, -3.01 ]
Heterogeneity: Chi2 = 2.97, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 5.50 (P < 0.00001)
Total (95% CI) 2113 2082 100.0 % -3.31 [ -4.17, -2.45 ]
Heterogeneity: Chi2 = 12.35, df = 9 (P = 0.19); I2 =27%
Test for overall effect: Z = 7.51 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.69, df = 4 (P = 0.15), I2 =40%
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Analysis 1.87. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
87 Heart rate, first treatment measurement.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 87 Heart rate, first treatment measurement
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall
Ankolekar 2013 25 79.6 (20.68) 16 74.31 (15.89) 0.6 % 5.29 [ -5.95, 16.53 ]
Bath 2001 16 82.7 (12.1) 21 70.1 (12) 1.3 % 12.60 [ 4.76, 20.44 ]
ENOS 2015 2000 78.95 (15.08) 2011 77.27 (14.9) 92.4 % 1.68 [ 0.75, 2.61 ]
Rashid 2002 60 80.05 (11.24) 30 75.5 (7.71) 5.1 % 4.55 [ 0.59, 8.51 ]
Willmot 2006 12 72.79 (11.12) 6 65.5 (12.16) 0.6 % 7.29 [ -4.30, 18.88 ]
Total (95% CI) 2113 2084 100.0 % 2.02 [ 1.13, 2.91 ]
Heterogeneity: Chi2 = 10.19, df = 4 (P = 0.04); I2 =61%
Test for overall effect: Z = 4.44 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
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Analysis 1.88. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
88 Heart rate, first treatment measurement, by stroke type.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 88 Heart rate, first treatment measurement, by stroke type
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ischaemic
Ankolekar 2013 16 77.06 (20.59) 11 69.05 (10.82) 0.6 % 8.01 [ -3.93, 19.95 ]
Bath 2001 14 82.29 (12.89) 19 71.05 (12.08) 1.1 % 11.24 [ 2.57, 19.91 ]
ENOS 2015 1664 78.72 (14.91) 1678 77.05 (15.02) 77.9 % 1.67 [ 0.66, 2.68 ]
Rashid 2002 54 80.59 (11.21) 30 75.5 (7.71) 4.8 % 5.09 [ 1.02, 9.16 ]
Willmot 2006 11 74.5 (9.88) 5 62.2 (10.16) 0.7 % 12.30 [ 1.65, 22.95 ]
Subtotal (95% CI) 1759 1743 85.1 % 2.12 [ 1.14, 3.09 ]
Heterogeneity: Chi2 = 11.50, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 4.27 (P = 0.000020)
2 ICH
Ankolekar 2013 5 94.2 (21.73) 1 114 (0) Not estimable
Bath 2001 2 85.5 (4.95) 2 61 (8.49) 0.4 % 24.50 [ 10.88, 38.12 ]
ENOS 2015 310 80.07 (15.85) 319 78.16 (14.15) 14.5 % 1.91 [ -0.44, 4.26 ]
Willmot 2006 1 54 (0) 1 82 (0) Not estimable
Subtotal (95% CI) 318 323 14.9 % 2.56 [ 0.25, 4.88 ]
Heterogeneity: Chi2 = 10.26, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 2.17 (P = 0.030)
Total (95% CI) 2077 2066 100.0 % 2.18 [ 1.29, 3.08 ]
Heterogeneity: Chi2 = 21.89, df = 6 (P = 0.001); I2 =73%
Test for overall effect: Z = 4.78 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
-20 -10 0 10 20
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Analysis 1.89. Comparison 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke, Outcome
89 Heart rate, first treatment measurement, by time to randomisation.
Review: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke
Comparison: 1 Glyceryl trinitrate (GTN) compared with no GTN for acute stroke
Outcome: 89 Heart rate, first treatment measurement, by time to randomisation
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 < 6 hours
Ankolekar 2013 24 79.4 (21.1) 15 74.73 (16.35) 0.6 % 4.67 [ -7.15, 16.49 ]
ENOS 2015 144 80.11 (14.76) 129 78.49 (16.09) 5.9 % 1.62 [ -2.06, 5.30 ]
Subtotal (95% CI) 168 144 6.4 % 1.89 [ -1.62, 5.40 ]
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
2 6.1 to 12 hours
Ankolekar 2013 1 84.5 (0) 1 68 (0) Not estimable
ENOS 2015 224 79.54 (17.07) 214 79.67 (15.32) 8.6 % -0.13 [ -3.16, 2.90 ]
Subtotal (95% CI) 225 215 8.6 % -0.13 [ -3.16, 2.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
3 12.1 to 24 hours
ENOS 2015 541 79.22 (14.9) 526 77.53 (15.07) 24.5 % 1.69 [ -0.11, 3.49 ]
Rashid 2002 1 79 (0) 2 69.5 (9.19) Not estimable
Subtotal (95% CI) 542 528 24.5 % 1.69 [ -0.11, 3.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
4 24.1 to 36 hours
ENOS 2015 593 79.37 (15.09) 610 75.73 (14.58) 28.1 % 3.64 [ 1.96, 5.32 ]
Rashid 2002 9 75.22 (12.02) 4 77 (3.56) 1.1 % -1.78 [ -10.37, 6.81 ]
Willmot 2006 1 75 (0) 1 48 (0) Not estimable
Subtotal (95% CI) 603 615 29.2 % 3.44 [ 1.79, 5.09 ]
Heterogeneity: Chi2 = 1.47, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 4.10 (P = 0.000042)
5 > 36 hours
Bath 2001 16 82.7 (12.1) 20 70.4 (12.23) 1.2 % 12.30 [ 4.31, 20.29 ]
ENOS 2015 498 77.53 (14.32) 532 77.51 (14.47) 25.6 % 0.02 [ -1.74, 1.78 ]
Rashid 2002 50 80.94 (11.11) 24 75.75 (8.13) 3.9 % 5.19 [ 0.71, 9.67 ]
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(. . . Continued)
Study or subgroup NO donor Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Willmot 2006 11 72.59 (11.64) 4 68.25 (10.97) 0.5 % 4.34 [ -8.42, 17.10 ]
Subtotal (95% CI) 575 580 31.3 % 1.23 [ -0.36, 2.82 ]
Heterogeneity: Chi2 = 12.42, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 2113 2082 100.0 % 1.91 [ 1.02, 2.80 ]
Heterogeneity: Chi2 = 19.95, df = 9 (P = 0.02); I2 =55%
Test for overall effect: Z = 4.21 (P = 0.000025)
Test for subgroup differences: Chi2 = 5.82, df = 4 (P = 0.21), I2 =31%
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. Cerebrovascular disorders/
2. exp Brain ischemia/
3. Carotid artery diseases/ or Carotid artery thrombosis/
4. exp stroke/
5. exp Hypoxia-ischemia, brain/
6. Cerebral arterial diseases/ or Intracranial arterial diseases/
7. exp “Intracranial embolism and thrombosis”/
8. exp basal ganglia cerebrovascular disease/
9. exp intracranial hemorrhages/
10. (stroke$ or cerebral vasc$ or cerebrovasc$ or cva or transient isch?emic attack$ or tia$).tw.
11. (brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebr$ or mca$ or anterior circulation).tw.
12. (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$).tw.
13. 11 and 12
14. (brain or cerebral or intracranial).tw.
15. (h?emorrhage or h?ematoma or bleed$).tw.
16. 14 and 15
17. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 13 or 16
18. exp nitric oxide donors/
19. nitric oxide/
20. nitroglycerin/
21. Nitric-Oxide Synthase/ai [Antagonists & Inhibitors]
22. arginine/
23. nitroprusside/
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24. (nitric$ or nitro$ or glyceryl trinitrat$ or GTN or arginine).tw.
25. or/18-24
26. 17 and 25
27. limit 26 to human
Appendix 2. Embase search strategy
1. Cerebrovascular disorders.mp. or cerebrovascular disease/
2. exp Brain ischemia/
3. Carotid artery diseases/ or Carotid artery thrombosis/
4. exp cerebrovascular accident/
5. exp brain hypoxia/ or exp brain ischemia
6. Cerebral artery disease/
7. exp occlusive cerebrovascular disease/
8. exp basal ganglion hemorrhage/
9. exp brain hemorrhage/
10. (stroke$ or cerebral vasc$ or cerebrovasc$ or cva or transient isch?emic attack$ or tia$).tw.
11. (brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebr$ or mca$ or anterior circulation).tw.
12. (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$).tw.
13. 11 and 12
14. (brain or cerebral or intracranial).tw.
15. (h?emorrhage or h?ematoma or bleed$).tw.
16. 14 and 15
17. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 13 or 16
18. exp nitric oxide donor/
19. nitric oxide/
20. glyceryl trinitrate/
21. Nitric-Oxide Synthase/
22. arginine/
23. nitroprusside sodium/
24. (nitric$ or nitro$ or glyceryl trinitrat$ or GTN or arginine).tw.
25. or/18-24
26. 17 and 25
27. limit 26 to human
28. limit 27 to (clinical trial or randomized controlled trial or controlled clinical trial or multicentre study or phase 1 clinical trial or
phase 2 clinical trial or phase 3 clinical trial or phase 4 clinical trial)
Appendix 3. Web of science / Science Citation Index search strategy
1. Cerebrovascular disorders.TI/TS
2. Brain ischemia.TI/TS
3. Carotid artery diseases or Carotid artery thrombosis.TI/TS
4. Stroke.TI/TS
5. Brain hypoxia.TI/TS
6. Cerebral artery disease.TI/TS
7. Occlusive cerebrovascular disease.TI/TS
8. Basal ganglia cerebrovascular disease.TI/TS
9. Intracranial hemorrhages.TI/TS
10. (stroke$ or cerebral vasc$ or cerebrovasc$ or cva or transient isch?emic attack$ or tia$).TI/TS
11. (brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebr$ or mca$ or anterior circulation).TI/TS
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12. (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$).TI/TS
13. 11 and 12
14. (brain or cerebral or intracranial).TI/TS
15. (h?emorrhage or h?ematoma or bleed$).TI/TS
16. 14 and 15
17. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 13 or 16
18. nitric oxide donor.TI/TS
19. nitric oxide.TI/TS
20. glyceryl trinitrate.TI/TS
21. Nitric-Oxide Synthase.TI/TS
22. arginine.TI/TS
23. nitroprusside sodium.TI/TS
24. (nitric$ or nitro$ or glyceryl trinitrat$ or GTN or arginine).TI/TS
25. or/18-24
26. 17 and 25
27. 26 Refined by: DOCUMENT TYPES: (CLINICAL TRIAL)
WH A T ’ S N E W
Last assessed as up-to-date: 7 September 2016.
Date Event Description
7 September 2016 New search has been performed Addition of three new trials with 4070 participants. In
total, five trials with 4197 participants are now included
in the review. We have added subgroup analyses and
new outcomes, and updated the Background
7 September 2016 New citation required and conclusions have changed With the addition of newdatawe conclude that glyceryl
trinitrate (GTN) does not alter outcome overall in acute
stroke.When administered within six hours, GTNmay
improve clinical outcomes and therefore warrants fur-
ther study
H I S T O R Y
Protocol first published: Issue 3, 1996
Review first published: Issue 1, 1998
Date Event Description
4 September 2008 Amended Converted to new review format.
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(Continued)
13 August 2002 New search has been performed Data from two trials have been added. The review has been expanded to
include patients with primary intracerebral haemorrhage (as well as ischaemic
stroke)
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